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Abstract 
 
Background: Recent studies have revealed an association between genetic variants at the 
ADAMTS7 (a disintegrin-like and metalloprotease with thrombospondin type 1 motif, 7) 
locus and susceptibility to coronary artery disease (CAD). ADAMTS-7 has been reported 
to facilitate vascular smooth muscle cell (VSMC) migration and promote neointima 
formation. We sought to study the functional mechanisms underlying this relationship and 
to further investigate the role of ADAMTS-7 in atherosclerosis.  
 
Methods and Results: In vitro assays showed that the CAD-associated non-synonymous 
single nucleotide polymorphism rs3825807, which results in a serine to proline (Ser-to-
Pro) substitution at residue 214 in the ADAMTS-7 pro-domain, affected ADAMTS-7 pro-
domain cleavage. Immunohistochemical analyses showed that ADAMTS-7 localised to 
vascular smooth muscle cells (VSMCs) and endothelial cells (ECs) in human coronary 
and carotid atherosclerotic plaques. Cell migration assays demonstrated that VSMCs and 
ECs from individuals who were homozygous for the adenine (A) allele (encoding the 
Ser214 isoform) had increased migratory ability compared with cells from individuals 
who were homozygous for the G allele (encoding the Pro214 isoform). Western blot 
analyses revealed that media conditioned by VSMCs of the A/A genotype contained more 
cleaved ADAMTS-7 pro-domain and more of the cleaved form of thrombospondin-5 
(TSP-5, an ADAMTS-7 substrate that had been shown to be produced by VSMCs and 
inhibit VSMC migration). In in vitro angiogenesis assays, ECs of the A/A genotype 
exhibited increased capillary-like network formation. ADAMTS-7 over-expression in 
ECs by transfection of an ADAMTS7-214Ser expressing plasmid significantly accelerated 
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EC migration and in vitro angiogenesis, whereas ADAMTS-7 knockdown by shRNA had 
opposite effects. Preliminary proteomics analyses of conditioned media of ECs over-
expressing ADAMTS-7 and ECs with ADAMTS-7 knockdown indicated that ADAMTS-
7 can cleave thrombospondin-1 (TSP-1), a well-recognised angiogenesis inhibitor.  
 
Conclusion: The results of this study indicate that rs3825807 has a functional effect on 
ADAMTS-7 maturation, TSP-5 cleavage, VSMC and EC migration, and angiogenesis. As 
VSMC migration and angiogenesis play important roles in atherosclerosis, these results 
provide a mechanistic explanation for the association between rs3825807 and CAD. 
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Chapter 1  
Introduction 
 
1.1 Cardiovascular diseases (CVDs) – the number one global killer 
 
Epidemiological studies of cardiovascular diseases (CVDs), specifically atherosclerotic 
coronary heart disease, started in the early 20th century, but for several decades, little 
progress was made to explain the disease mainly because of the lack of systematic 
approach (Luepker 2009). The first systematic study of CVDs was carried out in 1947 by 
Keys and colleagues who observed the occurrence of coronary heart disease (CHD) 
among Minnesota businessmen with 30 years follow up. The study revealed a significant 
relationship between CHD incidence and systolic blood pressure and serum cholesterol 
level (Keys et al. 1963).  A year later, the National Heart, Lung and Blood Institute 
(NHLBI) established the Framingham Heart Study with the goal to understand the 
development of heart diseases by studying lifestyles of the residents of Framingham and 
Massachusetts. This study also found that elevations of blood pressure and cholesterol 
levels were associated with an increased incidence of (Kannel et al. 1961). The 
Framingham study first proposed the risk factor concept in which physiological and 
behavioral characteristics such as blood pressure, blood lipids, and cigarette smoke acted 
as predictors of subsequent disease events (Nabel and Braunwald 2012). Numerous 
studies around the world in the following decades adopted this method, confirming that 
the risk factors described by the early surveys predicted disease outcomes in different 
populations (Luepker 2009). These risk factors have been categorised into two major 
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groups: the group of risk factors with a dominant genetic component and the one with 
main underlying cause contributed by the environment (Table 1.1).  
 
Table 1.1 Risk factors for atherosclerosis 
Risk factors with significant genetic component Environmental factors 
Myocardial infarction Smoking 
Stroke Diet 
Total cholesterol Exercise 
HDL cholesterol infection 
Total triglycerides Fetal environment 
BMI Air pollution 
Blood pressure Alcohol consumption 
Lp(a) level  
Homocysteine level  
Type 2 diabetes  
Age  
Gender  
                   
                 Cited from (Lusis et al. 2004) 
 
With the identification of these risk factors, the concept that vascular disease and its 
complications, such as myocardial infarction and stroke, could be prevented was 
introduced. By controlling the risk factors for CVDs, such as lowering blood pressure, 
reducing plasma lipid concentration, and eradicating smoking, considerable progress has 
been made in reducing CVDs incidence and mortality in populations worldwide. But 
according to the latest World Health Organization (WHO) data in 2011, ischaemic heart 
disease and stroke are still the top two leading causes of death worldwide (Figure 1.1). 
Thus, further understanding of the pathogenesis of CVDs and development of new 
treatments for the disease are required. 
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Figure 1.1 World Health Organization data of cardiovascular diseases. A: Distribution of 
major causes of death globally, with cardiovascular diseases the leading causes of death in the 
world, which are responsible for over 17 million deaths per year. B: Distribution of global non-
communicable diseases (NCD, including CVDs, cancer, diabetes et al) by cause of death. Cited 
from <Global atlas on cardiovascular disease prevention and control. Geneva, World Health 
Organization, 2011>.  
 
 
1.2 Atherosclerosis – common cause of CVDs 
 
Atherosclerosis, a chronically progressing disease, is the primary cause of CHD and stroke. 
It is characterised by accumulation of lipids in large and medium sized arteries and 
subsequent formation of the atherosclerotic plaque composed of inflammatory cells, 
smooth muscle cells, lipids and extracellular matrix proteins  (Figure 1.2) (Libby et al. 
2011).  
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Figure 1.2 Atherosclerotic plaque formation. A: Normal structure of muscular arteries. B: The 
early steps of atherosclerosis: leukocytes attach and migrate into intima and monocyte-derived 
macrophages internalize lipids and transform to form-cells; C: SMC migration and their 
production of ECM contribute to the fibrous cap formation, as the plaque enlarges, endothelial 
cells migrate, proliferate and form neo-vessels to supple the growth of the plaque. D: Vulnerable 
plaque rupture and thrombosis formation. Figure cited and modified from (Libby et al. 2011). 
 
 
1.2.1 LDL retention and EC dysfunction 
 
Although considerable progress has been made in atherosclerosis research in the past 50 
years, surprisingly, little is known about the early development of human atherosclerosis. 
The slow development of this disease makes it difficult to distinguish between lesion 
initiation and progression (Nakashima et al. 2008). There are two main hypotheses 
explaining initiation of atherosclerosis.  
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1.2.1.1 Response-to-injury hypothesis 
 
The response-to-injury hypothesis was postulated by Ross, Glomset, and co-workers. This 
hypothesis originally presupposed endothelial desquamation as the key event in 
atherosclerosis initiation (Ross and Glomset 1976, Ross and Glomset 1976). However, it 
is now clear that the developing atheroma is covered by an intact endothelial layer 
throughout most stages of lesion progression (Williams and Tabas 1995). Thus, a refined 
response-to-injury hypothesis states that endothelial injuries that are insufficient to cause 
gross denudation but severe enough to cause endothelial cell dysfunction are key to 
atherosclerosis initiation (Ross 1993, Williams and Tabas 1995). Normally, the 
endothelial cells resist adhesion by leukocytes. However, risk factors of atherosclerosis 
such as high level of lipids, hypertension, hyperhomocysteinemia, blood flow turbulence, 
or smoking can injure the monolayer of endothelial cells and increase the permeability of 
endothelial layer. This increased permeability could facilitate lipid diffusion, mostly 
consisting of low-density lipoprotein (LDL) particles, into subendothelial space where 
they become trapped and modified by oxidation resulting in atherogenic ox-LDL particles.  
 
1.2.1.2 Response-to-retention hypothesis 
 
The response-to-retention hypothesis, proposed by Williams and Tabas in 1995, is another 
theory of atherosclerosis initiation (Williams and Tabas 1995). This hypothesis states that 
the retention of atherogenic lipoproteins associated with the extracellular matrix (ECM) 
in the arterial intima is an initial event in early atherogenesis, and the endothelial 
dysfunction is neither necessary nor sufficient for atherogenesis (Williams and Tabas 
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1995). This hypothesis further postulates that lipoprotein retention begins with 
predisposing stimuli (e.g. mechanical strain and/or cytokines) that enhance local synthesis 
of proteoglycans with high binding affinity for lipoproteins. These atherogenic 
lipoproteins enter the arterial intima and are bound and retained by proteoglycans 
(Williams and Tabas 1995, Little et al. 2002, Tabas et al. 2007). Positively charged 
residues of lipoproteins are bonding, via electrostatic interaction, with negatively charged 
side chains of proteoglycans called glycosaminoglycans (GAG) (Chait and Wight 2000, 
Kaplan and Aviram 2001, Williams 2001). The hypothesis further states that in their 
bound state the lipoprotein-proteoglycan complexes exhibit increased susceptibility to 
modification, via oxidation and/or aggregation, which in turn signal their uptake by 
macrophages to form foam cells (Kaplan and Aviram 2001, Nakashima et al. 2008) (see 
section 1.2.2 for further discussion). Furthermore, retained and modified lipoproteins 
enhance the production of proteoglycans with a high affinity for lipoproteins causing a 
cascade effect of the process (Chang et al. 2000). Thus, the response-to-retention 
hypothesis emphasizes the central role that ECM – lipoprotein play in atherosclerosis 
initiation (Nakashima et al. 2008).  
 
In conclusion, these two hypotheses are not mutually exclusive. The response-to- retention 
hypothesis does not rule out the contribution of endothelial cell dysfunction to 
atherosclerosis initiation. Furthermore, these two theories are also consistent with the 
chronic inflammation hypothesis because retained and modified lipoproteins can stimulate 
the recruitment of inflammatory cells, such as monocytes and T-lymphocytes (Nakashima 
et al. 2008).  
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1.2.2 Leukocyte activation and foam cell formation 
 
Modified LDL particles, mostly in the form of ox-LDL, can initiate expression of adhesion 
molecules by endothelial cells, including: intercellular adhesion molecule-1 (ICAM-1), 
vascular cell adhesion molecule-1 (VCAM-1), E-selectin and P-selectin (Kume et al. 1992, 
Khan et al. 1995, Shi et al. 2000, Eriksson et al. 2001). Moreover, increased permeability 
of endothelium and altered expression of adhesion molecules on the cell surface further 
promote recruitment of leukocytes by a process of rolling/adhesion to activated 
endothelial cells, subsequently allowing migration through the endothelial layer into the 
intima further aided by the action of chemokines (Ross 1999, Libby 2002, Libby et al. 
2002). Monocyte chemoattractant protein-1 (MCP-1) is an important chemokine that 
recruits monocytes into intima (Gu et al. 1998). These monocytes migrate through the 
endothelial layer and mature into macrophages in response to cytokines/chemokines, such 
as the macrophage colony-stimulating factor (M-CSF) (Figure 1.2 B). These macrophages 
take up the trapped and modified LDL through scavenger receptors (SRs) e.g. SR-A and 
CD36 on their surface. The macrophages continually take up modified LDL and 
eventually become foam cells and contribute toward lesion progression (Ross 1999, Libby 
et al. 2002, Libby et al. 2011). At this stage, the accumulation of lipids in the 
subendothelial space can be observed as fatty streaks in the intima, which is the form of 
the earliest atherosclerotic lesion (Napoli et al. 1997).  
 
Activated T lymphocytes are also involved in development of atherosclerotic lesions. 
(Hansson 2005). T lymphocytes can attach to adhesion molecules expressed on ECs, such 
as VCAM-1, and migrate through the EC layer into the intima, where they are activated 
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by macrophages that express class II major histocompatility complex (MHC-II) (Ross 
1999). Although a significant decrease in the extent of atherosclerosis found in 
lymphocyte-deficient mice reflects an anti-atherosclerotic effect of T-lymphocytes 
(Uchida et al. 2010), cytokines secreted by different types of activated T-lymphocyte exert 
either pro-atherogenic or anti-atherogenic effects. The cytokines secreted by activated T-
helper type 1 cells (Th1), such as interferon-γ (IFN-γ), exert pro-atherogenic effects. A 
significant reduction in atherosclerotic lesion was reported in IFN-γ deficient ApoE 
knock-out mice (Gupta et al. 1997, Whitman et al. 2002). This effect of IFN-γ is due to 
the dual activity of this cytokine. On the one hand it can activate macrophages to produce 
pro-inflammatory mediators including IL-1, IL-6 and TNF-α which are pro-atherogenic 
(Hansson 2001), while on another hand it can up-regulate the expression of SR-A and 
CD36 which increase ox-LDL uptake by macrophages (Lusis 2000). IFN-γ also inhibits 
production of ECM by SMC, increases production of metalloproteinases to degrade the 
ECM and induces apoptosis of foam cells. All these actions weaken the fibrous cap of an 
atherosclerotic lesion that protects the blood from the thrombogenic lipid core of the 
plaque, ultimately contributing the plaque rupture (Libby 2000, Lusis 2000, Libby 2006). 
Meanwhile, the major cytokines of Th2 cells counter the effect of Th1 cytokines and exert 
anti-atherogenic effect (Binder et al. 2004, Hansson 2005). IL-10 is a Th2-derived 
cytokine and IL-10 deficient mice showed increased cholesterol accumulation in 
macrophages and overall increase in size of atherosclerotic lesions, while over-expression 
of IL-10 in mice led to reduction in atherosclerotic lesion (Mallat et al. 1999, Pinderski et 
al. 2002, Caligiuri et al. 2003).     
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1.2.3 SMC migration and fibrous cap formation 
 
Both SMC proliferation and migration are important processes in the formation of the 
fibrotic lesions and the progression of atherosclerosis (Figure 1.2 C) (Schwartz 1997, 
Libby et al. 2011). Vascular smooth muscle cell migration from the media to the intima is 
another dominant process that contributes to the progression of the plaque. Normally, 
VSMCs are restricted to the media of blood vessels, maintaining a 
contractile/differentiated phenotype and have low ability to migrate and proliferate. 
However, on various environmental cues, VSMCs can undergo transition from a quiescent, 
contractile/differentiated phenotype to a synthetic/dedifferentiated phenotype, with a high 
rate of migration/proliferation (Owens 1995, Hao et al. 2003, Wang et al. 2009). Activated 
macrophages and T lymphocytes in the plaque can secrete multiple cytokines and growth 
factors, such as platelet-derived growth factor-BB (PDGF-BB) and transforming growth 
factor-β (TGF-β), that can stimulate VSMCs to transit from a quiescent phenotype to a 
synthetic/migratory phenotype and to migrate into the intima from the media layer (Lusis 
2000, Owens et al. 2004, Wang et al. 2009). The fibrous cap consists of a mixture of 
leukocytes, lipids, and debris, which may form a necrotic core. The lesion can grow larger 
due to continued leukocyte recruitment, SMC migration/proliferation and ECM 
production (Ross 1999). Apart from cytokines and growth factors secreted by the 
macrophages and the activated endothelial cells, thrombin can also induce SMC migration 
and proliferation. ECM proteins also have effect on SMC phenotype transition, for 
instance, fibronectin, collagen I and collagen III can induce shifts towards the synthetic 
phenotype, while laminin, collagen IV and thrombospondin induce the opposite effect 
(Owens et al. 2004, Rzucidlo et al. 2007, Orr et al. 2009, Wang et al. 2009).  
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With the presence of many atherogenic cytokines, such as activated platelet released TGF-
β, migrated SMC in the intima then can proliferate and produce various ECM components, 
such as collagens, proteoglycans and fibronectin, resulting in the formation of a collagen-
rich fibrous cap (Geng and Libby 2002, Libby et al. 2002) (Doran et al. 2008). Although 
endothelial cells, macrophages and SMCs all contribute to ECM production, SMCs are 
the principal connective tissue producer in atherosclerotic lesions (Falk 2006), thus 
forming an extension part of this study, CHD-associated SNPs in the ADAMTS7 gene 
locus can affect ADAMTS-7 protein activation and cleavage of its substrate TSP-5 and 
further affect SMC migration.  
 
1.2.4 Extracellular Matrix proteins and atherosclerosis 
 
The ECM is composed of a mixture of vastly different macromolecules including collagen, 
elastin, glycoproteins and proteoglycans, conferring tensile strength and viscoelasticity to 
the arterial wall. Not only does the ECM provide the structural integrity of the artery wall, 
but it also participates in several key events such as cell proliferation, migration, apoptosis, 
lipoprotein retention and thrombosis. Thus, ECM turnover and remodelling have been 
proved to be involved in the pathogenesis of multiple diseases, such as atherosclerosis, 
arthritis and cancer (Katsuda and Kaji 2003). The following sections will look at the key 
components of ECM in greater detail in terms of their involvement in atherosclerosis.  
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1.2.4.1 Collagen 
 
Among these macromolecules, collagen is the principal constituent of vascular ECM. To 
date, 25 types of collagen have been identified and thirteen types of them are present in 
the vascular wall. Their main function is to help maintain the structural integrity of the 
vascular wall, enhance its flexibility, and in addition, play a role in various cellular events 
including adhesion, proliferation, migration, and apoptosis. Five types of collagen 
(collagen I, III, IV,V and VIII) play pivotal roles in the pathogenesis of atherosclerosis 
because they accumulate in atherosclerotic lesions, as reviewed by (Plenz et al. 2003).  
 
Collagen I, III and V are fibrillar collagens and comprise up to 60% of the total protein 
found in atherosclerotic plaque (Plenz et al. 2003). Collagen I and III are rigid and elastic 
respectively, while collagen V forms thin fibres. Collagen I forms the bases of the collagen 
fibre networks with alterations in Collagen III and V proportions giving rises to tissue 
structures in determining vessels tensile strength and elastic resilience (Ottani et al. 2001, 
Plenz et al. 2003). Collagen IV is the predominant constituent of basement membrane 
which underlies the endothelium and surrounds SMCs in the arterial wall. Collagen VIII, 
a network-forming collagen, interacts with other components of ECM, may contribute in 
the maintenance of vessel wall integrity and structure (Plenz et al. 2003).  
 
Increasing evidence revealed that these collagens participate in cell processes, such as 
proliferation, migration and apoptosis. Fibrillar collagen I polymers inhibit VSMC 
proliferation and migration. In contrast, monomeric collagen I promote VSMC 
proliferation and migration (Chistiakov et al. 2013). Studies showed that Type IV collagen 
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expression increased in the atherosclerotic arteries, and that atherosclerotic lesions often 
contain thick deposition of Type IV collagen and multiple layers of basement membrane 
around SMCs (Stary et al. 1995, Rekhter 1999). Collagen IV can also induce apoptosis of 
vascular endothelial cells and SMCs, which may represent another pro-atherogenic effect 
of Type IV collagen (Panka and Mier 2003). Data also indicated that collagen VIII might 
promote VSMC migration and invasion in the atherosclerotic intima via interaction with 
integrin receptors and modulation of the synthesis of MMPs (Plenz et al. 2003). In vitro 
studies on cultured ECs demonstrated Collagen VIII involvement in processes of EC 
differentiation and organization and in vitro angiogenesis (Iruela-Arispe et al. 1991). 
 
1.2.4.2 Glycoprotein 
 
Various types of glycoprotein such as fibronectin and thrombospondin (TSP) are 
deposited in the atherosclerotic plaque. Like collagen, many of these glycoproteins have 
the ability to regulate cell proliferation and migration (Katsuda and Kaji 2003).  
Fibronectin is an adhesive glycoprotein, which possesses the ability to bind to various 
macromolecules as well as to cells, and influences the proliferation and migration of SMC 
(Katsuda and Kaji 2003).  TSPs are a family of large multimeric ECM proteins that 
influence adhesion, migration, proliferation and survival of a variety of cell types 
(Armstrong and Bornstein 2003). The family consists of thrombospondins 1-5 and can be 
categorised into two subgroups: (A) TSP-1 and TSP-2, which are homotrimers; (B) TSP-
3, 4 and 5 (also designated cartilage oligomeric matrix protein or COMP), which are 
homopentamers (Lawler 2000). The subgroup (A) attracted a lot of attention recently due 
to its ability to inhibit the migration and proliferation of cultured ECs and angiogenesis in 
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vivo (Armstrong and Bornstein 2003). However, TSP-1 has also been reported to have the 
ability to promote VSMC proliferation and migration (Patel et al. 1997) and to possess a 
latent TGF-β activation action (Crawford et al. 1998).  
 
1.2.4.3 Proteoglycan 
 
Proteoglycans are a group of macromolecules with a core protein to which 
glycosaminoglycans (GAG) are covalently attached (Ivey and Little 2008). Depending on 
the attached GAG chains, proteoglycans can be categorised into several families: 
chondroitin sulphate proteoglycans (CSPGs), dermatan sulphate proteoglycans (DSPGs), 
heparan sulphate proteoglycans (HSPGs), and keratan sulphate proteoglycans (KSPGs). 
Except for KSPGs, all other proteoglycans have been identified in blood vessels and 
synthesised by vascular cells. Endothelial cells produce mainly HSPGs (such as perlecan 
and syndecan), whereas VSMCs produce mainly CSPGs and DSPGs (like versican and 
biglycan). CSPGs and DSPGs that accumulate in the plaque show a marked affinity for 
native LDL particles and can accelerate oxidation of LDL, and further facilitate 
phagocytosis by macrophages. This in turn induces the deposition and retention of 
modified LDL particles, which can further cause endothelial injury and stimulate VSMC 
proliferation and migration, thereby leading to further progression of plaque (Hurtcamejo 
et al. 1992, Katsuda and Kaji 2003). HSPGs have been proposed to be antiatherogenic 
(Engelberg 2001), as decreased HSPGs are associated with increased atherosclerosis 
(Edwards et al. 2004, Tran et al. 2007, Tran-Lundmark et al. 2008). However, a 
proatherogenic effect of HSPG has also been reported (Tran-Lundmark et al. 2008). 
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1.2.5 Intraplaque angiogenesis and plaque progression 
 
Angiogenesis also plays an important role in plaque progression and stability. As the 
plaque enlarges, the ensuing hypoxia and/or inflammatory cell infiltration is thought to 
promote intraplaque angiogenesis. Endothelial cells migrate, proliferate and form neo-
vessels to support the growth of the plaque (Figure 1.2 C). In the early to mid-20th century, 
intraplaque angiogenesis and subsequent haemorrhage was hypothesized to be a major 
contributor to the progression of coronary atherosclerosis by several leading pathologists 
(Virmani et al. 2005). Much evidence now supports this hypothesis. Expression of the 
major angiogenic factors such as vascular endothelial growth factor (VEGF) is up-
regulated during atherogenesis (Donners et al. 2010). It has been reported that DNA 
vaccination against VEGFR2, the major receptor for VEGF inhibited atherosclerotic 
plaque growth by reducing plaque neovascularisation in LDL receptor (LDLR) deficient 
mice (Petrovan et al. 2007). Moulton and colleagues demonstrated that the treatment of 
hypercholesterolemic Apolipoprotein E (ApoE) null mice with the angiogenesis inhibitors 
reduced plaque neovascularisation and plaque size by 70% to 85% (Moulton et al. 1999, 
Herrmann et al. 2006).   
 
These studies clearly support the contribution of angiogenesis to plaque growth. However, 
the basic question remains about how angiogenesis contributes to plaque progression. One 
thought is that these immature blood vessels are inherently leaky, thereby increasing the 
infiltration of leukocytes, and thus amplifying the local inflammation. Data by Moulton 
et al. pointed out that a 60% reduction in CD31+ capillaries in the intima and the adventitia 
was correlated with a 31% reduction of plaque area and a 51% reduction in plaque 
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macrophage content. This finding clearly supported the notion that plaque angiogenesis 
may contribute to atherosclerosis progression by providing a vascular network for 
inflammatory cell infiltration (Moulton et al. 2003, Herrmann et al. 2006). Moreover, the 
new blood vessels in the plaque are characterised not only by paucity of tight junctions 
and a discontinuous basement membrane but also by a relative lack of SMC. These 
neovessels are not only leaky but also unable to control intraluminal pressure and therefore 
fragile and prone to micro-haemorrhage and thrombosis (Herrmann et al. 2006).  
 
Thrombin is a potent stimulator of SMC migration and proliferation. It triggers platelet 
release of growth factors such as platelet-derived growth factor (PDGF) from their alpha 
granules, stimulating SMC migration and proliferation which in turn contribute to plaque 
growth (Geng and Libby 2002, Libby et al. 2002, Libby et al. 2011). In addition, 
sequestration of red blood cells may contribute to the increase of free-cholesterol load of 
the plaque (Virmani et al. 2005). Plaque angiogenesis therefore contributes to the 
progression of atherosclerosis.  
 
1.2.6 Plaque rupture 
 
Atherosclerotic plaques that have a large lipid-rich necrotic core and/or a thin fibrous cap 
are prone to rupture. If this happens, the coagulation factors in the blood come in to contact 
with tissue factor, the main pro-thrombotic stimulus found in the lipid core of the 
atherosclerotic plaque which triggers thrombus formation (Figure 1.2 D) (Libby et al. 
2011). The thrombus can block the artery and cause acute ischaemic events (Libby et al. 
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2002). Plaque rupture is the most common cause of acute ischaemic complications of 
atherosclerosis, such as myocardial infarction (MI) and ischaemic stroke (Libby 1995, 
Davies 1996, Virmani et al. 2000). 
 
Several factors can contribute to formation of a thin fibrous cap. These include: SMC 
apoptosis, reduced ECM production, and increased ECM degradation. There is evidence 
suggesting that the cytokine IFN-γ produced by activated T lymphocytes in the plaque 
inhibits ECM production by SMCs whereas inflammatory cytokines such as interleukin-
1β (IL-1 β) and tumour necrosis factor alpha (TNF-α) can stimulate macrophages and 
other leukocytes in the plaque to produce ECM-degrading enzymes such as matrix 
metalloproteinases (MMPs)  (Libby et al. 2002). The rupture-prone plaques have fewer 
SMCs and are abundant in leukocytes. The repairing and protective capabilities of SMCs 
and their migration into the atherosclerotic lesion, proliferation, and ECM synthesis 
activity are considered beneficial for the stability of the plaque. Senescence and impaired 
function and/or death of SMCs are likely to be detrimental to the process. It is unknown 
why fewer SMCs are present at rupture sites, but apoptotic cell death could play an 
important role in plaque instability (Geng et al. 1997, Falk 2006).  
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1.3 Genetic basis of CVDs 
 
1.3.1 Familial clustering and heritable basis of CVDs 
 
Familial clustering of CHD had been noticed in the early last century and family history 
of CHD has long been considered a risk factor for the disease. Data of The Heath Family 
Tree Study and the NHLBI Family Heart Study indicate that high-risk families only 
represent about 11-14% of the general population but account for 72% of early CHD, 48% 
of CHD at all ages, 86% of early strokes, and 68% of all stroke, respectively (Williams et 
al. 2001). A number of twins or adoptee studies to estimate the extent of genetic influence 
have been reported. In a Swedish study of 21,000 twins born between 1886 and 1925, it 
was found that the relative hazard of both male twins dying of CHD before the age of 55 
years, as compared to those with only one twin, was 8.1 for monozygotic and 3.8 for 
dizygotic twins (Marenberg et al. 1994). One explanation for these findings is the notion 
that the etiology of CHD has a genetic component although shared environmental 
influences can not be ruled out. Furthermore, the landmark Danish study of 1000 families 
with adopted children revealed that the death of a biological parent before the age of 50 
years caused by vascular disease was associated with a 4.5-fold increase in mortality for 
the offspring from the same cause, whereas the death of an adoptive parent from similar 
causes did not significantly increase this risk (Sorensen et al. 1988), thereby strengthening 
the genetic-component argument. In addition, the anatomy of coronary disease, for 
instance, left main or proximal coronary disease, has also been revealed to be heritable 
(Fischer et al. 2005, Fischer et al. 2007), while coronary calcification and carotid intima-
media thickness are also more prevalent in those with a family history of premature CHD 
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(Wang et al. 2003, Nasir et al. 2004, Nasir et al. 2007). Taken together, these studies 
provided convincing evidence that CVDs have a heritable component. 
 
1.3.2 Genetic risk factors 
 
Since the Framingham study first proposed the risk factor concept, epidemiological 
studies have revealed quite a few risk factors for CVDs which can be grouped into factors 
with an important genetic component and those that are largely environmental. However, 
these studies indicate that family history of CVDs is the most significant independent risk 
factor. A substantial proportion of an individual’s susceptibility to CHD is attributable to 
genetic factors. The estimated heritability for CHD ranges from 40% to 60%. Multiple 
genes are implicated in risk factors such as blood pressure, total plasma cholesterol level, 
and type 2 diabetes (Lusis 2000). Identifying such genes can lead to a greater 
understanding of the pathogenesis of the disease and may contribute to better risk 
prediction, prevention, diagnosis and treatment of the disease.  
 
1.3.3 Monogenic and polygenic CVD 
 
In a small percentage of cases, CVD in a patient is caused by mutation of a single gene 
and can be inherited in a Mendelian fashion. An example of such case is familial 
hypercholesterolemia which is caused by mutations in one of the genes encoding the low-
density lipoprotein receptor, Apolipoprotein B100, proprotein convertase subtilisin/kexin 
type 9 and low density lipoprotein receptor adapter protein 1. However, in the vast 
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majority of cases, CVD is a complex disorder and has no predictable pattern of inheritance. 
It is believed to be associated with many DNA variants in multiple genes each having a 
modest effect size. Since the genes of most Mendelian diseases associated with CVD have 
been identified, current research is focused on the identification of genetic variants 
associated with susceptibility to complex CVD (Nabel 2003, Soutar and Naoumova 2007, 
Patel and Ye 2011). 
 
1.4 Genetic approaches to study CVDs 
 
To find the genetic factors involved in the pathogenesis of CVDs, several technologies 
have been used. The principle underlying these approaches obtains genetic information 
from different individuals, some with CVD and some without, and then determines 
differences between the two sets of genomes. Given current high costs of whole genome 
sequencing, various DNA markers are used to identify the disease predisposed genome 
regions. The following sections will look at the most important technologies in greater 
detail. 
 
1.4.1 Linkage study 
 
Linkage study is performed by identifying DNA markers, such as microsatellite 
polymorphisms (short tandem repeat DNA sequences), that co-transmit with the disease 
in families. Since the genomic positions of the co-transmitted DNA markers are known, 
they can be used as a tool to identify regions of the genome that contain genes that 
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predispose to disease. Several linkage studies of CHD have been reported (Kullo and Ding 
2007). 
 
For instance, Helgadottir and colleagues performed a linkage study with 1,068 
microsatellite markers in 713 individuals with a history of myocardial infarction from 296 
families in Iceland, and found a locus on chromosome 13 with a linkage signal. 
Subsequently, they fine-mapped the interval by genotyping additional 120 microsatellite 
markers and 48 SNPs in this region in 802 cases of myocardial infarction and 837 controls, 
and found that a 4-SNP haplotype spanning the ALOX5AP gene (encoding arachidonate 
5-lipoxygenase-activating protein) was associated with a two-fold higher risk of 
myocardial infarction (Helgadottir et al. 2004). A further study in a case-control set from 
England confirmed that the ALOX5AP gene was associated with CHD. It was also found 
to be associated with stroke in Icelandic and Scottish populations (Helgadottir et al. 2005).  
 
The largest linkage study of CHD to date is the British Heart Foundation Family Heart 
Study which included 4,175 CHD cases from 1,933 families recruited throughout the UK 
and genotyped 416 microsatellites. The study identified a locus on chromosome 2, with 
suggested linkage for CHD, logarithmic odds of linkage (LOD) scores of 2.70 and 2.10 
for coronary artery disease and myocardial infarction respectively (Samani et al. 2005), 
however, which are less than 3, the traditional significance threshold for a linkage (Dawn 
Teare and Barrett 2005). 
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Using this approach, more than 40 loci have been identified, but few of these have been 
replicated between studies (Stylianou et al. 2012). This may be due to a number of reasons 
including phenotypic heterogeneity and locus heterogeneity of complex disease and the 
low statistical power of this method to detect modest genetic effects (Patel and Ye 2011).  
 
1.4.2 Candidate gene association study 
 
Association studies directly compare allele frequencies of the genetic variants between 
those with a clinical condition (cases) and those without (controls) that are biologically 
unrelated. In contrast to linkage study, association study has greater statistical power for 
detecting genes with small effect sizes (Patel and Ye 2011).  
 
Due to the limitation of technology and knowledge of the human genome, previously, the 
association study approach was used only to study variation in genes related to known 
pathological pathways or risk factors for the diseases under investigation. The hypothesis 
for this so-called ‘candidate gene’ approach is that, if a given protein is encoded by a gene 
being involved in the pathogenesis of disease, variation in that gene may alter either the 
expression or function, or both, of that protein, consequently leading to disease. Although 
many studies using this approach have been reported and from these studies a number of 
genes have been suggested to be associated with CHD, there have also been a lot of 
discrepancies among the studies and few findings have been confirmed (Winkelmann et 
al. 2000). This is also true for candidate gene studies of other complex disorders. One 
likely explanation is that the sample sizes of those studies were too small, and therefore, 
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the studies were prone to false-positive and false-negative findings. Although this is not a 
problem specific to the candidate gene study approach itself, the technique does have some 
limitations.  Firstly, due to the nature of this approach, such studies can not identify novel 
disease genes and pathways. Secondly, such studies usually focus on gene exons, introns 
and immediate flanking regions, and therefore can not identify disease associated 
variations in the intergenic regions which contain DNA regulatory elements such as 
enhancers and silencers (Patel and Ye 2011).    
 
1.4.3 Genome-Wide Association Study (GWAS) 
 
In GWAS (Figure 1.3), study subjects are genotyped for up to over a million DNA markers 
directly. In contrast to the ‘candidate gene’ approach which specifically tests one or a few 
genetic regions, GWAS investigates the entire genome. This approach has only become 
feasible after the completion of the Human Genome Project, and subsequently the 
HapMap project. The former project has determined the sequence of the 3 billion base 
pairs of the human genome and the positions of its approximately 20,000 genes, while the 
later one identified genetic variations in the human genome. The majority of genetic 
variants are single nucleotide polymorphisms (SNPs), so far more than 10 million 
common SNPs (minor allele frequency >5%) have been identified by the HapMap project 
(Altshuler et al. 2010). It is estimated that SNPs account for over 80% of all human genetic 
variations that attribute to disease predisposition (Tregouet et al. 2009, Roberts et al. 2010). 
Because DNA variants that are near each other tend to be inherited together, they can be 
in linkage disequilibrium (LD). Taking advantage of the HapMap Project which has 
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provided comprehensive knowledge of LD among SNPs throughout the human genome, 
a smaller number of SNPs can be chosen as ‘tag’ SNPs to capture information on many 
more SNPs across the whole genome (Altshuler et al. 2010).  
 
Another important development that has made GWAS feasible is high-throughput 
genotyping that enables hundreds of thousands of SNP (and more recently up to two 
million SNPs) to be genotyped simultaneously in a microarray.   
 
 
 
Figure 1.3 GWAS flowchart. GWAS are population-based, hypothesis-free, case-control studies. 
Thousands of individuals with a disease phenotype are recruited from the population, and need to 
be matched by disease-free individuals from the same population. DNA from “cases” and 
“controls” are genotyped using micro-array chips that can examine up to several millions of SNPs 
simultaneously. Stringent association analysis (divided into two stages of discovery and validation, 
each requiring an independent subset of individuals) are used to identify variants with statistically 
different frequencies between “cases” and “controls”. P values of less than 5 x 10^-8 is used as 
stringent threshold to minimize the false positive association. Figure cited from (Patel and Ye 
2011).  
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In the last few years, the GWAS approach has led to the identification of many 
susceptibility genes for many common diseases such as hypertension, diabetes, and of 
special interest to this thesis, CHD. To date, 46 genetic loci for CHD have been identified, 
of which the best known is the chromosome 9p21 locus, which was reported by three 
independent groups in 2007. As a marker for the disease’s susceptibility, it has been 
replicated in many subsequent studies, strengthening its role in CHD pathogenesis. The 
functional study of 9p21 performed by our group revealed that the locus’ variation has an 
impact on cyclin-dependent kinase inhibitor 2A and 2B (CDKN2A and CDKN2B) 
expression in VSMCs and thus influences VMSC proliferation, which likely represents an 
important mechanism for the association between this genetic locus and susceptibility to 
CAD (Motterle et al. 2012). An updated list of published GWAS can be found in the 
catalog of published genome-wide association studies (http://www.genome.gov/ 
gwastudies/) at the National Human Genome Research Institute (NHGRI). 
 
The GWAS-identified loci define only the gene region nearest to the risk-associated SNPs. 
This means that in some cases the studies do not identify the causative gene itself and in 
almost all cases, never point to the causative SNP for the disease in question.  Additional 
studies are required to identify the causal variants, because their inclusion in the risk 
algorithm will improve risk prediction and reduce uncertainty. Furthermore, results of 
GWAS often do not reveal the mechanisms behind the observed genetic association. 
Therefore, one of the current challenges in molecular genetics is to identify these 
functional variants reported in GWAS and reveal the underlying cellular processes by 
functional studies (Zeller et al. 2012). In addition, most of the GWAS findings are not 
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relevant to any known risk factor for CVDs, the following studies of these findings can 
uncover novel pathways and therapeutic targets for the disease. 
 
1.4.4 GWAS and the ADAMTS7 gene locus 
 
In 2011, C4D consortium (The Coronary Disease Genetics Consortium) reported a large 
GWAS, with 575,000 genotyped SNPs in a discovery dataset comprising of 15,420 
individuals with CAD (cases) (8,424 Europeans and 6,996 South Asian) and 15,062 
controls. Replicated in an independent population sample of 21,408 cases and 19,185 
controls identified 5 loci newly associated with CAD (P<5 x 10-8 in the discovery and 
replication analysis). Furthermore, the study also confirmed the association of 11 
previously identified susceptibility loci, showing the great replicability of the study. The 
ADAMTS7 locus is among these 5 newly identified loci, with the lead SNP rs4380028, 
residing at 7.6 kb upstream of the ADAMTS7 gene, with risk allele C occurring at a 
frequency of 65% in the European population (Coronary Artery Disease Genetics 
2011)(Figure 1.4). 
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Figure 1.4 C4D Manhattan plot. The ADAMTS7 locus was identified with the SNP rs4380028 
as leading SNP to be associated with CHD. Figure cited from (Coronary Artery Disease Genetics 
2011).  
 
 
At the same time, CARDIoGRAM (Coronary ARtery DIsease Genome wide Replication 
And Meta-analysis) consortium performed a meta-analysis of 14 GWAS of CAD 
comprising 22,233 cases and 64,762 controls, all of European ancestry. They then 
genotyped the novel lead SNPs within the most promising loci, as well as a subset of 
previously reported CAD loci in up to 56,682 additional subjects (approximately half 
cases and half controls). Thirteen new loci were identified to be associated with CAD, and 
like the C4D study, this study showed very good replicability, with 10 of the 12 loci 
previously associated with CAD surpassing the genome-wide significance level. The 
CARDIoGRAM consortium also identified ADAMTS7 locus associated with CAD, but 
with a different lead SNP rs3825807, a non-synonymous SNP with the risk allele A 
(frequency 0.57) (Figure 1.5). Adenine to guanine nucleotide allele substitution results in 
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a Serine (Ser) to Proline (Pro) amino acid substitution in the pro-domain region of 
ADAMTS-7 protein (Schunkert et al. 2011). 
 
 
 
Figure 1.5 CARDIoGRAM Manhattan plot. Non-synonymous SNP rs3825807 in the 
ADAMTS7 gene coding region was identified to be associated with CHD. Figure cited from 
(Schunkert et al. 2011). 
 
 
Several months later, another GWAS also reported ADAMTS7 as a novel locus for 
coronary atherosclerosis, with lead SNP rs1994016, residing in intron 8 of ADAMTS7 
gene, with risk allele C (frequency 0.6) (Figure 1.6). But more interestingly, this SNP was 
found not to be associated with myocardial infarction (Reilly et al. 2011), suggesting that 
ADAMTS-7 participates in the development and early progression of atherosclerosis but 
not plaque rupture and thrombosis leading to myocardial infarction. 
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Figure 1.6 Lancet GWAS ADAMTS7 locus. Association of rs1994016 (risk allele C 60%) at the 
ADAMTS7 locus: (A) significant with angiographic CAD (AngCAD vs control); (B) not with 
early-onset myocardial infarction (MI vs control). Figure cited from (Reilly et al. 2011). 
 
 
Finally, the latest attempt to increase the power to identify the polygenic component of 
CAD, CARDIoGRAM and C4D consortium combined forces to form the largest GWAS 
meta-analysis of CAD undertaken to date, CARDIoGRAMplusC4D consortium, which 
involved over 190,000 individuals (63,746 cases/130,681 controls). Fifteen new loci 
associated with the disease were identified and brought the susceptibility loci count up to 
46. It is noteworthy that the ADAMTS7 locus was replicated to be associated with CAD, 
with rs7173743 as lead SNP, with risk allele T frequency 0.58 (Deloukas et al. 2013).  
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All these GWAS indicate that ADAMTS7 is a possible causal gene for CAD, but it 
remained unclear as to whether any of these SNPs, or other SNPs in LD have functional 
effects on ADAMTS7 expression/activity and have an effect on the biological processes 
related to CAD. The key question of how ADAMTS-7 plays a role in the pathogenesis of 
CAD needs to be further addressed.  
 
1.5 Extracellular matrix proteases and atherosclerosis  
 
Physiologically, remodelling of the ECM is an integrated process of tissue development 
and maintenance. Overall, proteolytic activity is essential in aiding cell migration, removal 
of damaged tissue, and synthesis of new proteins which need to undergo all appropriate 
quality control checks (Skjot-Arkil et al. 2010). ECM remodelling also plays an important 
role in many pathological conditions, namely, in atherosclerosis, as discussed in section 
1.2. VSMC migration from media to intima requires matrix proteases to catalyse the 
removal of the basement membrane around VSMC and to facilitate the cell’s interaction 
with the interstitial matrix. This could promote the VSMC switch from a quiescent and 
contractile phenotype to a migrating and proliferating phenotype, to mediate tissue repair. 
Moreover, degradation of ECM could free sequestered growth factors surrounding VSMC 
and produce new matrix fragments to further promote VSMC migration and proliferation. 
In addition, plaque rupture which accounts for more than 80% of fatal MI in men results 
from net destruction of the ECM primarily driven by matrix proteases (Newby 2005). 
Almost all types of cells in atherosclerotic plaques including macrophages, SMCs, 
endothelial cells and T lymphocytes can produce a variety of proteinases which have been 
implicated in ECM degradation and in the pathogenesis of atherosclerosis (Murphy and 
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Nagase 2008). For example, the ECM molecule thrombospondin-5 (TSP-5), the best 
studied substrate of proteinase ADAMTS-7 which has been identified by GWAS as a 
susceptible gene for CHD, could maintain the contractile phenotype of SMC, thus the 
degradation of this ECM molecule by ADAMTS-7 leads to SMC migration from media 
to intima and contributes to the plaque growth (Wang et al. 2009).  
 
1.5.1 Matrix metalloproteinase family (MMPs) 
 
A major enzyme group involved in ECM remodelling is that of the matrix 
metalloproteinases (MMPs) (Murphy and Nagase 2008). MMPs are a family of zinc-
containing proteolytic enzymes that share similar structure, especially from the 
arrangement of conserved domains, but differ in substrate specificity, their cellular source 
and inducibility. At present, 23 members of this family have been identified (Creemers et 
al. 2001). Numerous studies have demonstrated the presence of MMPs in atherosclerotic 
plaques and their involvement in the pathogenesis of atherosclerosis. Henney and 
colleagues were the first to demonstrate that stromelysins (a subgroup of the MMP family) 
are expressed in both macrophages and SMCs in atherosclerotic plaques (Henney et al. 
1991). Subsequently, Galis and colleagues showed that MMP-1, -3, and -9 are present at 
the protein level in macrophages, SMCs, lymphocytes, and endothelial cells, with 
particular concentration in the vulnerable shoulder regions of plaque (Galis et al. 1994). 
Multiple members of the MMP family have now been reported to be involved in the 
pathogenesis of atherosclerosis, linking their expression with CVD, as reviewed by Galis 
and colleagues (Galis and Khatri 2002).  
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1.5.2 The “A disintegrin and metalloproteinase” (ADAM) family 
 
The ADAMs are a family of both transmembrane and soluble proteolytic enzymes. 
Evidence suggests that members of this family are involved in the pathogenesis of CVD. 
For instance, Donners and colleagues showed that ADAM-10 was expressed in 
atherosclerotic plaques and associated with neovascularization through its interaction with 
VEGFR2 and mediation of VEGFR2 ectodomain shedding. In addition, they also reported 
that ADAM-10 could mediate VE-cadherin cleavage, increasing endothelial layer 
permeability and thus, leukocyte transmigration. Inhibition of ADAM-10 was shown to 
reduce endothelial cell and monocyte migration, which further confirmed that ADAM10 
plays a critical role in the pathogenesis of atherosclerosis (Donners et al. 2010). Also, it 
has been shown that the expression of ADAM-15 and ADAM-9 in human atherosclerotic 
plaques is seven-fold and nine-fold higher than in normal arteries (Al-Fakhri et al. 2003). 
Another member of this family, ADAM-17, was also reported to be involved in 
atherosclerosis (Holdt et al. 2008). However, the function of this family has not been well 
characterised, and therefore further studies are still required to understand their 
mechanisms of action in health and disease.  
 
1.5.3 The “ADAM with thrombospondin type-1 motifs” (ADAMTS) family 
 
ADAMTSs are a family of proteinases which are structurally and evolutionarily related to 
the ADAMs and more distantly related to MMPs (Jones and Riley 2005) (Figure 1.7). In 
contrast to ADAMs and MMPs, all members of this family are secreted metalloproteinases 
with a conserved ancillary domain containing one or more thrombospondin type-1 like 
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repeats (TS) (Apte 2009). Following secretion, ADAMTS proteases may anchor to the 
cell-surface, such as in the case with ADAMTS-7 (Somerville, Longpre et al. 2004), 
ADAMTS-9 (Somerville et al. 2004a, Somerville et al. 2004b, Koo et al. 2006) and 
ADAMTS-10 (Somerville, Jungers et al. 2004). Other ADAMTSs, on the other hand, 
anchor to the extracellular matrix (i.e. ADAMTS-1 and ADAMTS-5) (Kuno and 
Matsushima 1998, Somerville et al. 2003).  
 
 
 
Figure 1.7 Schematic representations of MMP, ADAM and ADAMTS structure. These three 
families of proteinases are structurally and evolutionarily related, especially with respect to their 
domain regions, all belong to the metzincin superfamily (Porter et al. 2005, Paulissen et al. 2009). 
Figure cited from (Paulissen et al. 2009). 
 
 
Like most zinc metalloproteases, ADAMTS proteases are synthesised as inactive 
zymogens. Proprotein convertases (PCs) will further process these zymogens by removing 
their pro-domain making these proteases active (Nakayama 1997, Zhou et al. 1999, 
Bergeron et al. 2000, Thomas 2002). Thus, these PCs have been demonstrated to have 
important roles in connective tissue organization, coagulation, inflammation, arthritis, 
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angiogenesis and cell migration (Apte 2004). Similar principles govern activation of some 
MMPs (Pei and Weiss 1995, Yana and Weiss 2000) and ADAMs (Cao et al. 2002, 
Leonard et al. 2005).  
 
Furin is the best studied of the PCs implicated in proprotein processing within the 
constitutive secretory pathway and is the major PC to activate the ADAMTS proteases 
(Thomas 2002). Furin mostly resides in the trans-Golgi network (TGN), and thus the pro-
domain processing that it mediates typically occurs intracellularly. But furin has also been 
detected at the plasma membrane (Mayer et al. 2003, Mayer et al. 2004) and as well as a 
shed, soluble form (Vidricaire et al. 1993). Previous studies on ADAMTS-1 (Kuno et al. 
1999, Longpre and Leduc 2004), ADAMTS-4 (Wang et al. 2004), and ADAMTS-7 
(Somerville et al. 2004) suggested that their zymogens were processed in the TGN by PCs, 
although some cell-surface processing of ADAMTS-7 was also observed (Somerville et 
al. 2004). ADAMTS-9 processing by furin was reported to occur at the cell-surface (Koo 
et al. 2006). Interestingly, the pro-domain processing of ADAMTS-9 was found to 
diminish its proteolytic activity against versican (Koo et al. 2007). Previously, analysis of 
ADAMTS-13 had shown no role for its propeptide in enzyme latency (Majerus et al. 2003). 
Thus, it appears that different mechanisms are used to process the pro-domain of the 
different members of the ADAMTS family, and that pro-domain cleavage can lead to 
activation in some ADAMTS family members but result in reduced activity in the case of 
ADAMTS-9 (Longpre et al. 2009). 
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To date, 19 members of this family have been identified in humans. Based on their 
sequence similarities and known substrates, the family members can be categorised into 
seven subgroups (Table 1.2). Among these subgroups, subgroup (a) is known as 
aggrecanases for their ability to process aggrecan; subgroup (b) can cleave the N-peptide 
of procollagen and thus are called procollagen N-proteinases; while subgroup (g)  only 
has ADAMTS-13, vWFCP (von Willebrand factor-cleaving protease), which is least like 
any other ADAMTS (Porter et al. 2005). The functions of the rest ADAMTS family 
members have not been clearly revealed yet.  In contrast to the MMP family, whose 
substrates are of much more broad-spectrum, ADAMTS family members have high 
substrate specificity, because the C-terminal ancillary regions of the enzymes, which 
influence protein recognition and matrix localization, reduce the risk of off-target effects.   
 
Table 1.2 Subgroups of ADAMTS family 
Subgroup  Function Member of ADAMTS family 
(a) aggrecanases ADAMTS-1,-4,-5,-8 and -15 
(b) procollagen N-proteinases ADAMTS-2,-3 and -14 
(c) Unknown ADAMTS-9 and -20 
(d) Unknown ADAMTS-7, -12 and ADAMTS-6, -10 
(e) Unknown ADAMTS-16 and -18 
(f) Unknown ADAMTS-17 and -19 
(g) vWFCP ADAMTS-13 
 
 
Several studies have demonstrated the involvement of ADAMTS family members in CVD. 
ADAMTS-1 has been shown to be localised to SMCs and macrophage foam cells in 
vascular lesions, and has been important in cleavage of versican (Jonsson-Rylander et al. 
2005, Wight 2005). In human fatty streak lesions, Jonsson-Rylander and colleagues 
 55 
observed ADAMTS-1 staining with stronger intensity in the VSMCs and foam cells in the 
lesion compared with the media layer, and in their in vitro cell experiments, they found 
significantly more ADAMTS-1 expression in migrating and proliferating VSMCs. 
Furthermore, in their in vivo model, they observed increased intimal hyperplasia when 
comparing ADAMTS-1 transgenic/ApoE-deficient mice with ApoE deficiency (Jonsson-
Rylander et al. 2005).  
 
ADAMTS-4 and ADAMTS-8 have also received attention due to their expression in 
macrophage-rich areas of human carotid atherosclerotic plaques and coronary unstable 
plaques. (Wagsater et al. 2008). It has been shown that there is an association of 
ADAMTS-4 serum levels with the presence and severity of CHD (Zha et al. 2010, Chen 
et al. 2011). ADAMTS-1 and ADAMTS-8 have also been revealed to have anti-
angiogenic activity (Vazquez et al. 1999).  
 
ADAMTS-13, also known as von Willebrand factor-cleaving protease (vWFCP), is 
required for proteolytic modification of the von Willebrand Factor to an optimal size for 
proper coagulation (Zheng et al. 2002). vWF is a carrier protein for clotting factor VIII, 
supports platelet aggregation, and also mediates platelet adhesion to areas of vascular 
damage by binding to both the surface glycoproteins of platelets and to the exposed ECM 
components (Soejima et al. 2001, Porter et al. 2005). Mutations in ADAMTS-13 cause 
thrombotic thrombocytopenic purpura (TTP) (Levy et al. 2001, Apte 2004). However, 
knowledge of the ADAMTS family protease is still very limited, and functions of the 
majority members in this family remains to be further investigated. 
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1.6 ADAMTS-7  
 
1.6.1 Identification and protein domain organization 
 
ADAMTS7 is a protein coding gene, which has 24 exons and maps to chromosome 15q24 
and spans 52.3 kb of genomic sequence in human. The protein encoded by the gene 
ADAMTS7 is a member of ADAMTS family. It was first identified and cloned in 1999 by 
Hurskainen et al. They identified ADAMTS-7 with two thrombospondin type-1 like 
repeats, having a similar domain structure to ADAMTS-5, -6 and -8 (Hurskainen et al. 
1999). However, in 2004, the same group reported a longer form of ADAMTS-7, or 
ADAMTS-7B. This was later characterised as the full-length version of the enzyme. They 
postulated that the previously cloned ADAMTS-7 may have an incomplete C terminus. 
The full length ADAMTS-7 has a domain organization similar to that of ADAMTS-12, 
with a total of eight TS repeats in its ancillary domain. The ADAMTS-7 protein is 
composed of 1686 amino acids with predicted molecular weight of 181 kDa (excluding 
the signal peptide) (Somerville et al. 2004). 
 
Similar to other members of the ADAMTS family, ADAMTS-7 is initially synthesised as 
a zymogen which contains a signal peptide, a pro-domain, a catalytic metalloproteinase 
domain, a disintegrin-like domain, a central TS repeat, a cysteine-rich domain (CRD), and 
7 additional TS repeats interspaced with two cysteine-free spacer domains. The secondary 
spacer domain is also a mucin-like domain, and like many ADAMTS proteases (e.g. 
ADAMTS-2, -3, -6, -10, -12, -16 and -19), ADAMTS-7 has a C-terminal PLAC (protease 
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and lacunin) domain containing six cysteines in the expected arrangement (Figure 1.8) 
(Somerville et al. 2004, Hanby and Zheng 2013, Patel and Ye 2013).  
 
 
 
Figure 1.8 Structure of ADAMTS-7. ADAMTS-7 shares similar structure with other members 
of the family, with a totally of eight TSP-1 like repeats in its C-terminal ancillary domain.  
 
 
1.6.2 Expression, localization and regulation 
 
1.6.2.1 Expression 
 
ADAMTS-7 is widely distributed in adult human tissues. ADAMTS7 expression was 
detected as a 5.5 kb transcript with heart, pancreas, kidneys, skeletal muscle, and liver 
having the highest level of expression. Two additional transcripts of 8 kb and 4.5kb were 
also found in skeletal muscle (Liu et al. 2006). ADAMTS7 mRNA has been found in 
normal human bone, cartilage, synovia, tendon, and ligament as well as in meniscus, 
skeletal muscle, and fat at lower levels (Liu et al. 2006, Hanby and Zheng 2013). The 
ADAMTS7 gene expression was also found in mouse embryos (Somerville et al. 2004). In 
a more recent study, RT-PCR in various rat tissues detected ADAMTS7 mRNA in the liver, 
embryo, ovaries, kidneys, testicle, lung, and thymus, and at lower levels in the spleen, 
heart, and brain.  Low levels of ADAMTS7 mRNA and protein in normal rat vascular walls 
was also reported by Wang and colleagues (Wang et al. 2009).  
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1.6.2.2 Localization 
 
Like all other members of ADAMTS family enzyme, ADAMTS-7 is a secreted protein, 
however, evidence supports the notion that ADAMTS-7 could attach to the cell membrane 
after secretion. Conditioned media of HEK293 cells stably expressing Myc-tagged murine 
ADAMTS-7 exhibited a band with molecular weight of 250 kDa by SDS-polyacrylamide 
gel electrophoresis (SDS-PAGE) and western blotting. The discrepancy in the observed 
ADAMTS-7 size compared to the predicted molecular weight maybe due to glycosylation 
as there are several potential glycosylation sites within the ADAMTS-7 sequence.  
Treatment of stable cells expressing ADAMTS-7 with 0.5M NaCl for 30 min, which 
released more ADAMTS-7 in the conditioned media, supports the cell surface localization 
theory of secreted ADAMTS-7. Moreover, ADAMTS-7 was detectable by surface 
biotinylation experiments, and in some cells, recombinant ADAMTS-7 appears to be 
transiently associated with the outer leaflet of the plasma membrane. All these findings 
indicate that ADAMTS-7 could be in close proximity to the cell membrane (Somerville 
et al. 2004, Hanby and Zheng 2013).   
 
1.6.2.3 Regulation 
 
ADAMTS-7 production can be regulated by cytokines, growth factors and free radicals. 
Wang et al. (2009) showed that both the mRNA and protein of ADAMTS-7 in VSMCs 
were induced by the proinflammatory cytokines TNF-α and IL-1β, and by the growth 
factor PDGF-BB. Elevation of ADAMTS-7 level in VSMC by TNF- α was time-and dose-
dependent as detected by RT-qPCR and Western blotting (Wang et al. 2009). Similarly, 
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Wagsater et al (2008) showed that the ADAMTS7 mRNA level was up-regulated by TNF-
α in the human monocyte/macrophage cell line THP-1 (Wagsater et al. 2008). Reactive 
oxygen species (ROS), such as hydrogen peroxide (H2O2), also increased ADAMTS7 
expression in VSMCs (Wang et al. 2009). In contrast, anti-inflammatory factor TGF-β 
downregulated ADAMTS7 expression (Chait and Wight 2000). Interestingly, 
proatherosclerotic factors, including ox-LDL and homocysteine, did not alter ADAMTS7 
expression in VSMCs (Wang et al. 2009, Hanby and Zheng 2013).  
 
Further studies revealed that ADAMTS7 expression could be transcriptionally regulated. 
Analysis of the ADAMTS7 promoter by using of the programs TESS and TFSEARCH 
revealed the presence of proinflammatory element binding sites, including transcription 
factor NF-κB and AP-1 sites. Chromatin immunoprecipitation (ChIP) assay confirmed the 
binding of NF-κB and AP-1 to the predicted binding sites within the ADAMTS7 promoter. 
Inhibition of NF-κB and AP-1 pathway by application of an ectopic IκB adenovirus or c-
Jun dominant-negative adenovirus ameliorated TNF-α induced ADAMTS7 elevation in 
VSMCs by 61% and 44%, respectively, whereas application of the two viruses together 
completely abolished TNF-α induced ADAMTS7 upregulation (Wang et al. 2009, Hanby 
and Zheng 2013). These data suggest that ADAMTS7 expression can be regulated at 
transcriptional level, and NF-κB and AP-1 are essential for TNF-α mediated ADAMTS7 
induction.  
 
A recent study provided evidence that ADAMTS7 expression could also be regulated by 
microRNA (miRNA). A miRNA is a small, non-coding RNA molecule, classically 22-
 60 
nucleotides long, which functions via base-pairing with complementary sequences within 
mRNA molecules of a target gene, usually resulting in gene silencing via translational 
repression or target mRNA degradation. A Bioinformatics database search predicted a 
target site for miR-29a/b in the 3’ untranslated region (UTR) of ADAMTS7, and 
experiments showed that a miR-29a/b mimic reduced ADAMTS7 mRNA and protein 
expression in VSMC, whereas anti-miR-29a/b increased ADAMTS7 expression levels (Du 
et al. 2012). These data suggest that miR-29a/b negatively regulates ADAMTS7 expression 
(Wang et al. 2010, Hanby and Zheng 2013).  
 
1.6.3 Activation 
 
The active or mature form of ADAMTS-7 is derived by cleavage of the pro-domain by 
proprotein convertases, such as furin. There are three conserved pro-domain processing 
sites (RVLR58, RVLRKR60 and RQQR220, mouse ADAMTS-7 sequence annotation) in 
both human and mouse ADAMTS-7 pro-domain. However, human ADAMTS-7 has four 
additional furin processing sites which are not present in mouse. The pro-domain seems 
to be processed sequentially, as shown by experiments using a short form of Myc/His-
tagged ADAMTS-7 consisting of the pro-domain and metalloprotease domain, designated 
ADAMTS-7Pro-Cat-Myc/His. SDS-PAGE of His-tagged proteins from mouse ADAMTS-7Pro-
Cat-Myc/His –expressing HEK293 cells demonstrated two major protein bands of 50 kDa and 
29 kDa on Coomassie Blue-stained gels, with several quantitatively minor intermediate 
bands. Western blotting using anti-c-Myc antibody demonstrated that these bands 
correspond to major forms of ADAMTS-7Pro-Cat-Myc/His. The amino acid sequence of the 
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50 kDa and 29 kDa major bands obtained by Edman degradation were 61DVSTTQ and 
221SVSKEK, respectively, indicating processing following RVLRKR60 (50 kDa band) and 
RQQR220 (29 kDa band). The amino acid sequence of the 29 kDa band from human was 
237SVSKEKW, similar processing site but in human ADAMTS-7 annotation (Somerville 
et al. 2004). It is not very clear where the pro-domain processing cellular site is located, 
whether it is intracellular (Golgi apparatus, by intracellular furin) or happens on the cell 
surface. It is possible that both of these mechanisms exist, depending on the tissue and/or 
cell type.  
 
So far, furin has been proved to be the major proprotein convertase for ADAMTS-7. CHO 
RPE.40 cells, which are furin-deficient, were used to determine which proprotein 
convertases could process ADAMTS-7. Cotransfection of this cell line with mouse 
ADAMTS-7Pro-Cat-Myc/His and furin, PACE4, PC6B or PC7 revealed that furin was able to 
process ADAMTS-7 completely to the mature form (29 kDa). But the other proprotein 
convertases (PACE4, PC6B and PC7) processed ADAMTS-7 inefficiently to its mature 
form (Somerville et al. 2004).  
 
1.6.4 Potential substrates of ADAMTS-7  
 
As with other ADAMTS family members, ADAMTS-7 is likely to have high substrate 
specificity, with three potential ADAMTS-7 substrates reported to date. These include 
TSP-5 (also known as cartilage oligomeric matrix protein, COMP); progranulin (PGRN, 
also designated granulin-epithelin precursor, GEP) and alpha2-macroglobulin (A2M). 
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ADAMTS-7 can cleave TSP-5, A2M inhibits ADAMTS-7 mediated TSP-5 cleavage 
while GEP also disturbs TSP-5 cleavage by ADAMTS-7 by forming complex protein-
protein networks (Luan et al. 2008, Hanby and Zheng 2013).  
 
1.6.4.1 TSP-5 – the best-studied substrate of ADAMTS-7 
 
TSP-5, the fifth member of the TSP family, also known as Cartilage Oligomeric Matrix 
Protein (COMP), is a 520 kDa pentameric glycoprotein with five identical subunits. It is 
highly expressed in the cartilage of joints, tendons, ligaments and vascular ECM (Riessen 
et al. 2001). TSP-5 is the best-known substrate of ADAMTS-7. Human TSP-5 mutations 
have been linked to two different autosomal-dominant forms of short-limb dwarfism: 
pesudoachondroplasia and multiple epiphyseal dysplasia, characterised by short stature, 
epiphyseal abnormalities, and early-onset osteoarthritis (Liu et al. 2006).  
 
To date, most research on TSP-5 has focused on its role in bone and joint diseases. 
Fragments of TSP-5 have been detected in diseased cartilage, synovial fluid, and serum 
of patients with knee injuries, posttraumatic, primary osteoarthritis and rheumatoid 
arthritis (Liu et al. 2006). Several MMPs have been reported to degrade TSP-5 in vitro, 
including MMP-1, -3, -9, -13, -19 and -20. ADAMTS-4 has also been reported to cleave 
TSP-5 in vitro (Liu et al. 2006). However, the role of these proteases in TSP-5 degradation 
remains to be elucidated in in vivo animal models. ADAMTS-7 was identified as TSP-5 
binding partner by a yeast two-hybrid screen using TSP-5 EGF-like domains as a bait. 
The direct interaction between TSP-5 and ADAMTS-7 was further characterised by using 
in vitro GST pull-down assays, indicating that purified human TSP-5 directly binds to the 
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C-terminus of ADAMTS-7. This interaction was verified using a coimmunoprecipitation 
(Co-IP) assay (Liu et al. 2006). Using ADAMTS-7 deletion mutants, the four C-terminal 
TS repeats of ADAMTS-7 were verified to be responsible for binding with TSP-5 EGF-
like domain. More importantly, the same research group demonstrated that recombinant 
ADAMTS-7 cleaved TSP-5 in vitro, and the cleavage of TSP-5 by ADAMTS-7 was zinc 
ion and pH-dependent (Liu et al. 2006).  
 
Several studies have also suggested an important role of TSP-5 in vascular disease. TSP5 
mRNA and protein expression were detected in cultured human VSMCs by Northern 
blotting and immunoprecipitation, and were found to be increased by growth factors TGF-
β1 and TGF-β3 stimulation (Riessen et al. 2001). In vitro attachment assays demonstrated 
strong adhesion of VSMC to TSP-5 coated surfaces (Riessen et al. 2001). TSP-5 coated 
membranes also supported the migration of VSMC indicating TSP-5 may play a critical 
role in the adhesion and migration of VSMC (Riessen et al. 2001).  Furthermore, TSP-5 
has not only been found in normal human vessels but also in atherosclerotic and restenotic 
human arteries (Riessen et al. 2001). Strong staining of TSP-5 was found on the vast 
majority of VSMCs in human atherosclerotic and restenotic lesions (Riessen et al. 2001). 
These data indicate that TSP-5 may play a role in the pathogenesis of vascular disease 
setting such as atherosclerosis through regulating VSMC adhesion and migration (Riessen 
et al. 2001). More recent studies have underscored the important role of TSP-5 in vascular 
disease (Wang et al. 2009, Du et al. 2011). First, these studies demonstrated that 
ADAMTS-7 facilitated VSMC migration through cleaving TSP-5 (Wang et al. 2009). 
TSP-5 was shown to maintain the contractile and quiescent phenotype of VSMCs by 
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interacting with α7β1 integrin, and it was shown that cleavage of TSP-5 by ADAMTS-7 
could switch VSMC phenotype from a quiescent one to a migratory one, facilitating 
VSMC migration and neointima formation after artery injury (Wang et al. 2009). Another 
study revealed that TSP-5 bound directly to bone morphogenetic protein-2 (BMP-2) 
through its C terminus and that inhibited BMP-2 receptor binding blocked BMP-2 
osteogenic signaling, indicating that TSP-5 inhibits osteochondrogenic transition of 
VSMC and that TSP-5 is a novel inhibitor of vascular calcification (Du et al. 2011).  
 
1.6.4.2 Granulin-epithelin precursor (GEP) 
 
GEP, also known as progranulin, proepithelin, or plasma cell-derived growth factor, is a 
88 kDa (593-aa) growth factor that is secreted from cells. GEP contains seven and a half 
repeats of a cysteine-rich motif in the order of P-G-F-B-A-C-D-E, where A-G is full repeat, 
and P is the one-half motif (Jian et al. 2013). Cleavage of GEP by proteases liberates 
smaller, 6 kDa peptides, which are named granulin A, granulin B, granulin C, etc. 
Epithelin 1 and epithelin 2 are synonymous with granulin A and granulin B, respectively. 
These 6 kDa peptides possess biological activity of their own, such as the ability to inhibit 
thrombin (Hanby and Zheng 2013).  The precursor GEP has distinctive biological 
functions as well, for instance, it blocks the TNF-α signaling pathway by binding and 
exerting its anti-inflammatory activities through TNF receptors (Tang et al. 2011, Kawase 
et al. 2013). Granulin B, on the other hand, stimulates IL-8 expression in epithelial cells 
and is considered a proinflammatory molecule (Jian et al. 2013). GEP has also been 
implicated in wound healing, tumor growth and atherosclerosis. GEP is abundantly 
expressed in several human cancers, such as ovarian cancer (Davidson et al. 2004) and 
 65 
hepatocellular carcinoma (Ho et al. 2008). An anti-GEP monoclonal antibody reduced 
tumor cell proliferation and tumor angiogenesis with reduced microvessel density and 
tumor VEGF level. GEP knock-out mice exhibited severe atherosclerotic lesions 
compared with GEP wild type mice using an ApoE knock-out background mice model 
(Kawase et al. 2013). These findings suggest great complexity of its role in human 
diseases.  
 
Several proteinases have been reported to cleave GEP, including MMP-9, -12, and -14, 
elastase, and proteinase 3 (Jian et al. 2013). The interaction between ADAMTS-7 and 
GEP was revealed by a yeast two-hybrid assay, and a Co-IP assay further verified this 
interaction in vivo. Subsequent experiments demonstrated that 4 C-terminal TS repeats of 
ADAMTS-7 are required and sufficient for its interaction with GEP; each granulin unit of 
GEP but not the partial repeat is sufficient for binding to ADAMTS-7 C-terminal TS 
repeats. In an in vitro digestion assay, a recombinant ADAMTS-7 catalytic domain was 
able to cleave GEP and liberate smaller fragments (Bai et al. 2009). More fragments were 
observed when using intact ADAMTS-7 rather than using the catalytic domain alone, 
indicating that the full length of ADAMTS-7 cleaves GEP more efficiently. These data 
indicate that ADAMTS-7 is a novel GEP convertase (Bai et al. 2009). However further 
evidence is needed. In addition, studies also demonstrated that GEP can interact with TSP-
5 and disrupt the cleavage of TSP-5 by ADAMTS-7, indicating these proteins act in 
concert to form protein-protein networks (Xu et al. 2007, Guo et al. 2010).  
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1.6.4.3 Alpha2-macroglobulin (A2M) 
 
A2M, a member of the macroglobulin family, is a high-molecular weight homotetrameric 
glycoprotein found in the blood circulation of different species (Luan et al. 2008). The 
A2M molecule is synthesised mainly in the liver, but also locally by macrophages, 
fibroblasts, and adrenocortical cells. Human A2M is found at relatively high levels (2-4 
mg/ml) in plasma and is the largest major non-immunoglobulin protein in plasma (Luan 
et al. 2008). Native A2M is composed of four identical 185 kDa subunits bound together 
via disulfide bonds, each of which has a unique sequence of amino acids that is susceptible 
to be cleaved by various proteases. Cleavage of this region, termed the ‘bait region’, 
triggers a conformational change in the structure of A2M and consequent entrapment of 
the proteases. Α2M does not inactivate the entrapped proteases, but instead, it hinders the 
access of substrates to the active site of the proteases. Thus the major function of A2M is 
inhibition of proteases (Hanby and Zheng 2013, Rehman et al. 2013). Α2M may act as a 
carrier protein because it binds to numerous growth factors and cytokines such as PDGF, 
basic fibroblast growth factor (b-FGF or FGF-2), TGF-β, TNF-α, IL-1β and IL-6. The 
biological activity of some growth factors and cytokines is inhibited when bound to A2M, 
like that of b-FGF, TNF-α and IL-1β, while some remain active, such as PDGF and IL-6 
(Rehman et al. 2013).  
 
ADAMTS-7, both in the intact and the truncated recombinant catalytic form, was 
demonstrated to be able to cleave A2M, as shown by altered migration of the protease and 
proteolysis of A2M by SDS-PAGE (Somerville et al. 2004). ADAMTS-7 was able to 
cleave A2M in vitro, giving rise to a major cleavage product with molecular weight 180 
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kDa and a faint fragment with molecular weight 105 kDa. Thus A2M can be considered a 
substrate of ADAMTS-7, and more importantly, A2M is the first identified endogenous 
inhibitor of ADAMTS-7 as A2M inhibits ADAMTS-7 mediated TSP-5 cleavage (Luan et 
al. 2008).  
 
1.6.5 ADAMTS-7 and bone and joint disease  
 
For years, investigation of the physiological roles of ADAMTS-7 has largely focused on 
its association with the pathogenesis of arthritis and disc disease. It is because of the 
observation that TSP-5 is predominantly found in the cartilage ECM, accounting for 1% 
of the wet weight of cartilage, and most importantly, increased fragments of TSP-5 were 
detected in the serum and synovial fluid of patients suffering from rheumatoid arthritis 
and osteoarthritis (Liu et al. 2006, Hanby and Zheng 2013). ADAMTS7 over-expression 
was also observed in the cartilage and synovium of patients with rheumatoid arthritis. In 
vitro cleavage of TSP-5 by recombinant ADAMTS-7 showed the same TSP-5 cleaved 
fragments as those found in the serum and synovial fluid of patients with rheumatoid 
arthritis and osteoarthritis (Liu et al. 2006). A series of studies suggested that under 
physiological conditions, the expression of normal levels of ADAMTS7 maintains the 
basal levels of TSP-5 cleavage in chondrocytes for chondrogenesis. However, in 
pathological states where ADAMTS7 expression is up-regulated, the excess TSP-5 
cleavage results in degenerative and inflammatory diseases of the joints and intervertebral 
discs (Liu et al. 2006, Xu et al. 2007, Bai et al. 2009, Hanby and Zheng 2013). 
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1.6.6 ADAMTS-7 and cardiovascular disease 
 
ADAMTS-7 was first demonstrated to play a role in the pathogenesis of vascular disease 
in 2008. A study using a rat balloon injury model demonstrated that ADAMTS-7 
facilitated VSMC migration by cleaving TSP-5 and promoted neointima formation 
following vascular mechanical injury (Wang et al. 2009). Neointima formation is regarded 
as an aggressive response to vessel injury such as that seen following coronary stent 
implantation (Patel and Ye 2013). Wang et al. demonstrated an initial decrease of 
ADAMTS-7 protein levels in the vessel wall within the first 24h after vascular injury, 
followed by a subsequent increase up to 2 weeks with maximal expression after 1 week. 
Notably, ADAMTS-7 accumulated preferentially in the neointima and colocalised with 
VSMCs (Wang et al. 2009). Overexpression of ADAMTS7 in VSMCs by an adenovirus 
infection method enhanced VSMC migration/invasion in in vitro experiments and 
increased neointima formation in vivo, while suppression of ADAMTS7 by small 
interfering RNA (siRNA) retarded VSMC migration in vitro and ameliorated neointima 
formation in response to injury in vivo  (Wang et al. 2009). ADAMTS-7 may exert its 
effect on VSMC migration by cleavage of its primary substrate TSP-5. TSP-5 fragments 
increased parallel to ADAMTS-7 levels following mechanical injury of rat carotid artery. 
Similarly, ADAMTS7 overexpression greatly decreased the full-length TSP-5 and 
increased fragments of TSP-5, while suppression of ADAMTS7 had the opposite effect. 
Furthermore, replenishment of TSP-5 by adenovirus infection method attenuated 
ADAMTS-7 mediated VSMC migration (Wang et al. 2009). Concordant results were 
shown recently in a mouse ADAMTS-7 knockout model where the loss of ADAMTS-7 
led to reduced neointima formation following carotid artery injury induced by ligation 
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(Aherrahrou et al. 2011). Since VSMC migration is an important process in atherogenesis 
while neointima formation is very relevant to restenosis after angioplasty, the results of 
these studies implicate ADAMTS-7 as an important player in the pathogenesis of CVDs. 
 
The importance of ADAMTS-7 in CVD has now been further confirmed by GWAS, with 
several SNPs in the ADAMTS7 gene locus found to be significantly associated with 
coronary artery disease (Coronary Artery Disease Genetics 2011, Reilly et al. 2011, 
Schunkert et al. 2011). However, it has remained unclear as to whether any of these SNPs 
found by GWAS or other SNPs in LD with them has a functional effect on ADAMTS7 
expression/activity and has an effect on the biological processes related to CAD. 
Functional studies of these variants at the ADAMTS7 gene locus will provide possible 
mechanisms underlying these associations.    
 
Furthermore, how ADAMTS-7 is involved in the pathogenesis of CAD needs to be further 
investigated. Although TSP-5 is being considered the primary substrate of ADAMTS-7, 
more substrates of ADAMTS-7 may emerge and further studies will extend our 
understanding of the disease pathogenesis and indicate possible therapeutic targets for the 
disease. 
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1.7 Hypothesis and Aims 
 
1.7.1 Hypothesis 
 
SNPs at the ADAMTS7 locus could affect ADAMTS7 mRNA expression and/or protein 
activity. Through this mechanism, these SNPs regulate VSMC and/or EC cell behaviours 
(i.e. proliferation, migration, senescence and/or apoptosis) and the development of 
atherosclerosis (Figure 1.9). 
 
 
            Figure 1.9 Hypothesis  
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1.7.2 Aims: 
 
1. To investigate effects of CAD-associated variants of the ADAMTS7 gene on 
proliferation, senescence, apoptosis and migration of VSMCs and ECs.  
 
2. To study whether CAD-associated variants of the ADAMTS7 gene influence 
ADAMTS7 gene expression in VSMCs and/or ECs.  
 
3. To investigate whether CAD-associated variants of the ADAMTS7 gene affect 
ADAMTS-7 protein maturation/activation and TSP-5 cleavage.  
 
4. To investigate effects of CAD-associated variants of the ADAMTS7 gene on 
angiogenesis 
 
5. To investigate effects of ADAMTS-7 on angiogenesis and related mechanisms. 
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Chapter 2 Materials and Methods 
 
2.1 Cell culture 
 
2.1.1 Human vascular smooth muscle cells (VSMCs) isolation and culturing 
 
The protocol for isolating and utilising VSMCs from umbilical cords was approved by the 
appropriate ethics committee. We used a well-established method (Motterle et al. 2012) 
to isolate the VSMCs. Briefly, umbilical cords were collected from The Royal London 
Hospital and placed in physiological saline solution (PSS) buffer for short preservation. 
Umbilical cords were then put in the Dulbecco's Modified Eagle's Media (DMEM, Sigma) 
and arteries were dissected out. After carefully removing the adventitia, the vessel was 
divided into small segments and placed onto 0.2% gelatin (Sigma) coated T25 flasks. In 
order to facilitate attachment of the arterial segments to the flasks, the flasks were 
incubated in a humidified incubator 37˚C/5% CO2 (all cell culture work in this project was 
carried out under this condition unless otherwise stated) for 2 hours upright to drain excess 
media. Then DMEM, supplemented with 20% FBS (Gibco), 2mM L-glutamine (Sigma), 
1% penicillin and streptomycin (Sigma), was added into the flasks. The flasks were placed 
in an incubator for 7 days without any disturbance. After this period media were replaced 
every 2-3 days, until cells reached 70% confluence, the remaining tissue blocks were 
removed, and cells were harvested with 0.25% trypsin-EDTA (Sigma) and passaged into 
sterile T25 flasks coated with 0.04% gelatin.  
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VSMCs were maintained with Smooth Muscle Cell Growth Media 2 (PromoCell, detailed 
supplements of this media, please see Appendix Table 2.1.1). At about 90% confluence, 
cells were harvested and subcultured in the ratio of 1:3 to three new 0.04% gelatin coated 
T25 flasks with the Smooth Muscle Cell Growth Media 2. Passage 2 to passage 5 VSMCs 
were used in this project.  
 
2.1.2 Human umbilical vein endothelial cells (HUVECs) isolation and 
culturing 
 
HUVECs were generously donated by Centre for Biochemical Pharmacology of William 
Harvey Research Institute. They were isolated using a well-established method (Ulrich-
Merzenich et al. 2002). Briefly, umbilical cords were collected from The Royal London 
Hospital and placed in physiological saline solution (PSS) buffer for short time 
preservation. During the isolation, Hank's Buffered Salt Solution (HBSS) was perfused to 
remove the blood remaining inside the umbilical vein. Afterwards, 3 ml of collagenase 
type I (1mg/mL in HBSS) was injected inside the vein and incubated for 15 minutes at 
37℃ with agitation. Thereafter, 20 ml of M199 media supplemented with 10% human 
serum was used to neutralize the collagenase type I and to collect the free ECs. HBSS 
perfusion was followed aiming at collecting more cells. All cells were then centrifuged at 
250 g for 5 minutes at RT. The cell pellet was then resuspended in M199 media 
supplemented with 10% human serum and transferred to a (0.2%) gelatin-coated T75 flask 
and incubated at 37°C, under a 5% CO2 humidified atmosphere. 
 
 74 
Primary EC culture was maintained with M199 (Sigma) media supplemented 15% FBS 
(Gibco) and EC culture growth factors (Final growth factor supplements concentration as 
described in Appendix Table2.1.2). Once the cells reached 90-100% confluence, cells 
were harvested with trypsin-EDTA and subcultured in the ratio of 1:3 into three sterile 
T75 flasks coated with 0.04% gelatin. Supplemented M199 media, prepared on described 
above, was used to further culture. 
 
2.1.3 Human Embryonic Kidney 293 (HEK293) cell line culturing 
 
Human Embryonic Kidney 293 (HEK293) cells were generously provided by Dr. Sadani 
Cooray from the Centre for Biochemical Pharmacology, William Harvey Research 
Institute. As the name implies, HEK293 cells, an adherent cell line, was originally derived 
from human embryonic kidney cells. Briefly, they were obtained from an aborted healthy 
fetus without known identity of the mother and the reason for the abortion. Then, these 
cells were cultured and transformed with an adenovirus. The number, 293, indicates 293rd 
experiment. HEK293 cells are very easy to grow and to be transfected and have been 
widely used in cell biology research for many years.  
 
HEK293 cells were maintained in DMEM supplemented with 10% FBS, 2mM L-
glutamine, 1% Penicillin-Streptomycin. Media was replaced every 2 days. At 90% 
confluence, cells were detached by Trypsin-EDTA and re-suspended at 1:3 dilutions in 
new flasks containing fresh pre-warmed media.  
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HEK293T cells were a generous gift from Dr. Qingzhong Xiao. HEK293T cell line, a 
variant of HEK293 cell line, contains the SV40 Large-T-antigen which allows for 
amplification of transfected plasmids and extended temporal expression of the desired 
gene products. This cell line is commonly used for the production of various viral vectors. 
HEK293T cells were maintained in DMEM supplemented with 10% FBS at 37˚C 
incubator with a humidified atmosphere and 5% CO2. Media was replaced every 2 days. 
Once the cells reached 90% confluence, cells were harvested and re-suspended at 1:3 
dilutions in new flasks containing fresh pre-warmed media. 
 
2.1.4 Preservation and recovery of cells 
 
Both isolated primary VSMCs, HUVECs and HEK293 cell line were preserved in liquid 
nitrogen for long term storage. Cells were cultivated to confluence, detached by Trypsin-
EDTA and re-suspended in freezing media (10% dimethylsulfoxide, 40% DMEM and 50% 
FBS) in cryovials at a concentration of 1 x 107 cells/ml. To prevent cell death during 
freezing, cells were initially taken down gradually to -80℃ using a freezing container 
(Nalgene® Mr. Frosty), and then transferred to liquid nitrogen for long-term storage.  
 
During recovery, cells were taken out from liquid nitrogen and transported on dry ice, 
quickly thawed by incubating at 37℃ in a water bath. After centrifuging at 250 g for 5 
minutes, cells were re-suspended in fresh pre-warmed media and plated onto appropriate 
tissue culture plastics for further experiments. 
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2.2 Immunocytochemistry of VSMC marker and ADAMTS-7 
 
Immunocytochemistry (ICC) is a commonly used technique, allowing visualisation of 
intracellular or extracellular proteins. This is achieved through the interaction between 
these proteins and their specific antibodies which are in turn labeled with enzymes or 
fluorophores. These tags develop color change or fluorescence which can be detected to 
show the localisation and/or interaction of proteins in any particular cell type. (For the 
titrations and the details for these antibodies used in ICC, see Appendix Table 2.2.1). 
 
VSMCs were harvested and seeded 25,000 cells per chamber well in 0.04% gelatin coated 
BD FalconTM 8 chamber culture slides (BD Biosciences) with Smooth Muscle Cell 
Growth Media 2, after 24 hours further culturing, ICC assays were performed. 
 
2.2.1 Verification of VSMCs by the specific marker alpha-actin 
 
To check the homogeneity of the isolated VSMCs cultures, immunocytochemistry was 
used to detect markers for VSMC (-smooth muscle actin, SMA), fibroblasts (DDR2) and 
ECs (CD144). 8 isolated primary VSMC cell lines from different individuals were chosen 
randomly for the immunocytochemical assays, 4 of which were subjected to double 
staining of alpha-actin and DDR2, the other 4 cells were stained with CD144. After 24 
hours culturing in BD FalconTM 8 chamber culture slides, cells were fixed with 4% 
paraformaldehyde in PBS for 15 minutes at room temperature. Thereafter, the cells were 
treated with (for double staining) or without 0.1% triton X-100 before blocking with 1% 
bovine serum albumin (BSA) in PBS for 30mins, and then incubated with a goat anti-
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human DDR2 polyclonal antibody (Santa Cruz Biotechnology) or a mouse anti-human 
CD144 monoclonal antibody (Santa Cruz Biotechnology), for 60mins at room 
temperature. The cells were then washed and incubated with a rabbit anti-goat IgG 
antibody conjugated with FITC fluorescence (Dako) and a mouse anti-human SMA 
monoclonal antibody conjugated with Cy3/red fluorescence (Sigma), or a rabbit anti-
mouse IgG antibody conjugated with FITC fluorescence (Dako). Subsequently, the cell 
nuclei were stained with 4, 6-diamidino-2-phenylindole (DAPI). After mounting with 
fluorescent mounting media (Dako), the cells were visualised using a fluorescence 
microscope with a digital imaging system. 
 
2.2.2 ADAMTS-7 staining in VSMCs 
 
Eight isolated primary VSMC cell lines were randomly chosen and subjected to 
ADAMTS-7 ICC staining. The cells were fixed, permeablised and blocked as described 
before and then incubated with a rabbit anti-human ADAMTS-7 (spacer domain) 
polyclonal antibody (Abcam, this antibody was used for ADAMTS-7 staining in ICC and 
IHC assays). After washing, the cells were incubated with a goat anti-rabbit IgG antibody 
conjugated with FITC fluorescence (Santa Cruz Biotechnology) and a mouse anti-human 
SMA monoclonal antibody conjugated with Cy3/red fluorescence (Sigma). Nuclei were 
stained with propidium iodide (PI). The slides were observed using confocal fluorescent 
microscope (Leica Microsystems, TCS SP5 MP) after mounting with fluorescent 
mounting media (Dako, S3023). 
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2.3 Immunohistochemical staining of human atherosclerotic plaque 
 
Similar to ICC staining, immunohistochemistry (IHC) staining can allow the visualization 
of a protein in the tissue sections by interaction between the protein and its specific 
antibody which is labeled with an enzyme or a fluorophore. In this study, formaldehyde-
fixed paraffin-embedded human carotid and coronary atherosclerotic plaque sections were 
used to detect the presence of ADAMTS-7 (Details for antibodies used in this section, 
please see Appendix Table 2.3.1) 
 
2.3.1 ADAMTS-7 and SMA double immunofluorescent staining in carotid 
atherosclerotic plaques  
 
Human carotid atherosclerotic lesions were collected from several hospitals in UK, 
including St. Bartholomew’s Hospital, Royal London Hospital, Cumberland Infirmary 
and Ayr Hospital. This work has been approved by Research Ethical Committee (REC, 
Project Number: 08/H0704/140). The plaque samples were collected from patients 
undergoing carotid artery endarterectomy procedure, fixed in formalin and transported to 
our lab. These samples were then embedded by paraffin and sectioned by Pathology 
Facility at the Barts Cancer Institute.  
 
Before staining, these sections were deparaffinised, rehydrated and incubated with sodium 
citrate for antigen retrieval. Briefly, all the sections were incubated at 45℃ for 30 minutes 
to facilitate the attachment of the tissue sections to the slides before being deparaffinised 
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in xylene. Subsequently, these sections were incubated in 100% ethanol, 70% ethanol and 
distilled water to rehydrate. The sections were then incubated in a pre-warmed retrieval 
solution (10mM sodium citrate, 0.05% Tween-20, pH 6.0) in a water bath at 95˚C for 
30min to retrieve antigens.  
 
For fluorescence immunohistochemical staining, sections were blocked with 1% bovine 
serum albumin. A mouse anti-human SMA antibody conjugated with Cy3/red 
fluorescence (Sigma), and a rabbit anti-human ADAMTS-7 (spacer domain) antibody 
along with a goat anti-rabbit IgG antibody conjugated with FITC fluorescence (Santa Cruz 
Biotechnology) were used for double staining. Nuclei were stained with DAPI (4, 6-
diamidino-2-phenylindole). After mounting, slides were examined using a laser scanning 
microscope (Zeiss LSM 510 Mark 4) and images taken using a digital camera.  
 
2.3.2 ADAMTS-7, TSP-5 and vWF single staining in carotid atherosclerotic 
plaques 
 
The same deparaffinisation and blocking procedures were carried out as described in 
section 2.3.1. Then sections were incubated with a rabbit anti-human ADAMTS-7 (spacer 
domain) antibody (Abcam) or a rat anti TSP-5 antibody (Millipore) or a rabbit anti-human 
vWF antibody (Abcam). Subsequently, the sections were incubated with a goat anti-rabbit 
IgG antibody conjugated with HRP or a Rabbit anti rat antibody conjugated with HRP 
(Dako), followed by DAB and counterstain with haematoxylin. After mounting, slides 
were examined and images were taken using a microscope with a digital camera. 
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A blocking peptide (Abcam) matching the epitope of the ADAMTS-7 (spacer domain) 
antibody (Abcam) was used to verify the specificity of ADAMTS-7 staining in carotid 
atherosclerotic plaque sections. Briefly, the rabbit anti-human ADAMTS-7 (spacer 
domain) antibody (Abcam) was incubated without or with a blocking peptide (Abcam) 
matching the epitope of this antibody (in the ratio of 5:1, 5 times amount of blocking 
peptide).  After deparaffinization and retrieval of antigen, blocking with 3% H2O2 and 10% 
goat serum, the sections were then incubated with ADAMTS-7 (spacer domain) antibody 
solution or peptide blocked antibody solution, followed an anti-Rabbit secondary antibody 
conjugated with HRP (Dako), then DAB (3,3´-diaminodbenzidine) and subsequently and 
counterstain with haematoxylin. After mounting, slides were examined and images taken 
using a microscope with a digital camera. 
 
2.3.3 ADAMTS-7 and SMA double staining in coronary atherosclerotic 
plaques 
 
Formaldehyde-fixed, paraffin-embedded sections of coronary atherosclerotic plaque 
sections were generously provided by Dr. Poston from the Centre for Microvascular 
Research, William Harvey Research Institute. The same deparaffinisation and blocking 
procedures were carried out as described in section 2.3.1. The sections were then subjected 
to staining using a mouse anti-human SMA antibody (Dako) and a rabbit anti-human 
ADAMTS-7 (spacer domain) antibody (Abcam), then with a biotinylated swine anti-
rabbit IgG secondary antibody (Dako) and subsequently an anti-mouse IgG alkaline 
phosphatase conjugated secondary antibody (Sigma), followed by avidin-conjugated 
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horseradish peroxidase (HRP), then DAB and subsequently NBT/BCIP (nitro-blue 
tetrazolium/5-bromo-4-chloro-3'-indolyphosphate). A methyl green counterstain was 
used before dehydrating and mounting the slides. The percentage of ADAMTS-7 stain 
area in coronary atherosclerotic plaque area and the percentage of SMA stain area in 
plaque area were quantified with the use of Image-Pro Software (Media Cybernetics). 
 
2.4 Genotyping 
 
Cell pellets of cultured VSMCs and ECs were collected for isolation of genomic DNA. 
Genomic DNA was isolated using the Wizard SV Genomic DNA Purification System 
(Promega). DNA concentrations of all samples were measured by Nanodrop2000 and 
diluted to 5 ng/µl for future use.  
 
2.4.1 Genotyping by the KASPar method 
 
Genotyping for rs3825807, rs1994016 and rs4380028 were performed by the 
KBiosciences Competitive Allele Specific PCR genotyping system (KASP) method. 
KASP is a homogeneous, fluorescent, endpoint-genotyping technology. Briefly, two 
allelic specific forward primers (one for each SNP allele) are designed; each of them 
contains a unique unlabelled tail sequence at the 5’ end. One common reverse primer is 
designed as well. Two 5’ fluor-labelled oligos, one labelled with FAM and one with HEX 
with sequences complementary to the 5’ unlabelled tail of allelic specific primers. 
Quencher oligos bind with the fluor-labelled oligos quenching the fluorescent signal until 
required. In the initial stage of PCR, the appropriate allelic specific primer binds directly 
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to SNP upstream of the DNA template (with the 3’ end of the primer positioned at the 
SNP site), the common primer also binds to template and the PCR proceeds. After the 
allelic specific primers incorporate into the new synthesised DNA sequence, the fluor-
labelled oligos can bind to the 5’ tail of the allelic specific primers, activating the 
fluorescence signal. If the DNA template only has one allele (homozygote), then only 
allelic specific primer can bind and one fluorescence signal can be detected (either FAM 
or HEX), and if the template has two alleles (heterozygote), then mixed signals will be 
detected (Figure 2.1). According the fluorescence signals, the genotype of DNA samples 
can be called. (Figure 2.2) 
 
 
 
Figure 2.1 Schematic representation of the KASPar genotyping method (Cited and modified 
from http://www.lgcgenomics.com/genotyping/kasp-genotyping-reagents/how-does-kasp-work/). 
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Figure 2.2. A representative KASPar genotyping clusters. 
 
 
Briefly, 7.5ng of DNA template of each VSMC or EC was added into 384 well micro-
plates and dried overnight, then the reaction mix was added into each of the wells and 
subjected to PCR (please see Appendix Table 2.4.1 for primers’ sequence), subsequently, 
fluorescence signals were detected by ABI Prism 7900 HT Sequence Detection System 
(Applied Biosystems) and the results were analysed by ABI Prism software version 2.3. 
The genotyping data were exported from the SDS software in a text file and the fluorescent 
calls were converted into allele calls. The genotype frequencies were checked for 
agreement with Hardy-Weinberg equilibrium using the HWE program 
(http://www.oege.org/software/hwe-mr-calc.shtml).  
 
 
 
Homozygote 1 
Heterozygote 
Homozygote 2 
Negative control 
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2.4.2 VSMC Genotyping for rs3825807 by restriction enzymes 
 
A restriction enzyme, also known as restriction endonuclease, is an enzyme that cuts DNA 
at specific recognition nucleotide sequences known as restriction sites. For one known 
SNP, the DNA sequence at the SNP location will vary between the alleles. If we can find 
one restriction enzyme can only recognise one allele but can not recognise the other one, 
and then this restriction enzyme can be used to distinguish the genotypes of DNA samples. 
To minimize the recognition site, the PCR technique is usually used to amplify a short 
fragment of DNA sequence that contains the SNP location. After amplification of DNA 
template, the PCR products are subjected to restriction enzyme digestion. Afterwards, 
PCR products are loaded on a 2% Agarose Gel and electrophoresis is performed. Different 
genotypes will display different band patterns. According to the number and the size of 
the bands, genotypes of the DNA samples can be called. This method is much more time 
consuming, so can only be used for small number of samples.  
 
 
 
Figure 2.3. A Schematic representation of the restricted enzyme digestion and representative 
genotyping results. 
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The genotyping results of VSMC samples for rs3825807 were verified by the restriction 
enzyme digesting method described above. The relevant sequence containing rs3825807 
was obtained from dbSNP website (http://www.ncbi.nlm.nih.gov/projects/SNP/). The 
NEBcutter V2.0 software (http://tools.neb.com/NEBcutter2/index.php) was used to 
search for differences in restriction sites between the different alleles. Hinf I was identified 
as a suitable restriction site for rs3825807 genotyping. PCR forward and reverse primers 
were designed using primer3 software (available at http://frodo.wi.mit.edu/, Appendix 
Table 2.4.2). The primers were designed in order to obtain a PCR product of about 561bp. 
However, there is another Hinf I recognition site in the PCR product sequence, which can 
cut both alleles of SNP rs3825807. This allowed the discrimination of the bands by 
agarose gel electrophoresis as cutting of the PCR products by the restriction enzyme will 
generate one fragment of 157bp and another of 404bp for G/G genotype, while for A/A 
genotype, three bands of 157bp, 201 bp and 183 bp will be detected. For A/G genotype, 
the Hinf I digestion will generate 4 bands of 157 bp, 183 bp, 201 bp and 404 bp (Figure 
2.3). Briefly, DNA fragment containing rs3825807 site were amplified by PCR (PCR 
reagents and conditions are described in Appendix Table 2.4.3). The conditions for Hinf 
I (New England Biolabs Inc.) digestion of the PCR product was 37˚C for 24 hours. 
Afterwards, the samples were subjected to electrophoresis on a 2% agarose gel and the 
bands were visualised by a UV imaging system. 
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2.4.3 Genotyping by sequencing 
 
DNA sequencing is the process of determining the nucleotide order of a given DNA 
fragment. The most commonly used DNA sequencing method is Sanger sequencing. In 
this method, a primer, a DNA polymerase, and four deoxynucleotides are used to generate 
new DNA strands that are copied from the DNA template. Four di-deoxynucleotides are 
also included to randomly terminate the DNA strand extension, thus resulting in a series 
of related DNA fragments that differ in length. The fragments are then size-separated by 
electrophoresis in a slab polyacrylamide gel, and the orders of the nucleotide of the DNA 
fragments can be determined. An alternative approach is to label each of the 
dideoxynucleotide chain-terminators with a separate fluorescent dye, which fluoresces at 
a different wavelength, these are detected and represented as 'peaks' of different colours, 
which can then be interpreted to determine the base sequence. 
 
The genotype of rs3825807 for some of the samples was further verified by sequencing. 
Briefly, 13 VSMCs DNA samples were randomly chosen and amplified by PCR using the 
primers and conditions described in section 2.4.2. After electrophoresis on 2% agarose 
gel, the PCR products were purified by SV gel and PCR clean-up system (Promega), and 
subjected to fluorescent dideoxy sequencing (Sanger sequencing) carried out by The Barts 
and The London Genome Centre. According to the colors of peaks at rs3825807 location, 
the genotype of these DNA samples were determined. 
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2.5 Cell proliferation, senescence and apoptosis assays 
 
These assays are designed to study whether the CHD-associated SNPs in ADAMTS7 locus 
affect SMC and/or proliferation, senescence and apoptosis, which play vital roles during 
the pathogenesis of atherosclerosis. One day before the assays, VSMCs or ECs were 
trypsinized and seeded in duplicate in 96 well-plates (5,000 cells per well) and cultured in 
proper cell culture media (described before) overnight to let the cells settle down. 
 
2.5.1. Proliferation assay 
 
2.5.1.1 VSMC proliferation assay 
 
5-Bromo-2'-deoxy-uridine (BrdU), a synthetic nucleoside that is an analog of thymidine, 
is not normally present in cellular DNA. However, during fast cell growth, if BrdU is 
present in high concentrations in the culture media, it can be incorporated into the cellular 
DNA, substituting for thymidine during DNA replication. The amount of BrdU 
incorporated is determined by a standard ELISA protocol, which involves "tagging" the 
incorporated nucleotide with an anti-BrdU antibody. And the amount of the BrdU is linear 
with proliferation of the cells. 5-bromo-2'-deoxy-uridine (BrdU) Labelling and Detection 
Kit III (Roche) was used to assess the proliferation of VSMCs. By this assay, proliferation 
of these isolated VSMCs can be measured to analyse whether SNPs in ADAMTS7 locus 
affect SMC proliferation.  
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For the proliferation assay, VSMCs were cultured for a further 12 hours in fresh media in 
the presence of 10μM BrdU. The labeled cells were then fixed with ethanol. Prior to 
incubation with a monoclonal antibody to BrdU, DNA was partially digested with 
nucleases to allow the antibody to access BrdU. Next, the anti-BrdU antibody [labeled 
with peroxidase (POD)] was added. Finally, the POD substrate ABTS was added. POD 
catalyzes the cleavage of ABTS, producing a colored reaction product. The absorbance of 
the samples (at approx. 405 nm) is determined with a standard microplate (ELISA) reader. 
 
2.5.1.2 EC proliferation assay 
 
The following cells were used for EC proliferation assays:  
 
ECs with different genotypes for rs3825807 
ECs transfected with pcDNA3.1 vector control plasmid 
ECs transfected with ADAMTS7-214Ser plasmid 
ECs transfected with ADAMTS7-214Pro plasmid 
ECs infected with non-target pLKO.1 control lentiviral particles 
ECs infected with ADAMTS7 shRNA lentiviral particles 
 
Cell proliferation assay kit (Fluorometric-Blue) was used to detect cell proliferation 
following manufacturer’s protocol. Briefly, 5000 cells / well were seeded into a 96-well 
plate. Twenty four hours later, fresh media with 10% proliferation assay reagent was 
added to the cells and they were further incubated for 6 hours. They were then harvested 
and subjected to fluorometer reading (Manual VICTOR2™, with Fluorescence and 
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Luminescence Technologies). The basic mechanism is that the proliferation assay reagent 
contains the redox dye resazurin which is not fluorescent, but upon reduction by viable 
metabolically active cells, the dye becomes highly fluorescent and the fluorescent signal 
is linear with viable metabolically active cell number. Therefore, viable metabolically 
active cells can be easily measured. BrdU assay was also performed to confirm the results 
of proliferation assay (please consult section 2.5.1.1 for full methodology description). 
 
2.5.2 VSMC senescence assay 
 
Senescence Associated ß-galactosidase (SA-ß-Gal) is an enzyme present in senescent cells, 
and it catalyzes the hydrolysis of X-gal, which produces a blue color in senescent cells. 
Thus the activity of this enzyme is used as a marker for senescence of cells.  
 
After the overnight culture, cell senescence was assessed using a 96-Well Cellular 
Senescence Assay Kit (Cell Biolabs Inc) to quantify SA-ß-Gal as per manufacturer’s 
instructions. 
 
2.5.3 VSMC apoptosis assay 
 
Apoptosis is a form of eukaryotic cell death (also known as programmed cell death), 
which is distinct from necrosis. Unlike necrosis which is characterised by cell swelling 
and rupturing of the plasma membrane due to its increased ion permeability, apoptosis is 
characterised by membrane blebbing, condensation of the cytoplasm, and the activation 
 90 
of an endogenous endonuclease. This Ca2+- and Mg2+-dependent nuclease cleaves double-
stranded DNA at the most accessible internucleosomal linker region, generating mono- 
and oligonucleosomes. In contrast, the DNA of the nucleosomes is tightly complexed with 
the core histones H2A, H2B, H3, and H4, and is thus protected from cleavage by the 
endonucleases. The yielded DNA fragments are discrete multiples of a 180-bp subunit, 
detected as a “DNA ladder” on agarose gels after extraction and separation of the 
fragmented DNA. The enrichment of mono- and oligonucleosomes in the cytoplasm of 
the apoptotic cell is due to the fact that DNA degradation occurs several hours before the 
plasma membrane breakdown, thus it can be used to detect apoptosis of cells. 
 
For the apoptosis assay, after the overnight culture, cell apoptosis was measured using a 
Cell Death Detection ELISAPLUS kit (Roche) to quantify histone-complexed DNA 
fragments. After lysis of the cells, cell lysates were placed into a streptavidin-coated 
microplate and incubated with a mixture of anti-histone-biotin and anti-DNA-peroxidase. 
During the incubation interval, nucleosomes will be captured via their histone component 
by the anti-histone-biotin antibody, which will in turn be fixed to the streptavidin-coated 
microplate. Simultaneously, anti-DNA-peroxidase binds to the DNA part of the 
nucleosomes. After removal of the unbound antibodies, the amount of peroxidase retained 
in the immunocomplex is photometrically determined with ABTS as the substrate.  
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2.6 Migration assay 
 
In order to investigate whether these CAD-associated SNPs affect the VSMC and/or EC 
migration, in vitro wound healing(scratch assays) and trans-well cell migration assays 
were performed. 
 
2.6.1 Migration assay (Scratch assay) 
 
The in vitro scratch assay is an easy straightforward method to study cell migration in 
vitro. This method is based on the observation that, upon creation of a new artificial gap, 
so called “scratch”, on a confluent cell monolayer, the cells on the edge of the gap will 
move toward the opening to close the “scratch” until new cell-cell contacts are established 
again. The basic steps involve creation of a “scratch” on a monolayer of cells, capture of 
images at regular intervals during cell migration to close the scratch, and finally, the 
comparison of the images to determine the rate of cell migration (Liang et al. 2007).  
 
2.6.1.1 VSMC scratch assay 
 
VSMCs were cultured on 6-well plates. When cells reach 100% confluence, parallel lines 
were drawn with a maker pen on the back of each well and a linear wound was made 
vertical to these parallel lines by scraping cells with a sterile pipette tip. After washing the 
cells with PBS once and DMEM once, different media treatments were performed as 
below:  
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(1) Complete media: DMEM supplemented with 15% FBS 
(2) Serum-free media 
(3) Serum-free media with 10ng/ml PDGF-BB 
(4) A/A genotype VSMC conditioned media  
(5) G/G genotype VSMC conditioned media  
 
Images of the wound at each crossing of the parallel lines and the gap were taken using 
an inverted microscope with a digital camera. The cells were then incubated at 37˚C with 
5% CO2, and images of the wound at each crossing of the parallel lines and the gap 
obtained again after 6, 9, and 12 hours, respectively. Image software was used to measure 
the distances between two edges of the wound of each picture taken at 0, 6, 9, 12 hours, 
respectively, and then the differences in distance between the two edges at the same 
crossing at 6, 9 and 12 hours comparing to the 0h point, respectively, were calculated. In 
media swapping assays, at the outset of the migration assay (i.e. at hour 0), the culture 
media of G/G genotype cells were replaced by A/A genotype cell conditioned media, and 
vice versa. 
 
2.6.1.2 EC scratch assay 
 
In order to investigate whether functional SNP rs3825807 affects EC migration, a 
migration assay was performed using ECs with different genotype of rs3825807. Effects 
of ADAMTS7 over-expression and knock-down on EC migration were also investigated 
by scratch assay, using the following cells:  
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ECs with different genotypes of rs3825807 
ECs transfected with pcDNA3.1 vector control plasmid 
ECs transfected with ADAMTS7-214Ser plasmid 
ECs transfected with ADAMTS7-214Pro plasmid 
ECs infected with non-target pLKO.1 control lentiviral particles 
ECs infected with ADAMTS7 shRNA lentiviral particles 
 
The assay was carried out as previously described (Liang et al. 2007). In brief, ECs were 
cultured on 12-well plates. When cells reached 100% confluence, parallel lines were 
drawn with a marker pen on the back of each well and a linear wound was made vertical 
to these parallel lines by scraping cells with a sterile pipette tip. After washing the cells 
with PBS and M199 media, fresh Human Endothelial-SFM (Life Technologies) was 
added. Thereafter, images of the wound at each crossing of the parallel lines were taken 
using an inverted microscope with a digital camera as time point 0 hour. The cells were 
incubated at 37˚C with 5% CO2, and images of the wound at each crossing of the parallel 
lines obtained again after 3, 6, and 9 hours. Image software was used to measure the 
distances between two edges of the wound at each crossing of the parallel lines at 0, 3, 6, 
9 hours. Then the difference in distance between the cell edges at fixed points compared 
at the different time point with 0h as reference was calculated. 
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2.6.2 VSMC trans-well migration assay 
 
Trans-well migration assay employs a 24 well plate and an insert chamber which has a 
filter with 8-μm pore. The cells are seeded onto the insert chamber and high serum media 
or media containing specific chemoattractants is added into the chamber of 24-well plate. 
Then, cells migrate from the top chamber through the coated filter pores to the bottom 
chamber due to higher concentrations of nutrients or of chemoattractants. Calculation of 
the migrated cell number and comparison with different experimental groups will give 
quantitative results of cell invasive/migratory ability. 
 
Trans-well migration assays were performed using polycarbonate membrane inserts (8-
μm pore size; Greiner Bio-One Inc.) in 24-well cell culture plates. For each well, 50,000 
VSMCs were seeded into the insert chamber covered with 200 μl of different media, as 
listed below: 
 
(1) Serum-free media with 1% BSA  
(2) HEK293 cell conditioned media containing ADAMTS-7Pro-Cat -214Ser  
(3) HEK293 cell conditioned media containing ADAMTS-7Pro-Cat -214Pro 
 
The inner chambers were pre-coated with 0.1% gelatin, and 500μl serum-free media with 
1% BSA and PDGF-BB (100ng/ml, Sigma) were added in the chamber of 24-well plate. 
After incubating at 37°C for 6 and 9 hours, cells remaining inside the inner chamber were 
completely scraped off with cotton swabs, and cells that had migrated through to the lower 
surface of the insert were fixed in 4% paraformaldehyde, followed by haematoxylin 
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staining. Images of five random high power fields (200x) were taken from each inset, and 
cells were counted by using Image J. Migration activity was expressed as the mean 
number of cells that had migrated per well from the representative five random high power 
fields.   
 
2.7 Real-time reverse transcription PCR (qRT-PCR) 
 
SNP rs3825807 is located in the coding region and is a non-synonymous SNP resulting in 
a serine (Ser) to proline (Pro) substitution in the pro-domain of ADAMTS-7 (Schunkert 
et al. 2011). SNP rs1994016 resides in intron 8 of ADAMTS7, whilst SNP rs4380028 is 
located 7.6 kb upstream of the gene. Considering their physical locations in relation to the 
ADAMTS7 gene, they might have an influence on ADAMTS7 mRNA expression. 
 
In order to investigate whether these SNPs affect expression of ADAMTS7 mRNA and 
thus may be linked with coronary artery disease, qRT-PCR was used to determine whether 
genotype-specific differences in mRNA level exist. 
 
2.7.1 RNA isolation 
 
Total RNA of VSMCs and ECs were isolated from their pellets using SV total RNA 
isolation kit (Promega). Briefly, cells were cultivated in the condition described in section 
2.1, at about 90% confluence, cells were washed with ice-cold PBS several times and 
harvested by scraping, and then cell pellets were collected by centrifuging at maximum 
speed for 2 minutes. Afterwards, 150 µl of lysis buffer provided with the kit was added to 
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lyse the pellets, and then the extraction was performed following the instructions of the 
kit. RNA concentration was measured by NanoDrop Spectrophotometer ND-2000.  
 
2.7.2 cDNA synthesis 
 
Total RNA samples of VSMCs and ECs were reverse transcribed into cDNA using 
ImProm-II™ Reverse Transcription System (Promega). Briefly, 1.25 µg of total RNA 
with 0.5ug of random primers were mixed (total volume 10 µl) and heated at 70℃ for 
5minutes to melt secondary structure within the template, subsequently, samples were 
quickly chilled at 4℃ for 5 minutes. Then samples were subjected to RT-PCR to 
synthesise cDNA (PCR reagents and conditions are outlined in Appendix Table 2.7.1). 
After RT-PCR, all the cDNA samples were diluted to 5 ng/µl for real-time PCR.  
 
2.7.3 Real-time RT-PCR  
 
Real-time RT-PCR, also called quantitative RT-PCR (qRT-PCR) is a PCR based 
technology, which is used to simultaneously amplify and quantify a targeted DNA 
sequence. Complementary DNA samples are reverse transcribed from RNA samples. 
Instead of the end-point detection of PCR reaction product in standard PCR, this procedure 
is able to detect the reaction progress in real time, by labelling the new synthesised DNA 
during the reaction. The detected quantity of mRNA could be expressed as absolute copies 
of DNA templates in the samples or relative amount when normalised to additional 
normalising genes, such as 18s rRNA, beta-actin or GAPDH. These genes are required 
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for the maintenance of basic cellular function, and their expression level is relatively 
constant. 
  
Two common labelling methods are used in this procedure; one is using non-specific 
fluorescent dyes that can intercalate with any double-stranded DNA; the other one is using 
sequence-specific DNA probes that are labelled with a fluorescent reporter, and this 
reporter only permits detection after hybridisation of the probe with its complementary 
DNA target. Comparing these two methods, the former one does not need a specific probe 
which is expensive, but can lead to greater variations in final results. The later method 
offers more accurate results at the expense of the assay. The most commonly used probe 
method is TaqMan Gene Expression Assay. 
 
In this assay, two primers and one probe are provided, which can recognise specifically to 
target DNA sequence. The TaqMan probe has a fluorophore (reporter) labelled to the 5’-
end of the oligonucleotide probe and a quencher at the 3’-end of probe. The emission of 
fluorescence signal by reporter is inhibited by the quencher as long as they are in proximity. 
During the extension of DNA strand, the annealed probe to the target sequence can be 
displaced and cleaved by the exonuclease activity of Taq polymerase, thus the reporter is 
separated from quencher and the fluorescence signals can be detected by an ABI Prism 
7900HT instrument. During each cycle of the PCR process, fluorescence signal can be 
detected; hence, DNA templates can be quantified in real time during the process 
according to the fluorescence signals release from reporter.  
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After qRT-PCR, each sample will have an amplification curve, which contains a baseline 
phase, log-linear phase and plateau phase. A threshold line for detection of DNA-based 
fluorescence is set above the baseline phase and crossing the log-linear phase. This line 
was chosen automatically by the SDS software, but can be set up manually as well. The 
number of cycles at which the fluorescence exceeds the threshold is called the threshold 
cycle (Ct). Once the reaction done, Ct values for each gene were given by the SDS 
software, and then the ΔΔCt method was used to calculate the relative expression 
differences among different genotype groups.  
 
The house-keeping gene beta-actin was used as internal reference to normalise gene 
expression in different genotype groups. The TaqMan Gene Expression Assay was used 
(Probes, qRT-PCR reagents and conditions are described in Appendix Table 2.7.2). The 
cDNA samples were loaded into a 384 well plate and running on Applied Biosystem 
7900HT by the Barts and The London Genome Centre. And the results were analysed by 
the software SDS 2.3. 
 
2.8 Allelic imbalance analysis 
 
Allelic imbalance analysis is another method used in this study to investigate the effect of 
SNPs (Wang and Elbein 2007) on expression of ADAMTS7 mRNA level. Both cDNA and 
gDNA samples were amplified by PCR and subjected to fluorescent dideoxy sequencing, 
the allelic ratio of cDNA was compared and normalised to the ratio of gDNA.  
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Unlike qRT-PCR, where the expression level of ADAMTS7 mRNA is compared between 
different individuals with different genotypes, the method of allelic imbalance analysis 
compares the allelic expression level in mRNA of heterozygotes for SNP rs3825807. If 
the SNP affects the expression of mRNA levels of ADAMTS7, then one allele should have 
higher expression level of the mRNA than the other allele. This could be due to allelic-
specific binding of transcriptional factors, microRNA or other elements that can regulate 
gene expression. For instance, individuals in heterozygous for rs3825807, as observed in 
the GWAS, allele A is associated with CAD. If rs3825807 affects the expression level of 
ADAMTS7 mRNA, then the mRNA level of A allele should be higher than the level of G 
allele. If this were the case, after the sequencing, the allelic ratio of A/G should be >1 after 
normalisation by ratio of gDNA, otherwise, the SNP does not affect expression of mRNA 
level. 
 
VSMC gDNA and cDNA samples were prepared as described in section 2.1.4 and 2.1.7. 
ADAMTS7 cDNA sequence was obtained from Ensembl and PCR primers for 
amplification of a sequence containing the SNP rs3825807 were designed by the 
Primer3Plus programme (http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus. 
cgi/). PCR reactions using cDNA/gDNA as template were performed as described in 
Appendix Table 2.8.1. Thereafter, purified PCR products were subjected to fluorescent 
dideoxy sequencing (Sanger sequencing) carried out by The Barts and The London 
Genome Centre. Sequencing chromatograms were analysed using the PeakPicker program 
(Ge et al. 2005) which calculates relative peak heights of the A and G nucleotides at the 
SNP site in the chromatograms derived from cDNA and gDNA respectively, standardised 
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against reference peaks in flanking sequences. Mann-Whitney test was performed to 
determine whether a difference between the ratios of standardised A nucleotide peak 
height over standardised G nucleotide peak height from cDNA and the corresponding ratio 
from gDNA exists. 
 
2.9 ADAMTS7 plasmids cloning 
 
2.9.1 ADAMTS7Pro-Cat pCMV5 plasmid cloning  
 
A short form of ADAMTS7 plasmid, which was cloned by Somerville and colleagues and 
designated as ADAMTS7Pro-Cat Plasmid, expresses a protein consisting of the ADAMTS-
7 signal peptide, pro-domain and metalloproteinase domain which sustains proteolytic 
activity (Somerville et al. 2004). We decided to clone a similar plasmid with these domain 
sequences into the vector pCMV5. The vector pCMV5 contains an HA-tag in its C-
terminus and a multiple cloning site (MCS) for ease of insert manipulation (Figure 2.4).  
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Figure 2.4. The structure of pCMV5 vector and restricted enzymes in its multiple cloning site. 
 
 
2.9.1.1 Preparation ADAMTS7Pro-Cat plasmid insert cDNA and pCMV5 vector 
 
Nested-PCR technology was used to amplify ADAMTS7 cDNA sequence. Total RNA was 
extracted from VSMCs and reverse transcribed into cDNA (described in section 2.7). A 
pair of ADAMTS7 cDNA primers flanking the whole insert sequence was designed by 
Prime3Plus. Additionally, an inside pair of primers, which contain restriction enzymes’ 
recognising sites, were designed to amplify ADAMTS7 cDNA sequence which encodes 
552 amino acids of the ADAMTS-7 protein, including the ADAMTS-7 signal peptide, 
pro-domain and catalytic domain (Primers, reagents and reaction conditions of PCR were 
detailed in Appendix Table 2.9.1).  
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Amplified ADAMTS7 cDNA insert was purified using PCR clean-up system (Promega). 
The insert and the vector were digested with Kpn I and Hind III. After dephosphorylation 
of vector pCMV5, both insert and vector were purified by PCR clean-up system and 
subsequently subjected to ligation at 4 ℃ overnight using T4 DNA ligase (Promega). 
 
2.9.1.2 Transformation 
 
Transformation is a molecular method that can be utilised to introduce exogenous genetic 
materials (exogenous DNA such as plasmid) into a cell through cell membrane direct 
uptake. Transformation occurs naturally in some species of bacteria, but with very low 
efficiency and stringent conditions. Artificial competence can be induced in laboratory 
procedures that involve making the cell passively permeable to DNA by incubation in a 
solution containing divalent cations (often calcium chloride) under cold conditions (on 
ice), and then briefly heat-shocked. This method works very well for circular plasmid 
DNA and usually has very high efficiency, thus being widely used for transformation, 
especially for plasmid. After uptake, the exogenous DNA can be expressed by the host 
cell. By this method, we can get large amounts of plasmid DNA or recombinant protein 
in a short time.  
 
E. coli JM109 were used for the transformation. Briefly, 50 µl of competent cells were 
added to sterile Eppendorf tubes and incubated on ice for 30 minutes. The bacterial-DNA 
mixture was heat-shocked at 42℃  in a water bath for 60-70 seconds, followed by 
incubation on ice for 60-70 seconds. LB medium (500 µl) without antibiotics was added 
to each tube and incubated at 37℃ in a water bath for 1 hour. After centrifuging at 5000 
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rpm for 5 min, the resulting supernatant was discarded and the cells were resuspended in 
the remaining LB. The mixture was then plated to LB+Agar Petri dish plate with 
antibiotics and incubated overnight at 37℃ incubator (16-18 hours). 
 
2.9.1.3 Purification and identification of ADAMTS7Pro-Cat pCMV5 plasmid 
 
Colonies grown on the LB Agar plates were transferred into 5 ml LB medium with 
ampicillin (100 µg/ml) and placed into a shaking incubator (250 rpm) at 37℃ overnight. 
Plasmid DNA was then purified using Plasmid Miniprep Kits (Sigma) and subjected to 
sequencing at The Barts and The London Genome Centre. It unfortunately did not yield 
the correct ADAMTS7 cDNA inserted pCMV5 plasmid by cloning of ADAMTS7 cDNA 
into pCMV5 vector plasmid, as shown from DNA sequencing data. We have tried several 
times but were not successful in cloning this plasmid. ADAMTS7 cDNA is G/C rich, which 
makes it difficult to manipulate by PCR-based cloning. The poor quality of ADAMTS7 
cDNA inserts stands as the most possible reason for failure of this cloning work.   
 
2.9.2 Utilisation previously constructed ADAMTS7Pro-Cat short form and 
ADAMTS7 full length plasmids 
 
We used a previously constructed ADAMTS7Pro-Cat short form plasmid containing 
ADAMTS7 cDNA sequence for expressing a protein consisting of the ADAMTS-7 signal 
peptide, pro-domain and metalloproteinase domain and a ADAMTS7 full length plasmid 
containing ADAMTS7 cDNA sequences for expressing a protein consisting of the full 
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length ADAMTS-7 protein followed by a c-Myc epitope ligated into pcDNA3.1 basic 
vector containing an Ampicillin resistance region (Bai et al. 2009). These plasmids were 
generously provided by Professor Chuanju Liu from Medical School of New York 
University. After sequencing of these two plasmid, we found that the ADAMTS7 cDNA 
sequence contains the adenine (A) nucleotide at the rs3825807 site and therefore would 
be serine at position 214 of ADAMTS-7 pro-domain for both of these two plasmids. Thus, 
we named this plasmid ADAMTS7Pro-Cat -214Ser or ADAMTS7 -214Ser plasmid.  
 
2.9.2.1 Site-directed mutagenesis 
 
Site-directed mutagenesis is a molecular biology method that is used to make specific and 
intentional changes to the DNA sequence of a gene or any gene products, such as plasmid 
DNA (Edelheit et al. 2009). Using this technique, we can easily change (mutate) one 
nucleotide (a point mutation) or multiple nucleotides (multiple mutations) of template 
DNA to construct a new DNA sequence containing the mutation which can be used for 
studying the effect of this mutation on DNA, RNA and protein structure and biological 
activity. The basic procedure requires the synthesis of short DNA primers, which contain 
the desired mutation and is complementary to the template DNA sequence around the 
mutation site. The single-stranded primers are then extended using a DNA polymerase, 
which copies the rest of template DNA. The new copied DNA contains the mutated site.  
 
For plasmid manipulations, special highly efficient commercial mutagenesis techniques 
have been developed. The technique can be described as whole plasmid mutagenesis, 
where two complementary mutagenic primers are used to amplify the entire plasmid in a 
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thermocycling reaction using a high-fidelity non-strand-displacing DNA polymerase such 
as pfu polymerase. The newly synthesised plasmid will contain the desired mutation. 
Because the template plasmid is usually of E.coli origin, and thus is methylated which can 
be eliminated by enzymatic digestion with a restriction enzyme such as DpnI specific for 
methylated DNA.  This leaves the reaction with only the in vitro mutated plasmid which 
can be introduced to E. coli for amplification.  
 
Using ADAMTS7Pro-Cat-214Ser or ADAMTS7 -214Ser plasmid as a template, we carried 
out site-directed mutagenesis using Quikchange Lightning kit (Agilent Technologies) to 
change adenine (A) to guanine (G) at the rs3825807 site. The new plasmids were verified 
by DNA sequencing, then we named these two new plasmids ADAMTS7Pro-Cat-214Pro or 
ADAMTS7-214Pro plasmid, respectively, so the protein produced by these two new 
plasmids would be ADAMTS-7Pro-Cat-214Pro or ADAMTS-7-214Pro, respectively. The 
site-directed mutagenesis reaction was carried out in accordance to manufacturer’s 
recommendation (http://www.genomics.agilent.com/literature.jsp?crumbAction=push&t 
abId=AG-PR-1162&contentType=User+Manual) (see Appendix Table 2.9.2).   
 
After the thermocycling reaction, the reaction mixture was incubated with restriction 
enzyme DpnI at 37℃ in a water bath for 5 minutes to digest unmutated (methylated 
template) plasmid. Subsequently, the digested plasmids were transformed into XL-10 
Gold ultracompetent cells provided by the kit. 
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2.9.2.2 Transformation of mutated ADAMTS7Pro-Cat-214Pro or ADAMTS7-214Pro 
plasmid 
 
For mutated ADAMTS7Pro-Cat-214Pro or ADAMTS7-214Pro plasmid transformation, 45 
µl of XL-10 Gold ultracompetent cells (Agilent Technologies) were taken out from -80 ℃ 
freezer and thawed on ice. Two microliters of β-Mercaptoethanol (2-ME, provided with 
site-direct mutagenesis kit) was added into the cells, mixed gently and incubated on ice 
for 10 minutes (2-ME has been shown to increase transformation efficiency). 
Subsequently, 2 µl of DpnI digested plasmids were added to the cells and incubated on 
ice for 30 minutes. Then, the mixture was heat-shocked at 42 ℃ in a water bath for 30 
seconds, following incubation on ice for 2 minutes. 450 µl of preheated (42 ℃) LB broth 
media without antibiotics was added to each tube and incubated at 37 ℃ for an hour with 
shaking at 225 rpm. After that, the mixture was plated on a LB Agar plate containing 
Ampicillin (100 µg/ml) and incubated with the plate upside down at 37 ℃ for 18 hours. 
On the next day, a lot of colonies were found on the plate and 10 colonies were randomly 
chosen for identification.  
 
2.9.2.3 Plasmid identification 
 
The purpose of plasmid identification is to answer two questions: whether the plasmid 
was successfully introduced into the bacteria and whether the plasmid was successfully 
mutated?  
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Ten colonies of each plasmid transformed bacteria were chosen randomly and a small part 
of each colony was picked with sterile tips, and then lysed in 50 µl rapid lysis buffer (2% 
SDS, 10% Triton X-100) by incubation at 95℃ for 5 min. Five microliter of supernatant 
was then used as DNA template to perform PCR (Using the conditions described in 
Appendix Table 2.9.3) following centrifugation at 16,100 rcf for 5 minutes. Samples were 
then loaded onto a 2% agarose gel for electrophoresis to check the product size. A PCR 
band of 307 bp appeared on the agarose gel to indicate the plasmid with ADAMTS7 cDNA 
sequence was successfully introduced into the cells. To verify whether the mutation was 
successful, we performed DNA sequencing.  
 
It was showed a right band size for all of the chosen colonies, suggesting ADAMTS7 
plasmids was successfully transformed into these colonies. And then we randomly chose 
5 colonies among for each plasmid, and picked with sterile tips, put into 5 ml of LB Broth 
containing Ampicillin (100 µg/ml) and incubated at 37 ℃ overnight at 225 rpm in a 
rotation incubator. On the next day, 500 µl of cells suspension was mixed with sterile 
glycerol and kept at -80 ℃ as stock for future use, the rest was used to extract the plasmid 
DNA with QIAprep spin Miniprep kit (Qiagen) following manufacturer’s protocol. 
Plasmid DNA concentration was quantified with a NanoDrop Spectrophotometer ND-
2000 and subjected to fluorescent dideoxy sequencing (Sanger sequencing) carried out by 
The Barts and The London Genome Centre. By sequencing, it can be easily found out 
whether the mutation was successful. Successfully mutated plasmids and bacteria were 
used for subsequent applications. (Details for primers used for sequencing was described 
in Appendix Table 2.9.4 and 2.9.5).  
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2.10 Transfection 
 
Similar to transformation technology, transfection is a molecular method that can 
deliberately introduce exogenous DNA into cells, but this term is often used for non-viral 
methods targeting eukaryotic cells. Transfection of animal cells typically involves 
introduction of transient pores in the cell membrane, to allow the uptake of exogenous 
genetic material (such as plasmid DNA or siRNA constructs). Three methods can be used 
for this purpose: calcium phosphate transfection, electroporation and lipofection. The first 
method uses positively charged calcium and negatively charged phosphate which forms a 
DNA-binding precipitate. Addition of this complex to cells allows its uptake and thus 
transient transfection with plasmid DNA of choice (Bacchetti and Graham 1977). 
Electroporation, on the other hand, utilises an intense electric field which can transiently 
increase the permeability of the cell membrane allowing DNA entry (Neumann et al. 
1982). Finally, lipofection is a method that uses liposomes to transfect DNA into a cell. 
Liposomes are lipid vesicles which can easily fuse with the cell membrane, delivering the 
DNA into the cells (Felgner et al. 1987). This method has many advantages including high 
efficiency, ease of manipulation, reproducibility, low cell toxicity, and most importantly, 
its versatility for nucleic acid used and cell types targeted. It is suitable for all transfection 
applications. Thus this method is the most commonly used method for transfection in most 
laboratories.  
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2.10.1 ADAMTS7Pro-Cat plasmids HEK293 cell transfection 
 
ADAMTS7Pro-Cat short form plasmids were transfected into the HEK293 cell line to 
investigate whether rs3825807 is the functional SNP that can affect activation of 
ADAMTS-7 and SMC migration. HEK293 cells were cultured in 10% FBS supplemented 
DMEM, and when cells reached 40-60% confluence, transfection was performed. Briefly, 
2 ml of 5% FBS supplemented DMEM without antibiotics was added into cells 1 hour 
before transfection. Fugene 6 (Roche) was used, the ratio of Fugene 6 and plasmid was 
3:1 (3 µl Fugene 6 with 1 µg plasmid). After mixing Fugene 6 and plasmid with Optimal 
MEM (Promega), the mixture was incubated at RT for 30 minutes and added dropwise 
directly onto the cell layer. After 6 hour incubation, 2 ml of 10% FBS supplemented 
DMEM media with antibiotics was added into cells. After 16 hours, cells were replaced 
with serum-free media after washed in PBS several times. The serum-free culture media 
was harvested every day for 3 days. Harvested media were kept in -80 ℃freezer for further 
experiments.  
 
2.10.2 ADAMTS7 full length plasmids EC transfection 
 
Isolated primary EC cell lines were used for transfection of either ADAMTS7-214Ser or 
ADAMTS7-214Pro plasmid. In order to obtain optimal transfection efficiencies of primary 
cell lines, we purchased X-tremeGENE HP DNA Transfection reagent (Roche) for 
transfection. ECs were maintained in M199 media supplemented with 15% FBS and 
growth factors, and when the cells reached 50-70% confluence, transfection was 
performed. Briefly, the plasmid was mixed with Optimal MEM (Promega) in a sterile EP 
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tube, and then the X-tremeGENE HP DNA Transfection reagent was added into the 
mixture by gently pipetting up and down several times without touching the wall of the 
tube (the ratio of transfection reagent and plasmid was 3:1, 3 µl X-tremeGENE HP DNA 
Transfection reagent with 1 µg plasmid). Afterwards, the mixture was incubated at RT for 
15 minutes, then added dropwise directly onto the cell layer. These cells were further 
cultivated for 18-72 hours before application for further experiments. The transfection 
efficiency was detected by Western blotting.  
 
2.11 In vitro TSP-5 cleavage assay 
 
TSP-5 is the best characterised substrate of ADAMTS-7. In order to investigate the effect 
of the SNP rs3825807 on ADAMTS-7 proteolytic activity, we incubated recombinant 
TSP-5 protein with conditioned media which contained activated ADAMTS-7. Genotype 
specific differences in ADAMTS-7 proteolytic activity were analysed by Western blotting 
for TSP-5 cleavage patterns (Liu et al. 2006). 
 
2.11.1 In vitro TSP-5 cleavage by VSMC conditioned media 
 
Recombinant TSP-5 (2µg) (Abcam) was incubated with 5µl concentrated media (1µg total 
proteins/µl) conditioned by VSMCs of the A/A or G/G genotype, in a digestion buffer 
(Appendix Table 2.11.1) at 37°C water bath for 8 hours. The digests, along with 
undigested TSP-5 and concentrated conditioned media were subjected to Western blot 
analysis with an anti-TSP-5 antibody (Millipore).  
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2.11.2 In vitro TSP-5 cleavage by transfected HEK293 conditioned media 
 
Recombinant TSP-5 (2µg) (Abcam) was incubated with 1, 2 or 4 µl concentrated media 
(1µg total proteins/µl) from HEK293 cells transfected with either the ADAMTS7Pro-Cat -
214Ser or ADAMTS7Pro-Cat -214Pro plasmid (described in section 2.1.10), in a digestion 
buffer at 37°C water bath for 8 hours. The digests, along with undigested TSP-5 and 
concentrated conditioned media were subjected to Western blot analysis with an anti-TSP-
5 antibody (Millipore). 
 
2.12 ADAMTS7 shRNA lentiviral particles packing  
 
In contrast to over-expression of ADAMTS7 which upregulates the expression level of 
ADAMTS7 and thus increases the function of ADAMTS-7 in the cells, knock-down of 
ADAMTS7 will downregulate the ADAMTS7 expression and decrease ADAMTS-7 
function in the cells, thus both of these experiments give us valuable information of 
ADAMTS-7 biological function. 
 
2.12.1 ADAMTS7 shRNA lentiviral plasmid 
 
In order to investigate the effects of ADAMTS7 knock-down on EC migration, 
proliferation and in vitro angiogenesis (capillary-like network formation assay), 5 clones 
of MISSON® pLKO.1-puro ADAMTS7 shRNA plasmid in Bacterial Glycerol Stock were 
purchased from Sigma ( NM_014272, TRC Number: TRCN0000051233, 
TRCN0000051234, TRCN0000051235, TRCN0000051236, TRCN0000051237). This 
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work has been approved by College GM Safety Committee (GM Centre Registration 
Number: GM774). Personal training for genetic modification (GM) work has been 
obtained. Non-target pLKO.1 plasmid was generously donated by Dr. Xiao and used as 
vector control.  
 
ADAMTS7 specific shRNA sequence was inserted into the lentiviral vector pLKO.1 with 
a puromycin resistance region which can be used for selection of creating a stable infection 
cell line. These plasmids were provided as bacterial glycerol stock, and thus need to be 
propagated. ADAMTS7 shRNA pLKO.1 transfer plasmid for lentiviral particle packaging 
was then extracted. Briefly, each of the clones was propagated in 5ml LB broth with 
ampicillin (100 µg/ml), the plasmids have ampicillin resistance region and thus can 
propagate normally. Then ADAMTS7 shRNA pLKO.1 transfer plasmids were extracted 
from bacteria and quantified by Nanodrop-2000.  
 
2.12.2 ADAMTS7 shRNA lentiviral particle packaging 
 
In order to deliver ADAMTS7 shRNA efficiently into ECs, a lentiviral particle packing 
system was used. This system required four components: transfer vector which has 
specific shRNA sequence inserted into a lentiviral vector such as pLKO.1, packaging 
vector and envelope vector, and HEK293T cells as host cell to package the lentiviral 
particles. The ADAMTS7 shRNA pLKO.1 transfer plasmids were purchased from Sigma, 
packing plasmid psPAX2 and envelope plasmid pMD2.G were a kind gift from Dr. 
Qingzhong Xiao. HEK293T cells were used as host cells to package ADAMTS7 shRNA 
lentiviral particles. ADAMTS7 shRNA lentiviral particle packaging was performed 
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following protocol from Addgene (http://www.addgene.org/tools/protocols/plko/#E). 
Briefly, ADAMTS7 shRNA pLKO.1 transfer plasmids, packing plasmid psPAX2 and 
envelope plasmid pMD2.G (ratio 5:4:1) were co-transfected into HEK293T cells using X-
tremeGENE HP DNA Transfection reagent (Roche). Eighteen hours later, transfected 
cells were replaced with fresh DMEM with 15% FBS and further cultivated for 2 days 
before the first round of lentiviral particles’ harvest was performed. Afterwards, fresh 
media was added and harvested after two days for second round of lentiviral particles’ 
harvest. The harvested lentiviral particle solution was then filtered with 0.45 µm filter to 
remove cell debris, aliquoted and stored at -80℃ freezer for ADAMTS7 shRNA lentiviral 
particles infection.  
 
2.13 Infection of EC with ADAMTS7 shRNA lentiviral particles 
 
2.13.1 ADAMTS7 shRNA lentiviral particles transduction 
 
Delivery of foreign genetic material (DNA or RNA) into another cell using a viral vector 
is termed as transduction. Compared with traditional methods such as transfection to 
deliver genetic material, transduction can ensure that nearly 100% of cells are infected 
without severely affecting cell viability, especially for the cell lines that are difficult to 
transfect. Thus viral vectors provide a powerful method for molecular genetics 
experiments. Lentiviral vectors are created from lentivirus and modified by deletion of a 
part of the viral genome which is critical for viral replication. In such way, the modified 
viral vector can efficiently infect cells, and can also integrate its modified viral genome 
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into the host genome, thus using this viral vector and inserting shRNA or gene of interest 
into the viral vector can deliver shRNA or gene into the genome of target cells and stably 
express for long term.  
 
Infection of ECs with ADAMTS7 shRNA lentiviral particles was performed following 
protocol from Addgene (http://www.addgene.org/tools/protocols/plko/#E). Briefly, ECs 
were maintained normally and when the cells reached 70% confluence, fresh culture 
media containing 10 µg/ml Polybrene (Sigma) was added to cells. Polybrene is a cationic 
polymer used to increase the efficiency of viral infection. ADAMTS7 shRNA lentiviral 
particles solution were defrosted from -80℃ freezer and added directly into ECs to infect 
the cells. After 24 hours post-infection, virus containing media were replaced with fresh 
EC media. The cells were further cultivated for 4 days before harvesting for protein 
extraction to examine the knock-down effect of 5 clones of ADAMTS7 shRNA lentiviral 
vector by Western blotting.  
 
2.13.2 ADAMTS7 knock-down EC cell line selection 
 
The ADAMTS7 shRNA lentiviral particle solution that had the strongest knock-down 
effect on ADAMTS7 was chosen to establish stable ADAMTS7 knock-down EC cell lines. 
The lentiviral vector pLKO.1 has a puromycin resistance region which can be used to 
select infected cells. This puromycin resistance region would be integrated into EC 
genome along with ADAMTS7 shRNA sequence if the lentiviral particles successfully 
infected the cells, and thus these infected cells could survive and grow in the media 
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containing puromycin, while the non-infected ECs are sensitive to puromycin and could 
not survive.  
 
Because each cell line responds differently to puromycin selection, the optimal 
concentration of puromycin needs to be determined before selection of infected cell lines. 
Briefly, ECs were cultured in normal conditions until reached about 90% confluence, then 
media with puromycin was added into the cells with the final puromycin concentration 
from 1-4 µg/ml in 1 µg/ml increments. The optimal concentration of puromycin that 
results in complete cell death after 3-5 days in the media with puromycin should be used 
for selection. Finally, the concentration 2 µg/ml was chosen for cell line selection. 
 
ECs were infected with the chosen ADAMTS7 shRNA lentiviral particle solution as 
described earlier. After infection, media containing 2 µg/ml puromycin were added into 
cells to select stable infected cells for 10 days. During the selection, cells were handled 
normally with regular replacement of media containing puromycin and subculture.  
 
2.14 Western blotting assays 
 
2.14.1 Sample preparation 
 
2.14.1.1 VSMC Sample preparation  
 
VSMCs were cultured with primary smooth muscle cell culture media (as described in 
section 2.1). After the cells reached 90% confluence, they were starved with serum-free 
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media (Smooth Muscle Cell Basal Media 2, PromoCell). HEK293 cells were transfected 
with either ADAMTS7Pro-Cat-214Ser or ADAMTS7Pro-Cat-214Pro plasmid or vector control 
plasmid (as described in section 2.10) and starved with serum-free media. Following the 
same treatment, protein from conditioned media, cell surface washes or whole cell lysates 
were prepared as follows: 
 
The culture media were harvested daily for 3 consecutive days. Culture media were then 
concentrated by centrifugal concentrators (Millipore) according to the manufacturer’s 
protocol. Briefly, they were span down at 2000g for 5 minutes to remove cell debris. The 
supernatant was added into the filter column and centrifuged at 4000 g for 30 minutes. 
Afterwards, the concentrated sample was transferred into a sterile 0.5ml EP tube. In order 
to protect the proteolytic activity of ADAMTS-7 in the conditioned media for the in vitro 
digestion assay, protease inhibitor cocktail was not added into the concentrated samples.    
After each harvest of the serum-free media, cell surface washes samples were obtained by 
washing the cell layer with sterile 0.5M NaCl which can release ADAMTS-7 from the 
cell surface as previously described (Somerville et al. 2004). Afterwards, surface washes 
were concentrated by centrifugal concentrators as well (as described above). Protease 
inhibitor cocktail (Roche Applied Science, constituents are described in Appendix Table 
2.14.1) was added into concentrated samples. 
 
Starved cells were also scraped and lysed in protein lysis buffer (Appendix Table 2.14.2) 
to obtain total protein. To release the cell content, these were vortexed vigorously and 
sonicated for 2 minutes. Subsequently, they were incubated on ice for 45 min, then 
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supernatants were collected after centrifuging 16,100 rcf for 10 minutes at 4 ℃ and 
transferred into sterile tubes.  
 
2.14.1.2 EC Sample preparation  
 
Conditioned media and whole cell protein extracts of following cells were used for 
Western blotting:  
 
ECs with different genotypes of rs3825807 
ECs transfected with pcDNA3.1 vector control plasmid 
ECs transfected with the ADAMTS7-214Ser plasmid 
ECs transfected with the ADAMTS7-214Pro plasmid 
ECs infected with non-target pLKO.1 control lentiviral particles 
ECs infected with ADAMTS7 shRNA lentiviral particles 
 
ECs were cultured with M199 media supplemented with 15% FBS and growth factors. 
After cells reached 90% confluence, these cells were starved with Human Endothelial-
SFM (Life Technologies). The culture media was harvested daily for 48 hours. Afterwards, 
culture media were collected and concentrated by centrifugal concentrators (Millipore) as 
described in the previous section.  
 
Whole cell lysates of these cells were also prepared as described in section 2.14.1.1.  
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2.14.2 Protein concentration quantitation 
 
Protein concentration was determined by Bradford assay. The Bradford assay, a 
colorimetric protein assay, is the most commonly used protein assay. This assay is based 
on an absorbance shift of the dye Coomassie Brilliant Blue G-250 where under acidic 
conditions the red form of the dye is converted into its blue form to bind to the protein 
being assayed. The binding of the protein stabilises the blue form of the Coomassie dye 
which has an absorption spectrum maximum of approximately at 595 nm. The change in 
the absorbance at 595 nm is directly proportional to the amount of blue form of Coomassie 
dye (linear from 0 -2000 µg/ml protein concentration), and thus to the amount of protein 
present in the sample. The colour change observed in this assay is monitored and 
quantitated using a spectrophotometer.  
 
All the protein samples prepared above were quantitated using Bio-Rad Protein Assay 
Dye Reagent Concentrate (Bio-Rad). Briefly, 5x Assay Dye Reagent was diluted 4:1 with 
distilled water prior to use, then 2 µl of each protein sample was added into 1ml of diluted 
dye reagent (500x dilution), mixed well and incubated for 15 minutes at RT to stabilise 
the colour development. Subsequently, the samples were analysed by Bio-Rad’s 
SmartSpecTMPlus Spectrophotometer. The reading of the spectrophotometer then 
converted to the real protein sample concentration by multiplying 500 (dilution ratio).    
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2.14.3 Gel electrophoresis and protein transfer 
 
Sodium-dodecyl-sulphate polyacrylamide gel electrophoresis (SDS-PAGE) is a technique 
widely used to separate proteins based on their molecular size when an electric field is 
applied to a gel. SDS is an anionic detergent, which denatures proteins and confers the 
polypeptide with a negative charge proportional to its size (molecular weight).  
 
Equal amounts of protein (20-40 µg, depending on the assay) from each sample were 
mixed with 5x protein loading buffer (Recipe as described in Appendix Table 2.14.3), 
heated for 5 min at 95°C and loaded onto a SDS-PAGE gel. The gel consists of a 
separating gel and a stacking gel and the gel was made using Bio-Rad minigel system (Gel 
details are described in Appendix Table 2.14.4 and 2.14.5). A prestained protein marker 
was also loaded onto the gel, either ColorPlusTM Prestained Protein Ladder (10-230 kDa, 
NEB) or Prestained Protein Marker (7-175 kDa, NEB). The electrophoresis was 
performed according to the manufacturer’s instructions. Briefly, 90 V for 30 minutes in 
the stacking gel and then 160 V until the samples reached the bottom in Bio-Rad Mini-
Protean® tank with running buffer (Recipe described in Appendix Table 2.14.6).  
 
Proteins separated by electrophoresis were then electro-blotted onto a nitrocellulose 
membrane (Hybond ECL, GE Healthcare) for 2.5 h at constant voltage of 60V with an ice 
bag in the transfer buffer (Recipe described in Appendix Table 2.14.7) to assure optimal 
temperature conditions during the transfer process.  
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2.14.4 Immunoblotting  
 
The membranes were blocked in 5% non-fat milk/1x TBST (Recipe described in 
Appendix Table 2.14.8) for 1 hour at RT, followed by primary antibodies at 4℃ overnight, 
including anti-ADAMTS-7 pro-domain antibody (Abcam), anti-ADAMTS-7 spacer 
domain antibody (Abcam) which were used to detect ADAMTS-7 protein in conditioned 
media, cell surface washes and cell lysate of VSMC and EC; anti-TSP-5 antibody 
(Millipore) was used to detect the cleaved TSP-5 fragment in VSMC conditioned media 
and digests in in vitro TSP-5 digestion assay; anti-ADAMTS-7 pro-domain antibody 
(Abcam) and anti-cMyc antibody (Sigma-Aldrich) was used to detect ADAMTS-7 in 
conditioned media, cell surface washes and cell lysate of transfected HEK293 cells; anti-
TSP-1 antibody (R&D system) was used to detect TSP-1 protein in EC conditioned media. 
Thereafter, appropriate secondary antibodies were incubated with membranes at RT for 1 
hour after three times washing with 1x TBST, 10 minutes each time. Secondary antibodies 
including anti-rabbit IgG conjugated with HRP (for ADAMTS-7 antibodies, Cell 
signalling); anti-rat IgG conjugated with HRP (for TSP-5 antibody, Dako); anti-mouse 
IgG conjugated with HRP (for c-Myc and TSP-1 antibody, Cell signalling) (Antibodies 
details described in Appendix Table 2.14.9). Amersham ECL Plus Western blotting 
Detection Reagents (GE healthcare life science) and Amersham Hyperfilm ECL (GE 
healthcare life science) were used to develop the plot. Then the films were scanned using 
Epson Perfection V500 Photo Scanner and densitometry analysis was performed using 
Adobe Photoshop.  
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2.15 EC Capillary-like network formation assay 
 
EC is the major cell type involved in angiogenesis, which is not only participating in 
pathological processes including tumour biology and atherosclerosis, but also vital in 
growth and development, as well as reproduction and tissue repair. In response to 
angiogenic signals, such as VEGF and FGF-2, ECs release proteases to degrade the 
surrounding ECM, migrate towards angiogenic signals, proliferate and form new blood 
vessels and eventually form three-dimensional vasculature. In vivo angiogenesis assays, 
such as sponge implantation, corneal, zebrafish, chick chorioallantoic membrane (CAM) 
and tumor angiogenesis models, are considered to be the most informative of these but are 
often expensive, time-consuming and require specialist training to perform (Staton et al. 
2004). In vitro assays tend to be more rapid, less expensive and easier to interpret. In vitro 
angiogenesis assays operate on the principle that ECs form tubule-like structures when 
cultured on a supportive matrix. Assays involving a matrix derived from murine tumours, 
Matrigel, are now the most common in in vitro tubule formation assays (Donovan et al. 
2001). This assay is widely used to identify stimulators or inhibitors of angiogenesis, as 
well as investigate genes and signalling pathway involved in angiogenesis. In this assay, 
substances that promote angiogenesis facilitate the formation of capillary-like structure, 
while the inhibitors of angiogenesis disturb its formation. This assay involves endothelial 
migration and proliferation, one protein or compound that affects either of these processes 
will affect the outcome of the assay.  
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In order to investigate the effect of SNP rs3825807 on angiogenesis, EC capillary-like 
network formation assay was performed. The assay was also used to assess the effect of 
ADAMTS7 over-expression and knock-down on angiogenesis.  
 
The following cells were used to for capillary-like network formation assay: 
 
ECs with different genotypes of rs3825807 
ECs transfected with pcDNA3.1 vector control plasmid 
ECs transfected with ADAMTS7-214Ser plasmid 
ECs transfected with ADAMTS7-214Pro plasmid 
ECs infected with non-target pLKO.1 control lentiviral particles 
ECs infected with ADAMTS7 shRNA lentiviral particles 
 
MatrigelTM Basement Membrane Matrix (BD) was defrosted at 4℃ in an ice bath one day 
before the assay. The next day, Matrigel was added into a 96-well plate (50µl/well) and 
incubated in 37℃ incubator for 1 hour. Afterwards, 15,000 cells per well in 100 µl Human 
Endothelial-SFM (Life Technologies) were added directly into the Matrigel coated well.  
The cells were then incubated at 37˚C with 5% CO2, and images of the capillary-like 
structure at each well were obtained after 3, 6, and 9 hours, respectively using a light 
microscope with a digital camera. ImageJ’s angiogenesis analyser was used to analyse the 
capillary-like structure of each well at 3, 6 and 9 hours after seeding. 
 
 
 123 
2.16 Proteomics  
 
TSP-5, the best studied ADAMTS-7 substrate known to regulate SMC migration, is not 
expressed in ECs (Riessen et al. 2001). Thus, it is likely that the effect of ADAMTS-7 on 
EC migration and angiogenesis is not through cellular TSP-5 mediated mechanism. Hence, 
a proteomic analysis was performed with the aim to identify the possible previously 
unknown substrates for ADAMTS-7, which might play a role in mediating the effect of 
ADAMTS-7 on angiogenesis.  
 
Proteomics has become an increasingly common method for identifying proteins and 
characterise their amino acid sequences and posttranslational modifications. It requires 
proteolytic digestion of proteins prior to their analysis by mass spectrometry. The most 
common proteomic method is termed bottom-up proteomics. The proteins can be purified 
by 2-dimensional gel electrophoresis (2D-GE) resulting in one or a few proteins for 
proteolytic digestion prior to analysis by mass spectrometry. Alternatively, a protein 
mixture can be digested directly by protease, followed by separation of peptides by liquid 
chromatography (LC) coupled to tandem mass spectrometry, a technique known as 
shotgun proteomics.  
 
In shotgun proteomics, the protein mixture from cells (either whole cell lysates or secreted 
proteins in conditioned media) is digested by a protease to produce a peptide mixture. The 
most commonly used enzyme is trypsin, because it cleaves specifically after the basic 
residues arginine (Arg) and lysine (Lys), if these are not followed by proline (Pro). The 
peptide mixture is then loaded directly onto a chromatography column (High-Performance 
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Liquid Chromatography, HPLC) to separate the peptides through hydrophobicity and 
charge. Subsequently, the peptides are ionised and separated by mass to charge ratio (m/z) 
in the first stage of tandem mass spectrometry (MS1). These peptides are further 
fragmented during collision-induced dissociation, producing fragmentation of peptides 
that are broken at different positions. The charged fragments are then separated in the 
second stage of tandem mass spectrometry. Afterwards, the fragmentation mass 
spectrometry data are analysed by commercially available software such as Mascot and 
the interpretation can reveal the peptides’ sequence, or part of it, i.e., a sequence tag. This 
is then compared against a protein database to identify the best matched protein. Finally, 
the identified protein can also be quantified by various methods such as Spectral Index 
Normalised Quantitation (SINQ).  
 
The following EC cell lines were used for the proteomics analysis in this project:  
 
(1) HUVECs cultured in normal condition to serve as a control 
(2) HUVECs transfected with the ADAMTS7-214Ser plasmid 
(3) HUVECs infected with ADAMTS7 shRNA lentiviral particles 
 
These cells were starved with Human Endothelial-SFM (Life Technologies). The culture 
media were harvested daily for 48 hours. Afterwards, culture media were collected and 
concentrated by centrifugal concentrators (Millipore) according to the manufacturer’s 
protocol. Briefly, after span down at 2000g for 5 minutes to remove cell debris, the 
supernatant was added into the filter column and centrifuged at 4000 g for 30 minutes. 
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The concentrated samples were transferred into a sterile tube and sent to Central 
Proteomics Facility, Oxford University for proteomic analysis.  
 
2.17 Bruneck Study cohort 
 
Subjects of this study were residents of the Bruneck area in Italy, who participated in the 
Bruneck Study, details of which have been described previously (Kiechl and Willeit, 
1999a; Kiechl and Willeit, 1999b; Willeit et al, 2000). DNA samples for genotyping were 
available for 787 subjects. Ultrasound scanning of the right and left internal carotid and 
common carotid arteries was performed in 1990 and 1995 by the same experienced 
sonographer (Kiechl and Willeit, 1999a; Kiechl and Willeit, 1999b; Willeit et al, 2000). 
Atherosclerotic lesions were defined according to two ultrasound criteria: (1) wall surface 
(protrusion or roughness of the arterial boundary) and (2) wall texture (echogenicity). The 
atherosclerosis score, indicative of atherosclerosis severity, was calculated by summing 
all diameters at 8 well-defined segments of the common and internal carotid arteries.  
Incident atherosclerosis was defined by the occurrence of atherosclerotic lesions in 
segments previously free of atherosclerosis or enlargement of non-stenotic lesions by a 
relative increase in the plaque diameter exceeding twice the measurement error of the 
method. Intima-media thickness was assessed in plaque-free sections of the common 
carotid arteries. 
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2.18 Southampton Atherosclerosis Study (SAS)  
  
A total of 1730 Caucasian patients underwent diagnostic or interventional coronary 
angiography at the Southampton General Hospital were recruited, of which 1342 had >50% 
diameter stenosis in at least one of the major epicardial coronary arteries, and the 
remaining 388 subjects showed normal angiogram. Demographic and clinical data were 
recorded including age, gender, height, weight, occupation, smoking status, presence or 
absence of hyperlipidaemia (defined as cholesterol >5.2mmol/l  and/or 
triglyceride >3mmol/l), HDL level, LDL level, triglyceride level, hypertensive status 
(>160/95mmHg), diabetic status, the use of lipid-lowering drugs (mainly statins), 
presence or absence of previous myocardial infarction and family history of coronary 
artery disease (in a first degree relative below 65 years of age). Total cholesterol, HDL, 
LDL and triglyceride levels were measured using standard quality controlled enzymatic 
methods at the Southampton General Hospital. Data for total cholesterol, HDL, LDL, and 
triglyceride levels were available for 1591, 1060, 479, and 1465 subjects, respectively. 
One single consultant cardiologist assessed each angiogram. Demographical and clinical 
characteristics of the SAS subjects are described in (Ye et al, 2003). DNA was previously 
isolated from peripheral blood samples from these subjects and utilised for genotyping in 
this project. (This part of work was done by other group members, the information above 
was cited from PhD thesis of Dr. Anna Motterle) 
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2.19 Bioinformatics 
 
F-SNP (available from Queen’s University at http://compbio.cs.queensu.ca/F-SNP/) was 
used to identify possible functional effect of these GWAS-identified CAD-associated lead 
SNPs at the ADAMTS7 gene locus, including functional assessment of protein coding, 
splicing regulation, transcriptional regulation, post translation by using various tools and 
databases (more information, please visit the ‘Resource section’ at 
http://compbio.cs.queensu.ca/F-SNP/).  
 
PSIPRED (available from University College London Department of Computer Science 
Bioinformatics Group at http://bioinf.cs.ucl.ac.uk/psipred/) was used to predict possible 
functional effect of non-synonymous SNP rs3825807 on secondary structure of 
ADAMTS-7. 
 
QUARK (available from University of Michigan at http://zhanglab.ccmb.med.umich.edu 
/QUARK/) was used to predict possible functional effect of non-synonymous SNP 
rs3825807 on 3D structure of ADAMTS-7.  
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2.20 Statistical analyses 
 
Values for linkage disequilibrium (LD) between SNPs rs3825807, rs1994016 and 
rs4380028 in the HapMap and 1000 Genomes databases were obtained from Ensembl. 
Student’s t-test (two groups) and One-way ANOVA (three groups) were used to analyse: 
real-time RT-PCR results by the ∆∆Ct method; differences between genotypes in cell 
proliferation, senescence, apoptosis and migration distance in the scratch assay; band 
intensity in Western blot analyses. Paired Student’s t-test was performed to analyse: allelic 
expression imbalance analysis results; VSMC migrated numbers in the trans-well 
migration assay; in vitro TSP-5 digestion assay results; differences between over-
expression and controls or knock-down and control groups in EC migration and capillary-
like network formation assay. In the Bruneck Study, associations of rs3825807 with 
carotid atherosclerosis were tested by logistic and linear regression analyses. Base models 
were adjusted for age and sex. Multivariable models were adjusted for variables correlated 
with atherosclerosis parameters in the Bruneck cohort, including presence or absence of 
hypertension, smoking status, diabetes mellitus, level of alcohol consumption, levels of 
high density lipoprotein and low density lipoprotein, ferritin, fibrinogen, anithrombin III, 
the factor V Leiden mutation, body mass index, waist-to-hip ratio  and log-transformed 
concentrations of urinary albumin, high-sensitivity C-reactive protein and lipoprotein(a). 
Pearson linear Regression analysis was used to analyse the relationship of the proportion 
of ADAMTS-7 in the intima area and intima thickness of atherosclerotic plaque. Variables 
with a skewed distribution were normalised by logarithmic transformation. Mean and 
standard error of the mean (SEM) were calculated using SPSS10.0. All p-values were two-
sided, and p<0.05 defined as significance. 
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Chapter 3  
Functional study of ADAMTS7 variants in VSMC 
 
Three independent GWA studies revealed an association between genetic variants at the 
ADAMTS7 locus and the susceptibility to coronary artery disease. However, the 
mechanisms underlying these associations have remained unclear. Thus, functional 
studies of these variants at the ADAMTS7 gene locus were carried out in this part of study. 
Immunohistochemical analyses showed that ADAMTS-7 was expressed in human 
coronary and carotid atherosclerotic plaques, mostly localised to vascular smooth muscle 
cells (VSMCs) in the plaque. The colocalisation of ADAMTS-7 and VSMCs suggests 
they might be functionally related. Moreover, a previous study showed that ADAMTS-7 
could facilitate VSMC migration through cleavage of its substrate TSP-5 and thus promote 
neointima formation after mechanical injury of rat carotid artery. Thus, we carried out the 
functional studies of the CAD-associated SNPs in VSMCs. 
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3.1 Results 
 
3.1.1 Verification of SMCs isolated from human umbilical arteries 
 
ECs form a monolayer facing the lumen of the blood vessel, so during the isolation of 
VSMCs, these cells may also migrate from the tissue and contaminate the VSMC primary 
cell culture. Fibroblasts are predominantly located in the adventitial layer of the artery. 
Although this layer was carefully removed during the isolation, a small number of 
fibroblasts may still be left and thus may form part of the contaminant. To verify that the 
cells isolated from human umbilical arteries were smooth muscle cells and not vascular 
ECs or fibroblasts, several isolated primary VSMC cell lines were subjected to ICC 
staining for markers of VSMCs, ECs, and fibroblasts, respectively. 
 
VSMCs were isolated from approximately 160 human individuals’ umbilical cords. 
Among them, around 30 samples failed to propagate the VSMC primary cell cultures 
leaving us with primary VSMCs from approximately 130 individuals. Isolated cells 
showed typical SMC morphology (Figure 3.1 A), and strong fluorescent signal was 
observed when the cells were stained for the VSMC marker, SM α-actin (SMA, Figure 
3.1 B). Meanwhile, neither of the fibroblast cell marker DDR2 (Figure 3.1 C) nor the EC 
marker CD144 (Figure 3.1D) was detected, indicating that there was no detectable 
contamination of these two types of cells in the VSMC culture.  
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Figure 3.1 Verification of the homogeneity of VSMC cultures. Isolated VSMCs express high 
levels of the smooth muscle -actin (SMA, red). Neither of the fibroblast cell marker discoidin 
domain-containing receptor 2 (DDR2, green) nor the EC marker cluster of differentiation 144 
(CD144, green) is detected. A: Isolated VSMCs under bright field. B: staining with SM-actin-
Cy3/red (red); C: staining with DDR2-FITC (green); D: staining with CD144-FITC. Cell nuclei 
were stained with DAPI (blue). 
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3.1.2 Isolated VSMCs express ADAMTS-7 
 
Although ADAMTS-7 has been shown to be expressed in neointima of the blood vessel 
and colocalised with VSMCs in a rat injury model (Wang et al. 2009), the expression of 
ADAMTS-7 protein in human VSMCs had not been reported before. Thus, isolated 
VSMCs were subjected to ICC staining aiming to detect ADAMTS-7 protein expression 
in these cells. Eight primary cultures of VSMCs underwent double fluorescent 
immunostaining for SMA (red) and ADAMTS-7 (green). The nucleus was stained with 
propidium iodide (PI, blue). The staining showed that the ADAMTS-7 protein was 
expressed by human VSMCs (Figure 3.2).  
 
 
 
Figure 3.2 Representative images showing presence of ADAMTS-7 in cultured VSMCs. 
Isolated VSMCs express ADAMTS-7. A: staining with SM-actin-Cy3/red (red); B: staining with 
ADAMTS-7 - FITC (green); C: Cell nuclei staining with PI (blue); D: Merged.  
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3.1.3 ADAMTS-7 is expressed in human atherosclerotic plaques 
 
3.1.3.1 ADAMTS-7 fluorescence staining in carotid atherosclerotic plaques 
 
Sections of formalin-fixed paraffin-embedded tissue blocks of carotid atherosclerotic 
plaques were subjected to double fluorescent immunostaining for SMA (red) and 
ADAMTS-7 (green) and DAPI fluorescent staining for nuclei (blue). Confocal 
microscopy was used to examine the staining results. The experiment showed that 
ADAMTS-7 was expressed in the human atherosclerotic plaques, with strong staining in 
SMCs (Representative images are shown in Figure 3.3). 
 
 
Figure 3.3 ADAMTS-7 is detected by fluorescent immunostaining in human carotid artery 
atherosclerotic plaques. Carotid atherosclerotic plaque sections underwent to double fluorescent 
immunostaining for SMA (red), ADAMTS-7 (green) and DAPI fluorescent staining for nuclei 
(blue), followed by confocal microscopy examination. A: SMA staining; B: ADAMTS-7 staining 
with an anti-ADAMTS-7 spacer domain antibody; C: nuclear staining; D: merged image from 
SMA, ADAMTS-7 and nuclear staining.  
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In order to verify the specificity of the ADAMTS-7 staining in carotid atherosclerotic 
plaque sections, a blocking peptide (Abcam) matching the epitope of the ADAMTS-7 
(spacer domain) antibody (Abcam) was used (Figure 3.4). IHC staining of carotid artery 
atherosclerotic plaque sections with ADAMTS-7 spacer domain antibody showed that 
ADAMTS-7 was expressed in atherosclerotic plaques (Figure 3.4A). While the staining 
of ADAMTS-7 in carotid atherosclerotic plaque sections was totally blocked by using a 
blocking peptide matching the epitope of the ADAMTS-7 (spacer domain) antibody, 
indicating the ADAMTS-7 staining in the plaque by using this anti-spacer domain 
antibody is specific. 
 
 
 
Figure 3.4 ADAMTS-7 is present in human carotid artery atherosclerotic plaques. A: A 
representative image of single immunostaining shows that ADAMTS-7 (brown) is expressed in 
carotid atherosclerotic plaques. B:  Peptide blocking for ADAMTS-7 staining (a blocking peptide 
for ADAMTS-7 spacer domain antibody was used). 
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3.1.3.2 ADAMTS-7 staining in coronary atherosclerotic plaques 
 
ADAMTS-7 has been shown to facilitate VSMC migration and neointima formation in a 
rat vascular injury model of post-angioplasty restenosis (Wang et al. 2009). However, the 
mechanisms underlying post-angioplasty restenosis are different from the pathogenesis of 
atherosclerosis, thus the role of ADAMTS-7 in atherosclerosis remains to be elucidated. 
More importantly, several GWAS studies have reported that SNPs in the ADAMTS7 gene 
locus are strongly associated with CHD, making a strong case for ADAMTS7 as a 
candidate gene for CHD (Coronary Artery Disease Genetics 2011, Reilly et al. 2011, 
Schunkert et al. 2011). In order to examine whether ADAMTS-7 protein was expressed 
in atherosclerotic plaques, and if so, in which cell type, IHC staining was performed using 
coronary artery atherosclerotic plaque sections.  
 
Double immunostaining for ADAMTS-7 and the VSMC marker SMA showed that 
ADAMTS-7 was expressed and colocalised with a proportion of VSMCs in 
atherosclerotic plaques of coronary arteries (Figures 3.5). We observed that in the 
atherosclerotic plaques, VSMCs that accumulated ADAMTS-7 were mostly located near 
the intima-media border and the fibrous cap. ADAMTS-7 positive staining were detected 
both within cells (highlighted by black arrowheads) and in the extracellular spaces 
(highlighted by green arrowheads) (Figure 3.5B).  
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Figure 3.5 ADAMTS-7 is present in human coronary artery atherosclerotic plaques. Purple 
color (NBT/BCIP) indicates SMA staining, and dark brown color (DAB) indicates ADAMTS-7 
staining. Panel A, B and C show the same location at 4x, 10x and 20x respectively. Black arrows 
in panel B indicate cell positive for both SMA and ADAMTS-7, while green arrows indicate 
extracellular ADAMTS-7 staining. D: Negative control. (ADAMTS-7 spacer domain antibody 
was used for ADAMTS-7 staining; negative control was performed with the secondary antibody 
only for all the staining, or otherwise stated) 
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3.1.4 TSP-5 is expressed in human carotid atherosclerotic plaques 
 
TSP-5 is the best-studied substrate of ADAMTS-7 (Liu et al. 2006). A recent study in rats 
demonstrated that ADAMTS-7 facilitated VSMC migration by cleaving TSP-5, thereby 
promoting neointima formation following vascular mechanical injury (Wang et al. 2009). 
Studies have also shown that TSP-5 was expressed in human normal and atherosclerotic 
vessel wall and colocalised with VSMCs (Riessen et al. 2001). We verified TSP-5 
expression in human carotid atherosclerotic plaque by immunostaining using a TSP-5 
antibody as described in the Methods section of this chapter (Figure 3.6). As reported by 
Riessen and colleagues, TSP-5 was found to be present in human carotid atherosclerotic 
plaques and colocalised with a proportion of SMCs in the plaque (highlighted by black 
arrowheads in Figure 3.6A).  
 
 
 
Figure 3.6 TSP-5 is present in human carotid artery atherosclerotic plaques. Dark brown 
color (DAB) indicates TSP-5 staining. A: A representative image of IHC staining shows that TSP-
5 is present in human carotid atherosclerotic plaques and colocalises with a proportion of SMCs 
in the plaque (highlighted by black arrowheads). B: Negative control (with secondary antibody 
only).  
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3.1.5 Genotyping of VSMCs for CAD-related SNPs at the ADAMTS7 locus  
 
Genomic DNA from VSMCs was extracted and genotyped using the KASPar method for 
three CAD-associated SNPs at the ADAMTS7 locus. The successful genotyping rate was 
88.2% for rs3825807, 100% for rs1994016 and 97.6% for rs4380028. Out of these, 
thirteen samples were chosen for DNA sequencing to further confirm the genotype, among 
them 12 samples were correct, with one sample incorrectly genotyped. The restriction 
enzyme digestion method was also tested but showed less than 60% success rate. Finally, 
we combined the genotyping results of the three methods and obtained the following 
genotype information (Table 3.1, for detailed information of VSMC genotype, please see 
Appendix table 3.1.1) for the VSMC collection regarding the SNPs of interest. The 
genotype frequencies were in agreement with Hardy-Weinberg equilibrium.  
 
Table 3.1 CAD-related SNPs’ genotyping results for VSMCs 
 
SNP Genotype  Number Frequency (%) 
rs3825807 A/A 66 59 % 
  A/G 35 31 % 
  G/G 11 10 % 
 Total 112 100 % 
rs1994016 C/C 72 57 % 
  T/C 52 41 % 
  T/T 3 2 % 
 Total 127 100 % 
rs4380028 C/C 69 55 % 
  T/C 42 34 % 
  T/T 13 11 % 
 Total 124 100 % 
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Linkage disequilibrium values (r2) between these three SNPs in our VSMC sample 
collection were similar to those in the HapMap data set obtained using the SNAP 
Programme (Table 3.2).  
 
Table 3.2 Linkage disequilibrium values (r2) between the three ADAMTS7 SNPs studied 
SNP1 SNP2 HapMap  Our VSMC sample collection 
rs3825807 rs1994016 0.87 0.76 
rs3825807 rs4380028 0.52 0.67 
 rs1994016 rs4380028 0.57 0.63 
 
 
Genomic DNA was also extracted from coronary atherosclerotic plaques (n=55) and 
genotyped for SNP rs3825807 using the KASPar method. The genotype frequency in this 
sample collection is shown in Table 3.3.  
 
Table 3.3 Coronary artery plaque collection ADAMTS7 SNP rs3825807 genotyping results  
SNP Genotype Number Frequency (%) 
rs3825807 A/A 24 44 % 
  A/G 20 36 % 
  G/G 11 20 % 
  Total  55 100 % 
 
 
3.1.6 The CAD-related SNPs at the ADAMTS7 locus have no effects on VSMC 
proliferation, senescence and apoptosis 
 
The presence of ADAMTS-7 in atherosclerotic plaques and its colocalisation with 
VSMCs led us to investigate the role of the CAD-related ADAMTS7 SNPs in VSMC 
biological processes involved in plaque progression, such as proliferation, senescence, 
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apoptosis and migration.  Described in this section are results of assays of proliferation, 
senescence and apoptosis. Results of migration will be described in the next section. 
 
3.1.6.1 VSMC proliferation 
 
Proliferation of VSMCs isolated from different individuals was analysed using the BrdU 
labelling method (as described in section 2.5.1). No significant difference in proliferation 
was detected between the genotype groups of any of the three CAD-associated SNPs at 
the ADAMTS7 gene locus studied (Figure 3.7), indicating that the association between 
these SNPs and CAD was not through regulation of VSMC proliferation.  
 
 
 
Figure 3.7 CAD-related SNPs at the ADAMTS7 gene locus have no effect on VSMC 
proliferation. Data shown are values of cell proliferation as measured using BrdU assay (mean ± 
SEM). Statistically analysis performed using one-way ANOVA for SNP rs3825807 and 
rs4380028 and Student’s t-test for rs1994016 (due to small sample size of rare allele homozygote 
T/T genotype, we combined the heterozygote group with rare allele homozygote group to increase 
the power of our analysis). No statistical significance was found.  
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3.1.6.2 VSMC senescence 
 
The senescence assay method measuring the enzyme SA-ß-Gal produced by senescent 
cells was used. This assay showed no association between the SNPs studied and VSMC 
senescence (Figure 3.8).  
 
 
 
Figure 3.8 CAD-related SNPs at the ADAMTS7 gene locus have no effect on VSMC 
senescence. Data shown are values of cell senescence (mean ± SEM). Statistically analysis 
performed using one-way ANOVA for SNP rs3825807 and rs4380028 and Student’s t-test for 
rs1994016. No statistical significance was found.   
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3.1.6.3 VSMC apoptosis 
 
Apoptosis is programmed cell death, where the genome of the cells is degraded into small 
DNA-histone complexes, which can be quantified. VSMC apoptosis is a critical process 
during the progression of atherosclerosis and also destabilises the atherosclerotic plaque, 
making it prone to rupture. Plaque rupture can cause myocardial infarction and stroke.  
 VSMC apoptosis assay was performed to investigate whether any of the three CAD-
associated ADAMTS7 SNPs studied affect VSMC apoptosis. The assay showed no 
association between these SNPs and VSMC apoptosis (Figure 3.9). 
 
 
 
Figure 3.9 CAD-related SNPs at the ADAMTS7 gene locus have no effect on VSMC apoptosis. 
Data shown are values of cell apoptosis (mean ± SEM). Statistically analysis performed using one-
way ANOVA for SNP rs3825807 and rs4380028 and Student’s t-test for rs1994016. No statistical 
significance was found.  
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3.1.7 Influence of CAD-related ADAMTS7 SNPs on VSMC migration 
 
It is generally recognised that SMC migration plays an important role in atherosclerosis. 
A recent study in rats showed that ADAMTS-7 facilitated VSMC migration and promoted 
neointima formation after balloon injury (Wang et al. 2009). Thus, we sought to 
investigate whether the CAD-associated SNPs at the ADAMTS7 gene locus influence 
human VSMC migration. Scratch assays, as described in section 2.6.1, is a simple way to 
study cell migration. This method was used to study primary VSMCs from individuals of 
different genotypes for the CAD-associated ADAMTS7 SNPs.  
 
The scratch assay showed that VSMCs of the A/A genotype for rs3825807 had higher 
migratory ability, compared with G/G genotype of rs3825807 (p<0.05), and A/G genotype 
cells had migratory ability between that of A/A and G/G genotype cells; however, the 
difference between A/G and G/G genotypes was not significant (Figure 3.10).  
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Figure 3.10 SNP rs3825807 affects VSMC migration. A: Representative pictures of rs3825807 
homozygous genotypes at different time points of migration assay. B: Column chart represents 
migration distance (mean ± SEM) of VSMCs in DMEM supplemented with 15% FBS at different 
time points (n=5 for each genotype). One-way ANOVA (three genotype groups) and student’s t-
test (two genotype groups) was used to analyse the differences between genotype groups of the 
SNPs. * p<0.05 comparing A/A and G/G genotype group.  
 
 
The effect of SNP rs3825807 on VSMC migration was observed in several cell culture 
conditions including culturing in  media supplemented with 15% FBS (Figure 3.10), in 
serum-free media (Figure 3.11A), and in serum-free media with the addition of PDGF-
BB (Figure 3.11B). In the presence of PDGF-BB, SNP rs3825807 still had an influence 
on VSMC migration, more interestingly, A/A genotype VSMCs showed much faster 
migration rates than both A/G and G/G genotype cells (Figure 3.11B). However, PDGF-
BB treatment did not show strong stimulation on VSMC migration, possibly due to its low 
bioactivity after long period of storage.  
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Figure 3.11 Effect of SNP rs3825807 on VSMC migration in serum-free media with or 
without PDGF-BB. Column charts represent migration distance (mean ± SEM) of VSMCs with 
serum-free media with or without PDGF-BB (10ng/ml) at different time points (n=5 for each 
genotype). One-way ANOVA (three genotype groups) and student’s t-test (two genotype groups) 
was used to analyse the differences between genotype groups of the SNPs. * p<0.05 comparing 
A/A and G/G genotype group. # p<0.05 comparing A/A and A/G genotype group.  
 
 
The other two CAD-associated SNPs at the ADAMTS7 locus, rs1994016 and rs4380028, 
showed similar results to rs3825807, cells of the C/C genotype (risk allele homozygote) 
having greater migratory ability than cells of the C/T or T/T genotype (Figure 3.12-3.14). 
The similar effect of these three SNPs on VSMC migration is possibly due to the high LD 
between them.  
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Figure 3.12 SNPs rs1994016 and rs4380028 affect VSMC migration in serum-containing 
media. Column charts represent migration distance (mean ± SEM) of VSMCs in DMEM 
supplemented with 15% FBS at different time points (n=3~5 for each genotype). Student’s t-test 
was used to analyse the differences between genotype groups of the SNPs. * p<0.05 comparing 
C/C and T/C+T/T genotype group (we combined T/C and T/T due to availability of cells).  
 
 
 
 
Figure 3.13 SNPs rs1994016 and rs4380028 affect VSMC migration in serum-free medium. 
Column charts represent migration distance (mean ± SEM) of VSMCs in serum-free media at 
different time points (n=3~5 for each genotype). Student’s t-test was used to analyse the 
differences between genotype groups of the SNPs. * p<0.05 comparing C/C and T/C+T/T 
genotype group.  
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Figure 3.14 SNPs rs1994016 and rs4380028 affect VSMC migration in the presence of 
PDGF-BB. Column charts represent migration distance (mean ± SEM) of VSMCs in serum-free 
media with PDGF-BB (10ng/ml) at different time points (n=3~5 for each genotype). Student’s t-
test was used to analyse the differences between genotype groups of the SNPs. * p<0.05 comparing 
C/C and T/C+T/T genotype group.  
 
 
The results from the scratch assay showed that the CAD-associated SNPs at the ADAMTS7 
locus could affect VSMC migration. Therefore we postulated that these three CAD-
associated SNPs might affect ADAMTS7 expression or ADAMTS-7 activation. Since 
ADAMTS-7 is a secreted protein, VSMCs with higher migratory ability could presumably 
have more ADAMTS-7 in the conditioned media and therefore have the ability to promote 
cell migration. To investigate whether this was the case, we collected conditioned media 
from VSMC cultures of different genotypes for rs3825807 and concentrated the media. 
Then, we added the concentrated conditioned media of A/A genotype cells into G/G 
genotype cells at the beginning of migration assay, and, conversely, A/A genotype cells 
with conditioned media of G/G genotype cells. The assay confirmed the previous finding 
that A/A genotype VSMCs had greater ability to migrate than VSMCs of the G/G 
genotype in serum-free media condition. More importantly, G/G cells with conditioned 
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media of A/A genotype cells showed increased migratory ability compared with G/G cells 
with serum-free media, indicating that A/A genotype cells likely secrete a migration-
promoting factor into the media (Figure 3.15). This is consistent with our hypothesis in 
which the conditioned media from A/A genotype cells have more ADAMTS-7 and thus 
could promote VSMCs to migrate. Interestingly, A/A genotype cells with G/G genotype 
cell conditioned media did not show any effect on VSMC migration. One possible 
explanation is that A/A genotype cells can continuously secrete active ADAMTS-7 into 
the media, so the G/G genotype conditioned media could not affect the migratory ability 
of A/A genotype cells.  
 
 
 
Figure 3.15 Effect of SNP rs3825807 on VSMC migration. Primary cultures of VSMCs of the 
A/A or G/G genotype for rs3825807 were subjected to scratch assays, with or without media 
swapping at the outset of the assay (i.e. at hour 0 of the assay, the culture media of G/G genotype 
cells was replaced by A/A genotype cell conditioned media, and vice versa). Column chart shows 
migration distances (mean ± SEM) (n=3 for each genotype). Student’s t-test was used to analyse 
the differences between two groups. *p<0.05 comparing A/A genotype cells with SFM and G/G 
genotype cells with SFM; p<0.05 comparing G/G genotype cells with A/A genotype cells’ 
conditioned media versus G/G genotype cells with SFM.  
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3.1.8 CAD-related ADAMTS7 SNPs have no effect on ADAMTS7 mRNA level 
in VSMCs 
 
The results from the migration assays support our hypothesis that the CAD-associated 
SNPs influence VSMC migration due to their effect on ADAMTS-7 production and/or 
activity in the culture media. This could be due to some or all of these SNPs having a 
genotypic effect on ADAMTS7 mRNA expression level and consequently on ADAMTS-
7 protein level.  
 
In order to investigate whether these variants have an influence on ADAMTS7 mRNA 
level in VSMCs, cells of different genotypes for SNPs rs3825807, rs1994016 and 
rs4380028 were subjected to ADAMTS7 mRNA expression real-time RT-PCR analysis. 
No significant association between ADAMTS7 mRNA level and genotype for any of these 
SNPs was detected in these assays, although in the case of rs1994016, lower ADAMTS7 
mRNA levels in T/T genotype cells were observed (Figure 3.16), suggesting a possible 
genotypic effect of this SNP on ADAMTS7 expression, however, need larger sample size 
to reach significant level. 
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Figure 3.16 CAD-associated SNPs do not affect ADAMTS7 mRNA expression level in 
VSMCs. The ∆∆Ct method was used to analyse the data (beta-actin as internal control). Data 
shown are relative ADAMTS7 mRNA expression to beta-actin (mean ± SEM). One-way ANOVA 
was used to analyse the difference between genotype groups of the SNP, p>0.05. 
 
 
In addition to real-time RT-PCR, a second method was used to investigate whether the 
SNPs had an effect on ADAMTS7 mRNA expression level, specifically, an allelic 
expression imbalance analysis of ADAMTS7 was performed in VSMCs that were 
heterozygous for SNP rs3825807. If the SNP affects ADAMTS7 mRNA expression, the 
ratio of the A allele versus the G allele should be different in cDNA from the ratio in 
gDNA. The analysis showed no difference in the A to G ratio between cDNA and gDNA 
samples (Figure 3.17), indicating that the SNP did not have an effect on ADAMTS7 
expression.  
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Figure 3.17 CAD-associated SNPs have no effect on ADAMTS7 mRNA expression levels in 
VSMCs, determined by allelic expression imbalance assay. A: Chromagrams from gDNA and 
cDNA from isolated VSMCs, respectively. B: Schematic representation of the A/G ratios for 
gDNA and cDNA (mean ± SEM). Mann-Whitney test was performed to test a difference between 
the ratio of standardised A nucleotide peak height over standardised G nucleotide peak height 
from cDNA and the corresponding ratio from gDNA, n=10, P>0.05.  
 
 
Since the results of qRT-PCR and allelic imbalance assays demonstrated that the CAD-
associated SNPs at the ADAMTS7 locus had no effect on ADAMTS7 mRNA expression 
level, further experiments were conducted to investigate the possibility that they may have 
an impact on ADAMTS-7 protein activity. Of these SNPs, only rs3825807 causes an 
amino acid substitution, whereas rs1994016 is located in an intron and rs4380028 in the 
3’-flanking region of the ADAMTS7 gene. Thus the latter two SNPs are less likely to affect 
ADAMTS-7 protein activity than the non-synonymous SNP rs3825807. Therefore, the 
following experiments were focused on SNP rs3825807.  
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3.1.9 Effect of SNP rs3825807 on ADAMTS-7 pro-domain cleavage 
 
SNP rs3825807 is located in exon 4 of the ADAMTS7 gene and results in a serine (Ser) to 
proline (Pro) substitution in the pro-domain of ADAMTS-7 (Figure 3.18). 
 
 
 
Figure 3.18 Location of SNP rs3825807 and the resulting Ser-to-Pro substitution. The upper 
panel indicates the location of SNP rs3825807 in the ADAMTS7 gene. The middle panel is the 
schematic structure of ADAMTS-7 protein. The lower panel indicates the location of amino acid 
substitution resulted by SNP rs3825807 in ADAMTS-7 protein sequence. Figure cited and 
modified from (http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3825807) 
(Somerville et al. 2004) 
 
 
Although the qRT-PCR results showed that the rs3825807 genotype did not affect 
ADAMTS7 mRNA expression level, Western blotting analysis was carried out to 
investigate if the SNP had an effect on ADAMTS-7 protein level in VSMCs. The analysis 
showed no difference in ADAMTS-7 protein level between different genotypes for 
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rs3825807, supporting the finding that the SNP did not affect ADAMTS7 expression 
(Figure 3.19).  
 
 
 
Figure 3.19 No effect of the CAD-related SNP rs3825807 on ADAMTS-7 protein level. A: A 
representative image of Western blot analysis of whole cell protein lysates of VSMCs of the A/A 
and G/G genotype for rs3825807. Equal amounts of protein (20μg) for each genotype was loaded 
and subjected to Western blotting using an ADAMTS-7 pro-domain antibody. B: Data shown in 
column chart are full-length ADAMTS-7 band intensity (mean ± SEM) in Western blot (n=3 for 
each genotype). Student’s t-test was used to analyse the data, no statistical significance was found. 
 
 
The Ser-to-Pro substitution resulting from SNP rs3825807 occurs at amino acid residue 
214 of the ADAMTS-7 protein. This residue is located in the pro-domain and is 
immediately adjacent to a predicted core recognition site for furin, a proprotein convertase 
that has been demonstrated to cleave the ADAMTS-7 pro-domain, leading to its activation 
(Somerville et al. 2004). To investigate whether the SNP rs3825807 resulting in the Ser-
to-Pro substitution had an effect on ADAMTS-7 pro-domain cleavage, Western blot 
analyses of conditioned media of VSMCs of different genotypes for this SNP were 
performed. Western blot analyses showed that VSMC conditioned media contained 
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cleaved ADAMTS-7 pro-domain (detected by a specific antibody to pro-domain of 
ADAMTS-7). The analyses showed that the amount of the cleaved ADAMTS-7 pro-
domain in media conditioned by VSMCs of the A/A genotype was ~5 fold higher than in 
media conditioned by VSMCs of the G/G genotype (Figure 3.20). 
 
 
 
Figure 3.20 Effect of CAD-related SNP rs3825807 on ADAMTS-7 pro-domain cleavage in 
conditioned media. A: A representative image of Western blot analysis of cleaved ADAMTS-7 
pro-domain in media conditioned by VSMCs of the A/A, A/G or G/G genotype for rs3825807. 
Equal amounts of proteins (20μg) for each genotype was loaded and subjected to Western blotting 
using an anti-ADAMTS-7 pro-domain antibody. B: Data shown in column chart are cleaved 
ADAMTS-7 pro-domain band intensity (mean ± SEM) (n=5 for each genotype). Student’s t-test 
was used to analyse the data, *p<0.05 comparing A/A and G/G genotypes.  
 
 
These data indicate that SNP rs3825807 has an effect on ADAMTS-7 pro-domain 
cleavage, supporting the hypothesis that SNP rs3825807 affects VSMC migration through 
its effect on ADAMTS-7 protein activation.   
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3.1.10 Influence of SNP rs3825807 genotype on TSP-5 cleavage 
 
It is possible that the cleavage of the pro-domain could lead to the release of the active 
form of ADAMTS-7 with proteolytic activity to process its substrates. It has been shown 
that VSMCs produce the extracellular matrix protein TSP-5 which VSMCs adhere to 
(Riessen et al. 2001) and that ADAMTS-7 promotes VSMC migration via cleaving TSP-
5 (Wang et al. 2009). Following the finding that ADAMTS7 SNP influenced VSMC 
migration and ADAMTS-7 pro-domain cleavage, further experiments were carried out to 
investigate whether there was a difference in the concentration of cleaved TSP-5 in VSMC 
culture media between the three genotypes for rs3825807. The experiments showed that 
culture media of VSMCs of the A/A genotype for SNP rs3825807 contained more cleaved 
TSP-5, compared with the G/G genotype (Figure 3.21).   
 
 
 
 
Figure 3.21 Influence of CAD-related SNP rs3825807 on TSP-5 cleavage. A: A representative 
image of Western blot analysis of cleaved TSP-5 in media conditioned by VSMCs of the A/A, 
A/G or G/G genotype for rs3825807. Equal amounts of protein (20μg) for each genotype was 
loaded and subjected to Western blot analysis using a specific TSP-5 antibody.  B: Data shown in 
column chart are cleaved TSP-5 band intensity (mean ± SEM) (n=5 for each genotype). Student’s 
t-test was used to analyse the data, *p<0.05 comparing A/A and G/G genotypes.  
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We showed that the conditioned media of the A/A genotype cells could promote VSMC 
migration, and subsequent Western blotting analyses showed that conditioned media of 
A/A genotype cells contained more cleaved ADAMTS-7 pro-domain and TSP-5 
fragments. Thus, we further carried out in vitro assays of TSP-5 cleavage with media 
conditioned by VSMCs of either the A/A or G/G genotype to investigate whether 
conditioned media of A/A genotype cells have a higher ability to cleave TSP-5 than 
conditioned media of G/G genotype cells. The assays showed that the conditioned media 
were able to cleave TSP-5 and that the media conditioned by VSMCs of the A/A genotype 
had higher TSP-5 cleavage activity than media conditioned by VSMCs of the G/G 
genotype (Figure 3.22).  
 
 
 
Figure 3.22 In vitro TSP-5 digestion assay. A: A representative image of Western blot analysis 
of products from in vitro TSP-5 cleavage assays. Recombinant TSP-5 (2µg) was incubated, with 
or without 5µl concentrated media conditioned by VSMCs of the A/A or G/G genotype, in a 
digestion buffer at 37°C for 8 hours. The digests, along with undigested TSP-5, were subjected to 
Western blot analysis using an anti-TSP-5 antibody. B: Data shown in graph are ratio of cleaved 
TSP-5 band intensity versus full-length TSP-5 band intensity (mean ± SEM) (n=4 for each 
genotype). Student’s t-test was used to analyse the data, *p<0.05 comparing A/A (second column) 
with G/G (third column) genotype group.  
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3.1.11 SNP rs3825807 affects ADAMTS-7 activation  
 
To further assess the functional effects of the non-synonymous SNP rs3825807 that results 
in a Ser-to-Pro substitution in the ADAMTS-7 pro-domain, we transfected HEK293 cells 
with a plasmid to produce a recombinant protein consisting of the ADAMTS-7 signal 
peptide, pro-domain (of either ADAMTS-7-214Ser or ADAMTS-7-214Pro) and 
metalloproteinase domain followed by a c-Myc epitope tag. These two plasmids are 
identical except rs3825807 site.  In a previous study, HEK293 cells were transfected with 
a similar plasmid and then Western blot analyses was carried out using conditioned media, 
surface washes (with 0.5M NaCl), and lysates of the transfected cells (Somerville et al. 
2004). The authors showed that the recombinant protein underwent pro-domain cleavage, 
leading to an initially processed form (P1), an intermediate form (Pint) and a fully 
processed form (M) (as schematically illustrated in Figure 3.23A). The recombinant 
protein has been shown to retain its proteolytic ability to process one of its substrate, A2M 
(Somerville et al. 2004).  
 
In our study, Western blot analyses of conditioned media of transfected cells using an anti-
cMyc antibody showed three bands with sizes corresponding to the P1, Pint and M forms. 
The relative intensities of Pint and M bands (relative to P1 band) were ~1.7 and ~4 fold 
higher, respectively, when comparing conditioned media from ADAMTS7Pro-Cat-214Ser 
transfected cells with that of ADAMTS7Pro-Cat-214Pro transfected cells, indicating more 
processed ADAMTS-7 was released into the cell media in ADAMTS7Pro-Cat-214Ser 
transfected HEK293 cells than that of ADAMTS7Pro-Cat-214Pro transfected HEK293 cells.  
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Figures 3.23 SNP rs3825807 has an effect on ADAMTS-7 activation. Cultured HEK293 cells 
were transfected with a plasmid to produce a recombinant protein containing the ADAMTS-7 pro-
domain and metalloproteinase domain followed by a c-Myc epitope tag, with either serine (Ser) 
or proline (Pro) at residue 214 in the ADAMTS-7 pro-domain. A: A schematic diagram for the 
produced recombinant protein. P1, Pint and M indicate the previously reported initially processed 
form, intermediately processing form, and fully processed form, respectively; CP indicates a 
cleaved ADAMTS-7 pro-domain fragment. B:  A representative image of the conditioned media 
of the Western blot analysis using an anti-cMyc antibody. Equal amounts of protein (20μg) for 
each allele was loaded. C: Data shown in column chart are presentations of values (mean ± SEM) 
(n=4 for each allele). Statistical analysis was performed using Student’s t-test, *p<0.05 comparing 
ADAMTS-7Pro-Cat -214Ser and ADAMTS-7Pro-Cat -214Pro.  
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In Western blot analyses of conditioned media of transfected cells using an anti-
ADAMTS-7 pro-domain antibody, a cleaved pro-domain band was detected. The relative 
intensity of cleaved pro-domain band of ADAMTS-7 (relative to P1 band) was ~2 fold 
higher (Figure 3.24), when comparing conditioned media from ADAMTS7Pro-Cat-214Ser 
transfected cells with that of ADAMTS7Pro-Cat-214Pro transfected cells, indicating more 
ADAMTS-7 was activated in ADAMTS7Pro-Cat-214Ser transfected HEK293 cells than that 
of ADAMTS7Pro-Cat-214Pro transfected HEK293 cells. However, the cleaved pro-domain 
band of ADAMTS-7 detected in conditioned media of transfected cells was very weak 
(Figure 3.24A). 
 
 
 
Figures 3.24 SNP rs3825807 has an effect on ADAMTS-7 pro-domain processing. Cultured 
HEK293 cells were transfected with either ADAMTS7Pro-Cat-214Ser or ADAMTS7Pro-Cat-214Pro 
plasmids, and conditioned media were subjected to Western blot analyses using an anti-
ADAMTS-7 pro-domain antibody. Equal amounts of protein (20μg) for each allele was loaded. 
A: A representative image of the Western blot using an anti-ADAMTS-7 pro-domain antibody. B: 
Data shown in column chart are presentations of values (mean ± SEM). (n=4 for each allele). 
Statistical analysis was performed using Student’s t-test, *p<0.05 comparing ADAMTS-7Pro-Cat-
214Ser and ADAMTS-7Pro-Cat-214Pro.  
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These results support the hypothesis that the Ser-to-Pro substitution resulting from SNP 
rs3825807 affects ADAMTS-7 pro-domain processing. Interestingly, the Pint and P1 
forms of ADAMTS-7Pro-Cat-214Pro had a reduced electrophoretic mobility, compared 
with the Pint and P1 forms of ADAMTS-7Pro-Cat -214Ser (Figures 3.23B), which is in line 
with reports in the literature that proline-rich proteins tend to migrate more slowly in SDS-
PAGE, presumably due to conformational peculiarities that persist even under reducing 
conditions (Williamson 1994). Presumably, the conformational change of ADAMTS-7Pro-
Cat -214Pro affects the binding of furin and leads to reduced activation, but to know 
whether or not this is the case will require further studies. 
 
In order to address whether the cleaved pro-domain of ADAMTS-7 attached to cell 
surface, cell surface washes (with 0.5M NaCl) of HEK293 cells either transfected with 
ADAMTS7Pro-Cat-214Ser or ADAMTS7Pro-Cat-214Pro plasmids were subjected to Western 
blot. Western blotting using an antibody against the ADAMTS-7 pro-domain detected a 
cleaved pro-domain fragment in cell surface washes of the transfected cells, which was 
much stronger compared with the pro-domain signal in the conditioned media (Figure 
3.24A), suggesting binding of the cleaved pro-domain fragment to the cell surface (Figure 
3.25A). Noticeably, the intensity of this band was also ~2 fold higher in cell surface 
washes, similar as in conditioned media, when comparing media conditioned by HEK293 
cells transfected with ADAMTS7Pro-Cat-214Ser plasmid and media conditioned by 
HEK293 cells transfected with ADAMTS7Pro-Cat-214Pro plasmid (Figures 3.25B), 
supporting the SNP rs3825807 affects ADAMTS-7 pro-domain cleavage. 
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Figures 3.25 SNP rs3825807 affects amount of cleaved ADAMTS-7 pro-domain in the cell 
surface washes. Cultured HEK293 cells were transfected with either ADAMTS7Pro-Cat -214Ser or 
ADAMTS7Pro-Cat -214Pro plasmid. And then cell surface washes (with 0.5M NaCl) were subjected 
to Western blot analyses with an anti-ADAMTS-7 pro-domain antibody. A: Representative 
images of the Western blot using an anti-ADAMTS-7 pro-domain antibody. The same amount of 
proteins (20μg) for each allele was loaded. B: Data shown in column chart are presentations of 
values (mean ± SEM) (n=4 for each allele). Statistical analysis was performed using Student’s t-
test, *p<0.05 comparing ADAMTS-7Pro-Cat -214Ser and ADAMTS-7Pro-Cat -214Pro.  
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Western blot analyses of cell surface washes using an anti-cMyc antibody showed one 
major band with size corresponding to the P1 form, with similar intensities for cells 
transfected with either plasmid. The M form was almost undetectable, indicating the M 
form does not attach to the cell surface (Figure 3.26).  
 
 
 
Figure 3.26 Cell surface washes Western blotting with anti-cMyc. Cultured HEK293 cells 
were transfected with either ADAMTS7Pro-Cat-214Ser or ADAMTS7Pro-Cat-214Pro plasmids. And 
then cell surface washes (with 0.5M NaCl) were subjected to Western blot analyses using an anti-
cMyc antibody. A: A representative image of the Western blot. The same amount of proteins (20μg) 
for each allele was loaded. B: Data shown in column chart are presentations of values (mean ± 
SEM) (n=4 for each allele).  
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Western blotting analysis of whole cell lysates of HEK293 cells transfected with either 
the ADAMTS7Pro-Cat -214Ser or ADAMTS7Pro-Cat -214Pro plasmid detected the P1 form by 
using either an anti-cMyc antibody or an anti-ADAMTS-7 pro-domain antibody. In 
comparison, the cleaved ADAMTS-7 pro-domain band was much weaker, suggesting pro-
domain processing occurs mostly extracellularly (Figure 3.27).  
 
 
 
Figure 3.27 SNP rs3825807 has no effect on ADAMTS-7 total protein in cell lysates. Cultured 
HEK293 cells were transfected with either ADAMTS7Pro-Cat -214Ser or ADAMTS7Pro-Cat -214Pro 
plasmids, and cell lysates were subjected to western blot analyses with either an anti-ADAMTS-
7 pro-domain antibody or an anti-cMyc antibody. Equal amounts of protein (40μg) for each allele 
was loaded. A: Representative images of the Western blot analysed with an anti-ADAMTS-7 pro-
domain antibody and quantification data. B: Representative images of the Western blot analysed 
with an anti-cMyc antibody and quantification data. Quantification data shown in column chart 
are P1 band intensity (mean ± standard error of mean) (n=4 for each allele).  
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3.1.12 Further experiments confirming an effect of SNP rs3825807 on TSP-5 
cleavage 
 
To further test the effect of the Ser-to-Pro substitution resulting from SNP rs3825807 on 
TSP-5 cleavage, TSP-5 cleavage assays were carried out using media conditioned by 
HEK293 cells transfected with either of the plasmids described above. Recombinant TSP-
5 (2µg) was incubated with 1, 2 or 4 µl concentrated media (1µg total proteins/µl) 
conditioned by HEK293 cells transfected with either ADAMTS7Pro-Cat-214Ser or 
ADAMTS7Pro-Cat-214Pro plasmid, in a digestion buffer at 37°C for 8 hours. The digests, 
along with undigested TSP-5 and concentrated conditioned media, were subjected to 
Western blotting analysis with an anti-TSP-5 antibody.  
 
Similar to the TSP-5 in vitro digestion assay using VSMC conditioned media, the 
conditioned media of HEK293 cells transfected with either the ADAMTS7Pro-Cat-214Ser 
or ADAMTS7Pro-Cat-214Pro plasmid digested TSP-5. The digestion of TSP-5 is in the 
dose-dependent manner, and media conditioned by HEK293 cells transfected with the 
ADAMTS7Pro-Cat-214Ser plasmid had two fold higher TSP-5 cleavage activity than media 
conditioned by ADAMTS7Pro-Cat-214Pro plasmid transfected cells (Figure 3.28). 
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Figure 3.28 Influence of CAD-related SNP rs3825807 on TSP-5 cleavage. Recombinant TSP-
5 (2µg) was incubated with 1, 2 or 4 µl concentrated media (1µg total proteins/µl) conditioned by 
HEK293 cells transfected with either ADAMTS7Pro-Cat-214Ser or ADAMTS7Pro-Cat-214Pro plasmid, 
in a digestion buffer at 37°C for 8 hours. The digests, along with undigested TSP-5 and 
concentrated conditioned media, were subjected to Western blotting analysis using an anti-TSP-5 
antibody. A: A representative image of Western blot analysis of products from in vitro TSP-5 
cleavage assays. B: Data shown in graph are ratio of cleaved TSP-5 band intensity versus full-
length TSP-5 band intensity (mean ± SEM) (n=3 for each genotype). Statistical analysis was 
performed using Student’s t-test, *p<0.05 comparing ADAMTS-7Pro-Cat-214Ser and ADAMTS-
7Pro-Cat-214Pro.  
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3.1.13 Further experiments confirming an effect of SNP rs3825807 on VSMC 
migration 
                         
To further assess the effect of SNP rs3825807 on VSMC migration, media conditioned by 
HEK293 cells transfected with either of the plasmids described above were added to 
VSMC cultures, followed by migration assays. At hour 0 of the assay, A/A genotype 
VSMCs were treated with serum-free media, HEK293 cell conditioned media containing 
ADAMTS-7Pro-Cat-214Ser or HEK293 cell conditioned media containing ADAMTS-7Pro-
Cat-214Pro. G/G genotype VSMCs were treated in a similar manner.  The experiments 
showed that the migratory ability of G/G genotype VSMCs increased after the addition of 
HEK293 cell conditioned media containing ADAMTS-7Pro-Cat-214Ser, but did not 
significantly change after the addition of HEK293 cell conditioned media containing 
ADAMTS-7Pro-Cat-214Pro, suggesting a migration enhancing effect from ADAMTS-7Pro-
Cat-214Ser containing media which presumably had a higher concentration of active 
ADAMTS-7 (Figure 3.29).  
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Figure 3.29 Effect of SNP rs3825807 on VSMC migration by trans-well migration assay. 
Primary cultures of VSMCs of the A/A or G/G genotype were subjected to trans-well migration 
assays. At the beginning of the assay, A/A or G/G genotype VSMCs were replaced with serum-
free media, HEK293 cell conditioned media containing ADAMTS-7Pro-Cat-214Ser or ADAMTS-
7Pro-Cat-214Pro. Column chart shows migrated cell number (mean ± SEM) (n=4 for each genotype). 
Statistical analysis was performed using Student’s t-test, *p<0.05 comparing A/A genotype cells 
with serum-free media and G/G genotype cells with serum-free media; p<0.05 comparing G/G 
genotype cells with HEK293 cell conditioned media containing ADAMTS-7Pro-Cat-214Ser versus 
G/G genotype cells with serum-free media; § p<0.05 comparing G/G genotype cells with HEK293 
cell conditioned media containing ADAMTS-7Pro-Cat-214Ser versus G/G genotype cells with 
HEK293 cell conditioned media containing ADAMTS-7Pro-Cat-214Pro. 
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3.1.14 Protein modelling – SNP rs3825807 effect on ADAMTS-7 structure 
 
The functional effect of SNP rs3825807 was predicted by using F-SNP (available from 
Queen’s University at http://compbio.cs.queensu.ca/F-SNP/). The prediction 
demonstrated a deleterious effect of rs3825807 on ADAMTS-7 protein (Figure 3.30), 
predicting a different secondary structure between ADAMTS-7-214Ser and ADAMTS-7-
214Pro (Figure 3.31).  
 
 
 
Figure 3.30 Functional effect of SNP rs3825807 Prediction.  
(From http://compbio.cs.queensu.ca/F-SNP/) 
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Figure 3.31 SNP rs3825807 is predicted to affect the secondary structure of ADAMTS-7. 
(From http://compbio.cs.queensu.ca/cgi-bin/compbio/search/view_detail.cgi?id=13&snp_id= 
3825807&source_no=1&source_name=rs3825807.1.html&category=protein_coding&url=http://
snpeffect.vib.be/index.php). 
 
 
PSIPRED (available from University College London Department of Computer Science 
Bioinformatics Group at http://bioinf.cs.ucl.ac.uk/psipred/) was further used to predict 
possible functional effect of non-synonymous SNP rs3825807 on secondary structure of 
ADAMTS-7. The prediction indicated that the SNP rs3825807 resulted in amino acid 
substitution Ser-to-Pro would change the helix secondary structure of ADAMTS-7 near 
this amino acid substitution site (Figure 3.32). This predicted secondary structure change 
of ADAMTS-7 could potentially affect furin binding to its recognition site next to this 
amino acid substitution (if this binding happens).  
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Figure 3.32 ADAMTS-7 secondary structure prediction. Amino acid sequences of ADAMTS-
7Pro-Cat -214Ser or ADAMTS-7Pro-Cat -214Pro were subjected to secondary structure prediction on 
PSIPRED. The amino acid substitution Ser-to-Pro was predicted to change the local Helix 
structure of ADAMTS-7 protein. 
 
Protein-protein interaction is highly regulated by their 3D structure rather than secondary 
structure, thus we further used QUARK (available from University of Michigan at 
http://zhanglab.ccmb.med.umich.edu /QUARK/) to predict whether SNP rs3825807 
resulted amino acid substitution Ser-to-Pro has an effect on 3D structure of ADAMTS-7. 
However, the 3D structure prediction results of ADAMTS-7 were highly unreliable (the 
prediction results of protein’s 3D structure is scored from -3 to 3 for its accuracy and 
reliability, ADAMTS-7 3D structure prediction results had scores close to -3) (Data not 
shown). 
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3.2 Discussion 
 
Several GWAS have shown an association between SNPs at the ADAMTS7 locus and 
susceptibility to CAD. SNP rs3825807 was the lead SNP associated with CAD in one of 
these studies (Schunkert et al. 2011) and is in LD with the lead CAD-related SNPs, 
rs1994016 (Reilly et al. 2011) and rs4380028 (Coronary Artery Disease Genetics 2011, 
Schunkert et al. 2011), in two other  GWAS (r2>0.8 with rs1994016 and >0.5 with 
rs4380028, based on data from HapMap and the 1000 Genomes Project). While SNP 
rs3825807 is located in the coding region and is a non-synonymous SNP, SNP rs1994016 
resides in intron 8 of ADAMTS7 gene whilst SNP rs4380028 is located 7.6 kb upstream 
of the gene. These GWAS findings suggest that ADAMTS7 is a candidate gene for CAD. 
However, GWAS can not inform whether any of these SNPs, or other SNPs in LD with 
them, have a functional effect on ADAMTS7 expression or activity. Therefore, functional 
studies are required to investigate the molecular mechanism underlying the association 
between these SNPs and CAD, which was the primary aim of this project.  
 
At the outset of this project, apart from the findings from GWAS of an association between 
ADAMTS7 gene variants and CAD, there was only one reported study of ADAMTS-7 in 
vascular disease in which it indicated that ADAMTS-7 promoted neointima formation 
after mechanical injury of a rat model (Wang et al. 2009). Additionally, the authors 
showed that ADAMTS-7 facilitated VSMC migration through cleaving the extracellular 
matrix protein TSP-5, an ADAMTS-7 substrate that hinders VSMC migration and 
maintains VSMCs in their quiescent state (Riessen et al. 2001, Wang et al. 2009).  
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Before this project, there was no information in the literature about whether ADAMTS-7 
was present in human atheromas. By immunohistochemical analysis, our study showed 
that ADAMTS-7 was present in human atherosclerotic plaques, and colocalised with 
VSMCs and ECs. VSMCs that accumulated ADAMTS-7 were mostly located near the 
intima-media border and the fibrous cap. This finding together with findings of Wang et 
al in rats described earlier provided the rationale for studying the effects of the CAD-
associated ADAMTS-7 SNPs in human VSMCs. In this project, this was carried out with 
the use of human VSMCs isolated from umbilical arteries since they expressed ADAMTS-
7 as shown earlier and because such cells were more accessible (than VSMCs from other 
arteries) from a relatively large number of individuals required for the study. 
 
Before the functional assays, VSMCs isolated from umbilical cords of different 
individuals were genotyped for the CAD-associated SNP rs3825807, rs1994016 and 
rs4380028. The genotyping results showed these three SNPs were in substantial LD 
(rs3825807 with rs1994016 r2 ≈ 0.8, with rs4380028 r2>0.6, and rs4380028 with 
rs1994016 r2>0.6), which is consistent with data from HapMap and the 1000 Genomes 
project. As they are in high LD, it is possible that they may represent the same genetic 
signal.  
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3.2.1 Effect of SNP rs3825807 on ADAMTS-7 pro-domain cleavage, TSP-5 
cleavage, and VSMC migration 
 
One of the key findings of this study was that VSMCs of the A/A genotype had higher 
migratory ability than G/G genotype cells, and that A/A genotype cell conditioned media 
had an enhancing effect on migration of G/G genotype cells. The A allele of rs3825807 
was found by GWAS to be the CAD risk allele (OR 1.06-1.10) (Schunkert et al. 2011). 
The findings of our VSMC migration experiments suggest that the higher risk of CAD in 
individuals carrying the A allele might be in part due to increased VSMC migration which 
accelerates atherosclerosis progression, providing a possible mechanistic explanation for 
the association between the ADAMTS7 SNP and CAD. Similar to rs3825807, the other 
two CAD-associated SNPs, rs1994016 and rs4380028, exhibited genotypic effects on 
VSMC migration in our experiments, which could be due to LD between these three SNPs 
as discussed earlier. The finding from our study that in atherosclerotic plaques, ADAMTS-
7 positive VSMCs were predominantly located near the intima-media border is in line 
with the notion that ADAMTS-7 may play a role in VSMC migration during atherogenesis. 
In our study, the ADAMTS7 SNPs showed no effect on VSMC proliferation, senescence 
and apoptosis, suggesting that the association between these SNPs and CAD is unlikely 
to be due to a genotypic effect on VSMC proliferation, senescence or apoptosis.  
 
Although a high VSMC content would increase the stability of the atherosclerotic plaque 
and reduce the risk of plaque rupture to cause such an acute ischemic event as myocardial 
infarction (MI) and stroke (Libby 1995, Davies 1996), a genetic epidemiological study by 
Reilly et al. shows that ADAMTS7 variation is associated with coronary atherosclerosis 
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but not with risk of MI (Reilly et al. 2011). The findings of our study that the CAD-related 
ADAMTS7 genotypes enhance VSMC migration but have no effect on VSMC senescence 
and apoptosis are in line with that of the genetic epidemiological study by Reilly et al.  
 
In the study of Wang et al mentioned earlier, the authors demonstrated in a rat vascular 
injury model that overexpression of ADAMTS-7 in VSMCs by an adenovirus infection 
method enhanced VSMC migration, while suppression of ADAMTS7 by small interfering 
RNA (siRNA) retarded VSMC migration, indicating that the level of ADAMTS-7 can 
have an effect on VSMC migration (Wang et al. 2009). Following the human VSMC 
migration assays where we found that the CAD-associated ADAMTS7 SNPs had an effect 
on VSMC migration, we investigated whether these SNPs had an influence on ADAMTS7 
mRNA or protein levels in VSMCs. Real-time RT-PCR assays showed no association 
between these SNPs and ADAMTS7 mRNA level in the VSMC collection. This finding 
was supported by results of allelic imbalance assays. Thus, the results of these experiments 
suggest that effect of the ADAMTS7 SNPs on VSMC migration is unlikely to be due to 
any of these SNPs having an influence on ADAMTS7 expression level.  
 
Another possibility was that the CAD-associated ADAMTS7 SNPs have an effect on 
ADAMTS-7 enzymatic activity. Therefore, experiments to test this possibility were 
carried out. Since SNPs rs1994016 and rs4380028 are located in non-coding regions, the 
experiments were focused on the coding region, non-synonymous SNP which results in a 
Ser-to-Pro substitution in the ADAMTS-7 pro-domain.   
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The active or mature form of ADAMTS-7 is a product of pro-domain cleavage by 
proprotein convertases such as furin. Results of a previous study suggest that the 
ADAMTS-7 pro-domain is processed sequentially. In that study, after incubation with 
furin, a recombinant ADAMTS-7 consisting of the pro-domain and metalloprotease 
domain followed by a His-tag ,  showed two major bands, 50 kDa and 29 kDa respectively, 
with several intermediate bands, on PAGE gels detectable by either Coomassie Blue 
staining or using an anti-cMyc antibody. Edman amino acid sequencing of the 50 kDa and 
29 kDa major bands suggest that they were generated by cleavage at two furin cleave sites 
in the ADAMTS-7 pro-domain (Somerville et al. 2004).  
 
The Ser-to-Pro substitution resulting from SNP rs3825807 is at amino acid residue 214 
within the pro-domain of ADAMTS-7 (Figure 3.18). This residue is immediately adjacent 
to a predicted core recognition site for furin (Somerville et al. 2004). Thus, it is quite 
possible that this SNP could affect ADAMTS-7 pro-domain cleavage and maturation. This 
possibility was tested in our study, firstly by analysing conditioned media of VSMCs of 
different genotypes for SNP rs3825807, and subsequently by analysing conditioned media 
of HEK293 cells transfected with either a plasmid to produce the ADAMTS-7 Ser214 
isoform or a plasmid to produce its Pro214 isoform. The results of assays of the VSMC 
conditioned media will be discussed immediately below, and the results of the transfected 
HEK293 experiments will be discussed later.  
 
In Western blot analyses of VSMC conditioned media with the use of an anti-ADAMTS-
7 pro-domain antibody, a major band of approximately 34kDa was observed, which is 
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similar in size to the ADAMTS-9  pro-domain with glycosylation (37kDa) (Koo et al. 
2006). The intensity of this band was ~5 fold higher in lanes containing media conditioned 
by VSMCs of the A/A genotype for SNP rs3825807 than that in lanes containing media 
conditioned by VSMCs of the G/G genotype. This finding is consistent with the 
hypothesis that the SNP has an influence on ADAMTS-7 pro-domain cleavage. However, 
it is a concern that there is no proper loading control for Western blot analyses of VSMC 
conditioned media.  
 
Little cleaved ADAMTS-7 pro-domain was detected in VSMC lysates in our study, 
indicating pro-domain processing occurs mainly extracellularly. This is in line with the 
finding by Somerville et al from their study of ADAMTS-7 produced by transfected 
HEK293 cells (Somerville et al. 2004). Similarly, pro-domain cleavage of ADAMTS-9 
and ADAMTS-5 has been reported to occur at the cell surface (Koo et al. 2006, Longpre 
et al. 2009). In contrast, the furin processing products of ADAMTS-1 were shown to be 
present predominantly intracellularly (Longpre and Leduc 2004). Thus, it appears that 
different mechanisms are involved in the pro-domain processing of different members of 
the ADAMTS family. 
 
The findings that A/A genotype VSMC conditioned media contained more cleaved 
ADAMTS-7 pro-domain and had an enhancing effect on cell migration suggest the 
possibility that SNP rs3825807 affected VSMC migration due to its effect on ADAMTS-
7 pro-domain cleavage. It is likely that pro-domain cleavage leads to the release of the 
active form of ADAMTS-7 which has proteolytic activity to process its substrates. It has 
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been shown that ADAMTS-7 promotes VSMC migration via cleaving TSP-5 (Wang et al. 
2009). Therefore, we further investigated whether there was a difference in the 
concentration of cleaved TSP-5 in VSMC conditioned media between rs3825807 
genotypes. Western blotting analyses of VSMC conditioned media using an anti-TSP-5 
antibody detected a band of 70kDa in size, consistent of the ADAMTS-7 digested TSP-5 
fragment reported by Wang et al. (Wang et al. 2009). The analyses showed that media 
conditioned by VSMCs of the A/A genotype for rs3825807 contained approximately ~40% 
more cleaved TSP-5, compared with the G/G genotype, which is consistent with the 
postulation mentioned above. This is further supported by data from the TSP-5 in vitro 
digestion assays which showed that VSMC conditioned media were able to cleave TSP-5 
and that the media conditioned by VSMCs of the A/A genotype had higher TSP-5 
cleavage activity than media conditioned by VSMCs of the G/G genotype. However, there 
is also the possibility that the difference between the A/A and G/G genotypes in the TSP-
5 cleavage is due to an indirect effect of the SNP, for example by an genotype-dependent 
effect of ADAMTS-7 on activation of other enzymes that can also cleave TSP-5.  
 
Due to the rigidity of proline, the Ser-to-Pro substitution could potentially introduce a 
conformational change within the protein structure of ADAMTS-7, which might affect 
the secretion of the protein, the processing of the pro-domain, or its interaction with other 
molecules on the cell surface. However, there is no evidence to suggest that any of these 
is the case, as we found similar amounts of full-length ADAMTS-7 and its fragments in 
lysates of VSMCs of the A/A or G/G genotype, and little ADAMTS-7 pro-domain in cell 
lysates.  
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To summarise, the results of the assays of VSMCs suggest that: (1) the CAD-associated 
SNPs at the ADAMTS7 locus affect VSMC migration, (2) these SNPs do not affect 
ADAMTS7 mRNA  and protein levels, (3) the non-synonymous SNP rs3825807 resulting 
in the Ser-to-Pro substitution might affect ADAMTS-7 pro-domain cleavage, and (4) this 
might lead to a difference in TSP-5 cleavage. As the three CAD-associated ADAMTS-7 
SNPs studied are in LD, the experiments using plasmids for testing the non-synonymous 
SNP only (and not the other two SNPs) were subsequently carried out, which are further 
discussed below.   
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 3.2.2 Effect of SNP rs3825807 on ADAMTS-7 pro-domain cleavage, TSP-5 
cleavage and cell migration 
 
Effects of the non-synonymous SNP rs3825807 on ADAMTS-7 pro-domain cleavage and 
TSP-5 cleavage were further tested using HEK293 cells transfected with either a plasmid 
to produce the Ser214 form of ADAMTS-7 or a plasmid to produce the Pro214 form of 
this protein. The experiments showed that conditioned media of HEK293 cells transfected 
with the ADAMTS7Pro-Cat-214Ser plasmid contained more mature form and cleaved 
ADAMTS-7 pro-domain, than conditioned media of HEK293 cells transfected with the 
ADAMTS7Pro-Cat-214Pro plasmid. This finding supports the notion that the Ser-to-Pro 
substitution affects ADAMTS-7 pro-domain cleavage and activation. Noticeably, the 
cleaved pro-domain of ADAMTS-7 was found in conditioned media and more intense in 
cell surface washes, but not in cell lysate, indicating that the activation of ADAMTS-7 
happens at cell surface which is similar to ADAMTS-9 (Koo et al. 2006). This finding 
also suggests that the cleaved pro-domain could attach back to the cell surface, which is 
suggested by a previous study (Somerville et al. 2004), although the mechanism has not 
been elucidated. Interestingly, it appears that VSMCs and HEK293 cells have some 
different features in ADAMTS-7 pro-domain processing. It appears that in transfected 
HEK293 cells, multiple cleavage steps lead to the generation of a ~15kDa cleaved pro-
domain fragment, whereas in VSMCs, a larger cleaved pro-domain fragment (~34kDa) is 
detectable in conditioned media. It is also noteworthy that a very small amount of cleaved 
ADAMTS-7 pro-domain and M form were detected in cell lysate transfected HEK293 
cells, suggesting intracellular pro-domain processing of ADAMTS-7 in HEK293 cells is 
also occurring, although this process is not as efficient as on cell surface.  
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As a result of the rigidity of proline residue, it is possible that the Ser-to-Pro substitution 
can alter the conformation of the ADAMTS-7 pro-domain, reducing its accessibility to 
furin or other proteases and decreasing the efficiency of pro-domain processing. It is 
interesting that the Pint and P1 fragments of ADAMTS-7-214Pro had slower 
electrophoretic mobility than those of ADAMTS-7-214Ser (Figures 2.2.23B). Other 
studies have shown that proline-rich proteins tend to migrate more slowly in SDS-PAGE, 
presumably due to conformational peculiarities that persist even under reducing 
conditions (Williamson 1994). It is possible that the Ser-to-Pro substitution has a 
particularly persistent effect on the conformations of the Pint and P1 fragments.  
 
As discussed earlier, the Ser-to-Pro substitution at residue 214 is immediately adjacent to 
a predicted core recognition site for furin, the protease primarily responsible for 
ADAMTS-7 pro-domain processing (Somerville et al. 2004), although it is still unknown 
as to whether cleavage at this site does occur. Although cleavage at this site could 
potentially be affected by the Ser-to-Pro substitution at residue 214, it is unlikely to 
directly account for the reduced mobility of the Pint form of the ADAMTS-7-214Pro, as 
the cutting site to generate the Pint form is estimated to be >30 residues upstream of 
position 214, based on the sizes of the Pint bands of both alleles. 
 
Similar to the TSP-5 in vitro digestion assay using VSMC conditioned media, the 
conditioned media of HEK293 cells transfected with either the ADAMTS7Pro-Cat-214Ser 
or ADAMTS7Pro-Cat-214Pro plasmid was able to digest TSP-5 in a dose-dependent manner, 
and media conditioned by HEK293 cells transfected with the ADAMTS7Pro-Cat-214Ser 
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plasmid had two fold higher TSP-5 cleavage activity than media conditioned by 
ADAMTS7Pro-Cat-214Pro plasmid transfected cells. Again, similar to the results using 
VSMC conditioned media, migratory ability of the G/G genotype VSMCs  increased after 
the addition of media conditioned by HEK293 cells transfected with the ADAMTS7Pro-Cat-
214Ser plasmid, whereas media  conditioned by HEK293 cells transfected with the 
ADAMTS7Pro-Cat-214Pro plasmid had little effect. The results of these two experiments 
suggest a cell migration promoting and TSP-5 cleavage enhancing effect of conditioned 
media of HEK293 cells transfected with the ADAMTS7Pro-Cat-214Ser plasmid, presumably 
due to a higher concentration of active ADAMTS-7. 
 
These findings indicate that the Ser-to-Pro substitution reduced ADAMTS-7 pro-domain 
processing, TSP-5 cleavage and VSMC migration. We did not find evidence of between-
genotype difference in ADAMTS7 expression or secretion, or in VSMC proliferation, 
senescence and apoptosis. Taken together, these results indicate that the Ser-to-Pro 
substitution resulting from rs3825807 has an effect on ADAMTS-7 maturation, TSP-5 
cleavage and VSMC migration and in turn associates with atherosclerosis, providing a 
mechanistic explanation for the recently reported association between the SNP and CAD 
susceptibility. The SNP rs3825807 effect on ADAMTS-7 activation is possibly through 
affecting structure of ADAMTS-7 and binding to proprotein convertase, which is 
suggested by protein modelling results.  
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Chapter 4 
 Functional study of ADAMTS7 and SNP 
rs3825807 in endothelial cell migration and in 
vitro angiogenesis 
 
The first part of this project was focused on VSMCs and showed that the CAD-associated 
SNP rs3825807 had an effect on ADAMTS-7 maturation, TSP-5 cleavage and VSMC 
migration. As described earlier, immunohistochemical analyses of atherosclerotic plaques 
showed that ADAMTS-7 was present in VSMCs as well as endothelial cells. Since it 
would be possible that ADAMTS-7 might play a role in angiogenesis and since 
neovascularization contributes to atherosclerotic plaque progression, the aim of the second 
part of this project was to study possible effects of ADAMTS-7 and the non-synonymous 
SNP rs3825807 in endothelial cell behaviours and angiogenesis. It is worth noting that the 
immunohistochemical analyses of atherosclerotic plaques showed no significant 
expression of ADAMTS-7 in macrophages, another important cellular component in 
atheromas, and therefore, macrophages were not a focus of this project.  
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4.1 Results 
 
4.1.1 ADAMTS-7 colocalises with ECs in human atherosclerotic plaques 
 
IHC analyses of human atherosclerotic plaques revealed that ADAMTS-7 localised not 
only to VSMCs as described earlier but also localised to ECs of the neo-vessels within the 
plaques (Figure 4.1). Adjacent sections showed areas which were positive for the EC 
marker vWF (Figure 4.1B) as well as ADAMTS-7 (Figure 4.1A). Fluorescent 
immunostaining for ADAMTS-7 (green) also showed that positive staining in 
microvessels in human atherosclerotic plaques (Figure 4.1D). 
 
 
 
Figure 4.1 ADAMTS-7 colocalises with ECs and associates with neo-vessels in human 
atherosclerotic plaques. A & B: Atherosclerotic carotid artery sections were subjected to single 
immunostaining of von Willebrand Factor (vWF) or ADAMTS-7 (with a spacer domain antibody). 
Brown color with DAB indicates vWF or ADAMTS-7 staining. C: negative control for 
ADAMTS-7 and vWF staining (with secondary antibody only). D: Atherosclerotic coronary artery 
sections were subjected to fluorescent immunostaining for ADAMTS-7 (green), followed by 
fluorescent microscopy examination.  
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4.1.2 ECs express ADAMTS-7 
 
The finding of colocalisation of ADAMTS-7 with ECs in atherosclerotic plaques 
prompted us to test whether ECs express ADAMTS-7. Total RNA and whole cell protein 
extracts of HUVECs were subjected to ADAMTS7 RT-PCR and Western blotting. RT-
PCR showed high levels of ADAMTS7 mRNA (Figure 4.2A). The Western blotting 
analyses with either an ADAMTS-7 C-terminus antibody or an ADAMTS-7 pro-domain 
antibody also demonstrated the presence of ADAMTS-7 protein in ECs (Figure 4.2B&C). 
 
 
 
Figure 4.2 ECs express ADAMTS-7. A: RT-PCR shows that ECs express ADAMTS7. B&C: 
Representative images of Western blot analyses of ADAMTS-7 protein in EC lysates using an 
ADAMTS-7 spacer domain or pro-domain antibody. Equal amounts of protein (20μg) were loaded 
in each lane. 
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4.1.3 SNP rs3825807 genotyping results 
 
A collection of HUVECs from different individuals were used to investigate whether SNP 
rs3825807 has an effect on EC proliferation, migration and angiogenesis. Therefore, this 
collection was genotyped for rs3825807. The genotyping results are summarised in Table 
4.1.  
 
Table 4.1. Isolated ECs SNP rs3825807 genotyping results 
SNP Genotype Number Frequency 
rs3825807 A/A 26 58 % 
  A/G 13 29 % 
  G/G 6 13 % 
  Total  45 100 % 
 
 
4.1.4 SNP rs3825807 has no effect on EC proliferation 
 
Angiogenesis requires ECs to migrate towards the angiogenic stimuli, proliferate and form 
new vessels. Thus, the proliferation and migration of ECs are critical for neo-vessel 
formation. Therefore, proliferation assays were carried out to investigate whether SNP 
rs3825807 affects EC proliferation (Methods described in section 2.5.1.2). During 
optimization for the assay, 1,000-10,000 cells/well showed linear curves (Figure 4.3A), 
and 7500 cells/well was used in the subsequent experiments.  Subsequent EC proliferation 
assays were performed on HUVECs from 12 different individuals (n=4 for each 
genotype).The experiment showed no significant difference in EC proliferation between 
the three genotypes for SNP rs3825807 (Figure 4.3B). 
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Figure 4.3 SNP rs3825807 has no effect on EC proliferation. Primary cultures of ECs of the 
A/A, A/G or G/G genotype for rs3825807 were subjected to proliferation assay by using cell 
proliferation assay kit (Abcam). A: Optimization for proliferation assay. B: Column chart shows 
fluorescence signal intensity (mean ± SEM) of ECs of the A/A, A/G or G/G genotype for 
rs3825807 (n=4 for each genotype). One-way ANOVA (three genotype groups) and Student’s t-
test (two genotype groups) was used to analyse the difference between genotype groups, P>0.05 
comparing A/A and G/G genotype group.  
 
 
4.1.5 SNP rs3825807 has an effect on EC migration 
 
In addition to EC proliferation assays, migration assays were carried out to investigate 
whether SNP rs3825807 affects EC migration. Similar to the findings from VSMC 
analyses as described in Chapter 3 where the SNP showed an effect on VSMC migration, 
the EC experiment showed that the SNP also affected EC migration. A/A genotype ECs 
showed higher migratory ability, compared with G/G genotype cells (Figure 4.4), similar 
to our findings for VSMCs. In the VSMC migration experiment, three different conditions 
(i.e. with serum, serum-free, and serum-free plus PDGF-BB) were used, but the results 
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were similar in these different conditions. Therefore, only one condition (normal culture 
media with serum) was used in the EC migration experiment. 
 
 
 
Figure 4.4 SNP rs3825807 has an effect on EC migration. Primary cultures of ECs of the A/A, 
A/G or G/G genotype for rs3825807 were subjected to the scratch assay. A:  Representative 
pictures of migration at different time points. B: Column chart shows migration distances (mean 
± SEM) of ECs of the A/A, A/G or G/G genotype for rs3825807 (n=4 for each genotype). 
Student’s t-test (two genotype groups) was used to analyse the differences between genotype 
groups of the SNPs, *p<0.05 comparing A/A and G/G genotype group. 
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4.1.6 SNP rs3825807 has no effect on ADAMTS7 mRNA expression in ECs  
 
To investigate whether SNP rs3825807 has an effect on ADAMTS7 mRNA level in ECs, 
real-time RT-PCR was carried out with cDNA from ECs from different individuals. The 
analysis showed that ADAMTS7 mRNA levels in the ECs did not significantly differ 
among the three genotypes for rs3825807 (Figure 4.5).  
 
 
 
Figure 4.5 SNP rs3825807 has no effect on ADAMTS7 mRNA expression level in ECs. The 
∆∆Ct method was used to analyse the data. Data shown are values of mean ± SEM. One-way 
ANOVA (three genotype groups) and student’s t-test (two genotype groups) was used to analyse 
the difference between genotype groups of the SNP. No significant difference was found between 
genotype groups. 
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4.1.7 Augmented ADAMTS7 expression in ECs increases their migration 
 
Since the assays described above showed that genotypes for SNP rs3825807 had an 
influence on EC migration, further experiments with ADAMTS7 overexpression or 
knockdown in ECs were carried out to investigate whether ADAMTS-7 has an effect on 
EC migration. A previous study by Wang et.al showed that overexpression of ADAMTS7 
in VSMCs by an adenoviral infection method enhanced VSMC migration, while 
suppression of ADAMTS7 by siRNA retarded cell migration (Wang et al. 2009).  
 
In the overexpression experiment, HUVECs that were heterozygous for rs3825807 were 
transfected with either the ADAMTS7-214Ser plasmid or the ADAMTS7-214Pro plasmid 
(Methods described in sections 2.9.2 and 2.10.2). The experiment showed that ECs 
transfected with the ADAMTS7-214Ser plasmid had two fold increased migratory ability 
compared with the control group, while cells transfected with ADAMTS7-214Pro plasmid 
did not show a significant increase of cell migration (Figure 4.6). 
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Figure 4.6 Augmented ADAMTS7 expression accelerates EC migration. ECs were transfected 
with either ADAMTS7-214Ser or ADAMTS7-214Pro plasmid, or vector plasmid pcDNA3.1 as 
control, and then subjected to scratch assay. A: Representative pictures of migration assay for ECs 
transfected with either control plasmid pcDNA3.1 or ADAMTS7-214Ser plasmid at 6 hours point. 
B: Over-expression efficiency was tested by Western blot using an anti-ADAMTS-7 pro-domain 
antibody. C: Column chart shows migration distance (mean ± SEM) of ECs transfected with either 
ADAMTS7-214Ser or ADAMTS7-214Pro plasmid, or vector control plasmid at different time 
points (n=3 for each group). Student’s t-test (paired samples) to analyse the difference between 
two groups. * p<0.05 comparing control group and ADAMTS7-214Ser plasmid transfection group. 
# p<0.05 comparing ADAMTS7-214Ser plasmid and ADAMTS7-214Pro plasmid transfection 
group.  
 
 
 
 
 
 
 
 191 
4.1.8 ADAMTS7 knockdown impairs EC migration 
 
In the knockdown experiment, HUVECs were infected with ADAMTS7 shRNA (Methods 
described in section 2.12 and 2.13). The experiment showed that ADAMTS7 knockdown 
significantly impaired the migratory ability of ECs (Figure 4.7A). The migration of 
ADAMTS7 shRNA infected cells decreased by approximately 60%, as compared with non-
target control shRNA infected cells (Figure 4.7B), suggesting the important role of 
ADAMTS-7 in EC migration. 
 
 
 
Figure 4.7 ADAMTS7 knockdown impairs EC migration. ECs were infected with either 
ADAMTS7 shRNA or non-target shRNA as control, and then subjected to scratch assay. A: 
Representative pictures of migration assay for ECs infected with either non-target shRNA or 
ADAMTS7 shRNA at 6 hours point. B: Knock-down efficiency was tested by Western blot. 
Column chart shows migration distance (mean ± SEM) of ECs infected with either non-target 
shRNA or ADAMTS7 shRNA at different time points (n=6 for each group). Student’s t-test (paired 
samples) to analyse the difference between two groups, * p<0.05 comparing non-target shRNA 
control group and ADAMTS7 shRNA infection group.   
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4.1.9 Augmented ADAMTS7 expression in ECs increases capillary-like 
network formation 
 
Following the EC migration assays, capillary-like network formation assays were carried 
out with HUVECs transfected with either the ADAMTS7-214Ser plasmid or the 
ADAMTS7-214Pro plasmid to investigate whether ADAMTS7 and SNP rs3825807 have 
effects on angiogenesis (Methods described in section 2.15).   
 
In the overexpression experiment, ECs transfected with the ADAMTS7-214Ser plasmid 
had significantly increased capillary-like network formation, compared with the control 
group, while cells transfected with the ADAMTS7-214Pro plasmid did not show a 
significant increase in tube formation. Among the twenty parameters of angiogenesis 
generated using the angiogenesis analyser in Image J, almost all of them reached statistical 
significance when comparing the ADAMTS7-214Ser group and control group. The most 
important parameters, such as the number of nodes, the number of junctions and the total 
branching lengths are presented in Figure 4.8.   
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Figure 4.8 Augmented ADAMTS7 expression increases in vitro angiogenesis. ECs were 
transfected with either ADAMTS7-214Ser or ADAMTS7-214Pro plasmid, or vector control 
plasmid pcDNA3.1 as control, and then subjected to capillary-like network formation assay. A: 
Representative pictures of capillary-like network formation assay for ECs transfected with either 
control plasmid pcDNA3.1 or ADAMTS7-214Ser plasmid at 6 hours point. B, C &D: Column 
charts show number of nodes, number of junctions and total branching length (mean ± SEM) in 
capillary-like network formation assay of ECs transfected with either ADAMTS7-214Ser or 
ADAMTS7-214Pro plasmid, or vector control plasmid at different time points (n=3 for each group). 
Student’s t-test (paired samples) to analyse the difference between two groups, * p<0.05 
comparing control group and ADAMTS7-214Ser plasmid transfection group; # p<0.05 comparing 
ADAMTS7-214Ser plasmid and ADAMTS7-214Pro plasmid transfection group. 
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4.1.10 ADAMTS7 knockdown in ECs retards capillary-like network formation 
 
Capillary-like network formation assays were carried out with HUVECs infected with 
ADAMTS7 shRNA to investigate whether ADAMTS7 knock-down could affect 
angiogenesis 
 
In the knockdown experiment, ECs infected with ADAMTS7 shRNA showed a 40-50% 
decrease in capillary-like network formation compared with non-target shRNA infected 
cells, which is concordant with results of the migration assay which showed that 
ADAMTS7 knockdown decreased EC migratory ability by approximately 60%. All 
parameters generated by the angiogenesis analyser showed the similar results, and 
numbers of nodes, numbers of junctions and total branching lengths are presented in 
Figure 4.9.  
 
It is noteworthy that all the parameters of capillary-like network formation went down 
with the growth of time, in concordance with the observed reduction of capillary-like 
network of ECs. The capillary-like network was almost gone after 24 hours (data not 
shown). This phenomenon was also found but not obvious in ADAMTS7 overexpression 
experiments. Both control group (vector plasmid and non-target shRNA) showed the same 
trend, so it is possible that our ECs were injured during the treatment (trypsinisation for 
example) or some toxic component was in transfection and infection solutions.  
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Figure 4.9 ADAMTS7 knockdown retards in vitro angiogenesis. ECs were infected with either 
ADAMTS7 shRNA or non-target shRNA as control, and then subjected to capillary-like network 
formation assay. A: Representative pictures of capillary-like network formation assay for ECs 
infected with either control non-target shRNA or ADAMTS7 shRNA at 6 hours point. B, C &D: 
Column charts show number of nodes, number of junctions and total branching length (mean ± 
SEM) in capillary-like network formation assay of ECs infected with either non-target shRNA or 
ADAMTS7 shRNA at different time points (n=6 for each group). Student’s t-test (paired samples) 
to analyse the difference between two groups, * p<0.05 comparing non-target shRNA control 
group and ADAMTS7 shRNA infection group. 
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4.1.11 SNP rs3825807 affects EC tube formation 
 
Further angiogenesis assays were conducted to investigate whether untranfected ECs from 
individuals of different genotypes for SNP rs3825807 differ in their ability to form tubes. 
The assays showed that ECs of the A/A genotype had approximately 20% higher 
capillary-like network formation ability than G/G genotype cells, and this difference 
reached significance at the 9 hour time point. Although only 8 parameters showed 
statistical difference, many other parameters showed a similar trend (p values between 
0.05-0.1). Data for the numbers of nodes, the numbers of junctions and the total branching 
lengths are presented in Figure 4.10. The magnitudes of differences between genotypes in 
these assays were similar than those in the experiment where cells were transfected with 
the ADAMTS7-214Ser or ADAMTS7-214pro plasmid. This is not unexpected since 
endogenous expression levels of ADAMTS7 would be lower than the ADAMTS7 levels in 
cells transfected with the ADAMTS7-214Ser or ADAMTS7-214pro plasmid. The SNP 
rs3825807 effect on angiogenesis was abolished when ECs were transfected with shRNA 
to knock down ADAMTS7 (data not shown).  
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Figure 4.10 SNP rs3825807 has an effect on EC tube formation. Primary cultures of ECs of 
the A/A, A/G or G/G genotype for rs3825807 were subjected to the capillary-like network 
formation assay. A, B &C: Column chart shows the number of nodes, the number of junctions 
and the total branching length (mean ± SEM) of ECs of the A/A, A/G or G/G genotype for 
rs3825807 (n=3 for each genotype). Student’s t-test was used to analyse the differences between 
genotype groups of the SNPs, *p<0.05 comparing A/A and G/G genotype group. 
 
 
4.1.12 Preliminary data of proteomics analysis 
 
Previous studies described earlier show that ADAMTS-7 promotes VSMC migration by 
cleaving its substrate TSP-5. Since it has been reported that ECs do not express TSP-5 
(Riessen et al. 2001), a proteomics analysis of conditioned media of ECs was carried out 
to investigate whether there were yet unknown proteolytic targets of ADAMTS-7 that 
might affect EC migration and angiogenesis. In this experiment, ECs were either 
transfected with the ADAMTS7-214Ser plasmid to augment ADAMTS7 expression, or 
infected with shRNA to knock down ADAMTS7, or neither. Conditioned media of these 
cells were then collected and subjected to proteomics analysis carried out by the Central 
Proteomics Facility of University of Oxford (Methods described in section 2.16).  
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In this analysis, over 100 different proteins were detected in the conditioned media, and 
several proteins showed differences in their level (spectral counts) when comparing ECs 
with augmented ADAMTS7 expression, ECs with ADAMTS7 knockdown, and control ECs 
(Table 4.2). Among them, TSP-1 is of particularly interest. TSP-1 belongs to the TSP 
family which includes TSP-5, the best studied substrate of ADAMTS-7. More importantly, 
TSP-1 has been reported to be a strong angiogenesis inhibitor with the ability to inhibit 
EC migration (Good et al. 1990).  A previous study showed that another ADAMTS family 
member, ADAMTS-1, can cleave TSP-1 (Lee et al. 2006). In our proteomic analysis, the 
ADAMTS7 shRNA infected EC conditioned media sample had the highest TSP-1 spectral 
counts. A possible explanation could be that ADAMTS-7 can degrade TSP-1 and the 
reduction of ADAMTS-7 in the condition media of ECs infected with the ADAMTS7 
shRNA resulted in less TSP-1 degradation. In contrast, the ADAMTS7-214Ser transfected 
EC conditioned media sample showed that lowest TSP-1 spectral counts, which could 
possibly result from increased TSP-1 degradation due to a higher concentration of 
ATAMTS7 in the conditioned media of ECs transfected with the plasmid to over-express 
ADAMTS7. 
 
Table 4.2 Proteomics preliminary data 
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4.1.13 TSP-1 Western blotting preliminary results support the proteomics 
data 
 
To verify the proteomics analysis results for TSP-1, Western blot analyses were performed 
on conditioned media of ECs either transfected with the ADAMTS7-214Ser plasmid to 
augment ADAMTS7 expression, or infected with shRNA to knock down ADAMTS7, or 
neither. As shown in Figure 4.11, the Western blot analyses confirmed that conditioned 
media of cells infected with the ADAMTS7 shRNA had more undegraded TSP-1 whereas 
conditioned media of cells transfected with the ADAMTS7-214Ser plasmid had less 
undegraded TSP-1, as compared with conditioned media of control cells. These results are 
consistent with those of the proteomic analysis. Further experiments would be required to 
investigate if ADAMTS-7 can indeed degrade TSP-1 and if the effect of ADAMTS-7 on 
angiogenesis is, to certain extent, mediated by an effect on TSP-1. 
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Figure 4.11 Western blot analysis of TSP-1 in EC conditioned media. Conditioned media of 
ECs either transfected with ADAMTS7-214Ser plasmid or infected with ADAMTS7 shRNA, or 
ECs without any treatment as control group were subjected to Western blot to detect TSP-1 protein 
using a specific TSP-1 antibody. A: A representative image of Western blot shows weakest TSP-
1 band in over-expression group (Lane 2). While strongest TSP-1 band was found in knock-down 
group (Lane 3). Lane 1 represents the control group. Equal amounts of protein (40 µg) was loaded 
into each lane. B: Data shown in column chart are TSP-1 band intensity (mean ± SEM) (repeated 
3 times of Western blotting). Student’s t-test was used to analyse the difference between two 
groups, * p<0.05 comparing two groups.  
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4.2 Discussion 
 
Further to results described in Chapter 2 from the studies of VSMCs, the experiments 
described in this chapter reveal a role of ADAMTS-7 in angiogenesis with a 
genotypic/allelic effect of the non-synonymous SNP rs3825807.  
 
4.2.1 Effects of ADAMTS7 and SNP rs3825807 on EC migration and 
angiogenesis 
 
An important novel finding of this study is that ADAMTS-7 promotes EC migration and 
angiogenesis. This finding derived from migration and angiogenesis assays using ECs 
with either augmented ADAMTS7 expression or ADAMTS7 knockdown. The migration 
assays showed that over-expression of ADAMTS7 with ADAMTS7-214Ser plasmid 
doubled the migration distance compared with the control group. Similarly, the 
angiogenesis assays showed ECs transfected with the ADAMTS7-214Ser plasmid had 
increased ability for tube formation.  
 
In contrast to ECs transfected with the ADAMTS7-214Ser plasmid, ECs transfected with 
the ADAMTS7-214Pro plasmid did not show a marked increase in their ability to migrate 
or form tubes. This can not be explained by the possibility of  different transfection 
efficiency, as Western blot analysis showed that full length ADAMTS-7 protein was 
increased  to a comparable degree comparing cells transfected with ADAMTS7-214Ser 
and cells transfected with ADAMTS7-214Pro, both having significantly more ADAMTS-
7 than cells transfected with the empty vector (Figure 4.6B). One possible explanation 
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would be that the control cells and ADAMTS7-214Pro plasmid transfected cells had 
similar amounts of active ADAMTS-7. Although the total ADAMTS-7 was markedly 
increased in the cells transfected with the ADAMTS7-214Pro plasmid, the recombinant 
ADAMTS-7 expressed by this plasmid would be all ADAMTS-7-214Pro which would be 
resistant to activation (assumed based on data described in Chapter 3), and there was 
probably little increase in the amount of the active form of ADAMTS-7. The effects of 
ADAMTS-7 on EC migration and capillary-like network formation presumably derived 
from active ADAMTS-7. 
 
The results of the experiment using ECs inflected with ADAMTS7 shRNA supported a 
role of ADAMTS-7 in EC migration and angiogenesis, as ADAMTS7 knockdown severely 
impaired EC migration and tube formation.  
 
A key finding of the experiments described in the Chapter is that the CAD-associated 
ADAMTS7 SNP rs3825807 has a genotypic/allelic effect on EC migration and 
angiogenesis. This genetic effect is likely to be related to the function of ADAMTS-7, as 
ADAMTS7 knockdown abolished the effect of SNP rs3825807 on EC capillary-like 
network formation. The A/A genotype cells showed more capillary-like network  
formation, although only at 9 hour time point, but this effect was abolished when 
ADAMTS7 in ECs was knocked down by shRNA.  
 
Neovascularization arising from angiogenesis plays an important role in atherosclerotic 
plaque progression. Neovessels in the atherosclerotic plaque provide an additional route 
for leukocyte migration into the plaque, undermine plaque stability, and are the main 
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source of intra-plaque haemorrhage (Moulton et al. 2003, Herrmann et al. 2006). Thus, 
the finding of this study that the CAD-risk allele (A, Ser214) of SNP rs3825807 promotes 
angiogenesis provides another possible mechanistic explanation for the association 
between the SNP and CAD. 
 
4.2.2 TSP-1 - a possible substrate of ADAMTS-7? 
 
In the VSMC study, we found that the CAD-associated ADAMTS7 SNP affected VSMC 
migration through affecting ADAMTS-7 activation and TSP-5 cleavage. Could it be that 
the SNP affects EC migration through the same mechanism? This seems unlikely as a 
previous study showed that ECs do not express TSP-5 (Riessen et al. 2001). It is possible 
that ADAMTS-7 can degrade as yet unknown substrate proteins which mediate the effect 
of ADAMTS-7 on EC migration and angiogenesis. The possibility promoted us to use the 
proteomics analysis to research for the possible substrates of ADAMTS-7. 
 
Among the several proteins showed by the proteomic analysis to differ in their amounts 
among the different conditions (ADAMTS7 overexpression, ADAMTS7 knockdown, and 
control), TSP-1 is of particular interest. TSP-1 is a matricellular, calcium-binding protein 
that participates in cellular responses to growth factors, cytokines and injury (Chen et al. 
2000). Unlike members of subgroup B of the TSP family, i.e. TSP-3, TSP-4 and TSP-5, 
which are pentamers, subgroup A members includes trimeric TSP-1 and TSP-2. Each 
subgroup A member consists of three identical subunits each of which contains multiple 
domains: N- and C-terminal globular domains, a region of sequence with similarity to 
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procollagen, and three types of repeated sequence motifs, designated type 1, type 2 and 
type 3 repeats (Chen et al. 2000). TSP-1 binds to a wide variety of integrin and non-
integrin cell surface receptors, such as CD36, CD47 and proteoglycans, and initiates signal 
transduction. It regulates cell proliferation, migration and apoptosis in a variety of 
physiological and pathological settings, including wound repair, inflammation, 
angiogenesis and neoplasia (Chen et al. 2000).  
 
TSP-1 has been shown to be one of the major physiological activators of TGF-β in vivo. 
TGF-β is released from platelet α-granules upon platelet activation along with TSP-1, one 
of the major components of platelet α-granules. It has been shown that TSP-1 induced 
TGF-β activity accounts for 60% of the total TGF-β activity released (Murphy-Ullrich et 
al. 1992, Schultz-Cherry and Murphy-Ullrich 1993, Schultz-Cherry et al. 1994). Since 
TGF-β affects a wide range of physiological and pathological processes, including 
regulating cell growth, differentiation, adhesion, motility and death, it comes as no 
surprise that TSP-1, the major activator of TGF-β, is involved in a variety of physiological 
and pathological conditions (Chen et al. 2000).  
 
An inhibitory effect of TSP-1 on angiogenesis was revealed in 1990 by Good et al. who 
showed that a 140-kDa protein that inhibited angiogenesis derived from TSP-1. 
Subsequent studies showed that two sequences, one in the procollagen homology region 
and one in the second TSR, of TSP-1 inhibits angiogenesis (Good et al. 1990, Tolsma et 
al. 1993). Additionally, Dawson et al showed anti-angiogenic activity of the intact TSP-1 
molecule which contains the sequence that reportedly binds to CD36 (Dawson et al. 1997). 
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The interaction of TSP-1 with CD36 plays a significant role in the anti-angiogenic activity 
of TSP-1 both in vitro and in vivo (Dawson et al. 1997). CD36 mediates TSP-1 inhibition 
of EC migration and capillary-like network formation (Dawson et al. 1997). TSP-1 can 
also activate a P38/MAPK cascade that induces EC apoptosis via binding with CD36 (Guo 
et al. 1997, Jimenez et al. 2000). Furthermore, it has been reported that TSP-1 inhibits 
nitric oxide (NO) signaling pathway via CD36, as one of the mechanisms for the anti-
angiogenic effect of TSP-1 (Lawler and Lawler 2012). In addition to its inhibition of 
angiogenesis through binding with its ligand CD36, TSP-1 can also inhibit angiogenesis 
through its direct binding to VEGF and mediating the uptake and clearance of VEGF from 
the extracellular space (Gupta et al. 1999, Greenaway et al. 2007, Kaur et al. 2010, Lawler 
and Lawler 2012). 
 
Another reason makes TSP-1 very interesting and potentially relevant to the findings of 
our ADAMTS-7 study in angiogenesis is that it has been shown that ADAMTS-1 cleaves 
TSP-1 (Lee et al. 2006). ADAMTS-1 and ADAMTS-7 belong to the same protease family, 
while TSP-1 and TSP-5 (a known substrate of ADAMTS-7) belong to the same group of 
structure proteins with similar structures. The data from the proteomics and Western blot 
analyses described in this Chapter are consistent with the notion that ADAMTS-7 might 
be able to cleave TSP-1, although other possibilities can not be precluded, for example, 
ADAMTS-7 might be able to act on other proteases that in turn cleave TSP-1 or act on 
molecules that increase TSP-1 expression. To clarify these issues, further experiments will 
be required. 
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Chapter 5 Population study 
 
Although the several GWAS mentioned earlier have shown an association between SNPs 
at the ADAMTS7 locus and risk of CAD, they did not investigate whether the ADAMTS7 
SNPs influence atherosclerosis progression and severity. Since VSMC migration and 
angiogenesis are more relevant to atherosclerosis progression than to atherosclerosis 
initiation, it would be worth noting some results from analyses of relationships between 
the ADAMTS7 SNP rs3825807 and atherosclerosis severity scores, which were 
accomplished by other group members and our collaborators undertaken alongside the 
functional studies described in Chapters 3 and 4. These results are summarised in the 
following sections.  
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5.1 Bruneck study 
 
In a population based prospective study (the Bruneck Study), we observed an inverse 
association between the ADAMTS7 rs3825807 G/G genotype and atherosclerosis (Pu et al. 
2013). This genotype was associated with lower prevalence of carotid atherosclerosis 
[odds ratio (95% CI) =0.51 (0.31-0.84) and 0.53 (0.31-0.90) in the data from 1990 and 
1995 respectively, after adjustment for covariates], and similarly lower atherosclerosis 
scores [β (95%CI) =-0.45 (-0.78, -0.11) and -0.50 (-0.86, -0.14) in the same data, after 
adjustment for covariates] (Table 5.1).  
 
Table 5.1. Association between rs3825807 and carotid atherosclerosis in the Bruneck Study 
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5.2 Southampton Atherosclerosis Study 
 
In a study (the Southampton Atherosclerosis Study, SAS) of a large group of patients 
undergoing coronary angiography, we found that SNP rs3825807 was associated with the 
extent of >50% stenotic coronary lesions, with G/G genotype patients having significantly 
lower scores compared with patients of the A/A or A/G genotype, including Gensini score, 
Sullivan score, Duke index, and modified-Duke score (Figure 5.1). 
 
 
 
Figure 5.1. SNP rs3825807 associated with angiographic scores in CAD patients. 
Angiographically verified CAD patients who participated in the Southampton Atherosclerosis 
Study (SAS) were genotyped for SNP rs3825807. The severity of CAD was compared between 
the GG genotype patients and the AA and AG genotype patients by multiple angiographic scoring 
systems. A: Gensini angiographic scoring system; B: Sullivan scoring system; C: Duke index and 
D: modified-Duke score. Student’s t-test was used to ascertain differences between the two groups. 
*p<0.05 comparing A/A + A/G genotypes and G/G genotype. 
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5.3 ADAMTS-7 proportion in the plaque intima correlates with intima 
thickness 
 
In addition to the above two studies which showed an association between the ADAMTS-
7 SNP rs3825807 and atherosclerosis scores, a relevant finding from a concurrent study 
of coronary atherosclerotic plaques (n=34) into a relationship between ADAMTS-7 
immunostains and plaque intima thickness is also worth noting. This study showed that 
the percentage of ADAMTS-7 stain positive area in the intima was significantly correlated 
with the thickness of the intima of the atherosclerotic plaque (Figure 5.2).  
 
 
 
Figure 5.2. ADAMTS-7 proportion in intima correlates with plaque intima thickness in the 
human coronary atherosclerotic plaques. Atherosclerotic coronary artery sections were 
subjected to double immunostaining of smooth muscle α-actin (SMA) and ADAMTS-7. The 
percentage of ADAMTS-7 stain positive area and the intima thickness were analysed by Image 
Pro Plus. Pearson regression analysis was used to analyse the correlation of the percentage of 
ADAMTS-7 stain positive area in intima and the plaque intima thickness, p<0.05.  
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In summary, the results of this chapter along with results demonstrated in chapter 3 and 4  
indicate that ADAMTS-7 and the non-synonymous SNP rs3825807 have functional 
effects on VSMC and EC migration and angiogenesis, providing new insights into the 
biological roles of ADAMTS-7 and a mechanistic explanation for the association between 
ADAMTS7 gene SNPs, atherosclerosis severity and susceptibility to CAD. 
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Chapter 6 
General Discussion 
 
6.1 ADAMTS7 – a potential therapeutic target to CVDs 
 
GWAS, an approach which has only become feasible after the completion of Human 
Genome Project and subsequent HapMap project, has provided a very powerful method 
to study the genetic risk factors for polygenic complex diseases, such as CAD, 
hypertension and type-2 diabetes. Findings from GWAS have helped identify susceptible 
genes for these diseases. To date, almost 50 genetic loci have been identified to be 
associated with CAD susceptibility, typically with multiple SNPs at each of these loci 
associated with susceptibility of CAD (Deloukas et al. 2013). However, for many of these 
loci, the functional mechanisms leading to the genetic effect remain unknown. Functional 
characterisation of these genetic variants can aid the understanding of the underlying 
biological mechanisms and may facilitate the translation of the genetic discoveries to 
therapeutic development. The findings of our study that the SNP rs3825807 has an effect 
on ADAMTS-7 pro-domain cleavage, substrate TSP-5 cleavage, VSMC and EC 
migration, and angiogenesis are pertinent in this context. Many of the genes located in the 
CAD-associated genomic regions identified by GWAS have not been reported previously 
to be involved in the pathogenesis of CAD, thus functional studies of these genes will be 
required to determine whether or not they play a role in relevant pathophysiological 
processes. Such studies may identify novel pathways or mechanisms, ultimately leading 
to the discovery of novel therapeutic targets to treat the diseases. 
 
 212 
As discussed earlier, three GWAS published in 2011 revealed that SNPs at the ADAMTS7 
gene locus on chromosome 15q25 were associated with CAD (Coronary Artery Disease 
Genetics 2011, Reilly et al. 2011, Schunkert et al. 2011) including the non-synonymous 
SNP rs3825807 which results in a Ser-to-Pro substitution in the pro-domain of ADAMTS-
7, and SNPs rs1994016 and rs4380028 which respectively reside in intron 8 and 7.6 kb 
upstream of the ADAMTS7 gene. However the mechanisms underlying disease association 
have remained unclear. It remains to be investigated whether any of these SNPs, or other 
SNPs in LD with them, have a functional effect on ADAMTS7 expression and/or activity 
and whether they have an effect on the biological processes related to CAD. So in this 
study, we sought to investigate these questions.  
 
As described in Chapters 3 and Chapter 4, the results of this study indicate that the non-
synonymous SNP rs3825807 has an effect on ADAMTS-7 pro-domain cleavage, TSP-5 
cleavage, VSMC and EC migration, and angiogenesis. Therefore, it is plausible that the 
association between SNPs at the ADAMTS7 locus and CAD susceptibility is, possibly in 
part, due to the effect of SNP rs3825807 on VSMC migration and angiogenesis, which in 
turn contributing to the development and progression of coronary atherosclerosis. Thus, 
the results of this study provide a plausible mechanistic explanation for the association 
between SNPs at the ADAMTS7 locus and CAD susceptibility. Currently there is no 
evidence that the other CAD-associated SNPs at the ADAMTS7 locus, specifically 
rs1994016 and rs4380028, are functional. If they are functionally neutral, their association 
with CAD can be due to their LD with the functional SNP rs3825807. Genetic variants 
certainly affect individual’s susceptibility to CVD, thus the knowledge of individual’s 
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CVD associated SNPs, especially functionally significant variants, such as SNP 
rs3825807 identified in this study, might be used to predict disease risk. The more relevant 
clinical use for such genetic variants is in risk calibration, which is the ability of the 
genotype to improve the stratification of individuals into risk categories (Humphries, 
Drenos et al. 2010).     
 
The results of this study provide further evidence of an important role of the ADAMTS-7 
protease in VSMC migration, supporting the findings by Wang et al from their study in 
rats. Perhaps more importantly, our study leads to the novel finding that ADAMTS-7 plays 
an important role in EC migration and angiogenesis. The finding suggests potentially a 
previously unknown role of ADAMTS-7 in atherosclerosis, since neovascularization 
promotes atherosclerotic plaque growth, rupture and haemorrhage. These results suggest 
that ADAMTS-7 is a potential therapeutic target to treat CVDs. 
  
 
 
 
 
 
 
 
 
  
 214 
6.2 Future work 
 
This study provided a mechanistic explanation for the recently reported association 
between the ADAMTS7 SNP rs3825807 and CAD susceptibility, with part of this project 
already published (Pu et al. 2013). However, much more work still needs to be done to 
further investigate the roles of ADAMTS-7 in the pathogenesis of atherosclerosis. Some 
of such studies are discussed below. 
 
The studies described in Chapter 4 showed that ADAMTS-7 has an effect on EC migration 
and in vitro angiogenesis. Although the proteomic analysis provided a clue suggesting that 
TSP-1 is a likely substrate of ADAMTS-7 and might a mediator for the effect of 
ADAMTS-7 on EC migration and angiogenesis, further experiments need to be done to 
investigate whether this is the case and to elucidate the molecular mechanism. 
 
To determine whether TSP-1 is a proteolytic substrate of ADAMTS-7, in vitro digestion 
assay can be done by a recombinant TSP-1 with recombinant ADAMTS-7, or conditioned 
media of ECs transfected with the ADAMTS7 overexpression plasmid and conditioned 
media of ECs infected with shRNA to knock down ADAMTS7.  
 
To investigate whether ADAMTS-7 affects EC migration and angiogenesis through 
degradation of TSP-1, one strategy would be knock down/block TSP-1 in ECs and 
determine if it abolishes the differences in EC migration and angiogenesis between ECs 
with ADAMTS7 overexpression and ECs with ADAMTS7 knockdown. 
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According to our preliminary proteomic analysis data, several other proteins, apart from 
TSP-1, differ in their amounts between conditioned media of ECs with ADAMTS7 
overexpression and ECs with ADAMTS7 knockdown (Table 3.2.3). Further assays can be 
carried out to investigate whether these proteins are also substrates of ADAMTS-7 and 
their relationships with ADAMTS-7 functions.  
 
In a broader context, it would be interesting to investigate the role of ADAMTS-7 in other 
human diseases such as cardiomyopathy and cancer. One study revealed that the 
deficiency of TSP-5 caused dilated cardiomyopathy (Huang et al. 2013); thus ADAMTS-
7 might play a role in this disease. Furthermore, the effect of ADAMTS-7 on EC migration 
and angiogenesis might be relevant to tumour development and growth, since 
angiogenesis is a critical process in these processes.   
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Appendix I Reagents details 
 
Table 2.1.1 Smooth Muscle Cell Growth Media 2 supplements 
Supplements Final concentration 
Fetal Calf Serum 5% 
Recombinant human Epidermal Growth Factor 0.5 ng/ml 
Recombinant human Basic Fibroblast Growth Factor  2 ng/ml 
Recombinant human Insulin  5 µg/ml 
 
 
Table 2.1.2 Final growth factors supplements concentration for HUVEC 
Supplements Final concentration 
Thymidine 2.5 µg/ml    
Heparin 10 units/ml 
Endothelial cell growth supplement 4.5 µg/ml     
Beta-Endothelial Cell Growth Factor human 2.5 µg/ml     
 
 
Table 2.2.1 List of antibodies used in ICC 
Antibody Catalog No. Titration 
Goat anti-human DDR2 polyclonal antibody  sc-7555 1:100 
Mouse anti-human CD144 monoclonal antibody sc-9989 1:100 
Rabbit anti-goat IgG antibody  P0449 1:200 
Mouse anti-human SMA monoclonal antibody  C6198 1:200 
Rabbit anti-mouse IgG antibody  F0261 1:200 
Rabbit anti-human ADAMTS-7 spacer domain polyclonal antibody ab28557 1:100 
Goat anti-rabbit IgG antibody  sc-2012 1:100 
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Table 2.3.1 List of antibodies used in IHC 
Antibody Catalog No. Titration 
Mouse anti-human SMA monoclonal antibody  C6198 1:200 
Alkaline phosphatase conjugated mouse anti-human SMA antibody  C6198 1:100 
Rabbit anti-human ADAMTS-7 spacer domain polyclonal antibody ab28557 1:100 
ADAMTS-7 spacer domain antibody blocking peptide ab41240 1:100 
Rat anti-human TSP-5 antibody  MABT36 1:20 
Rabbit anti-human vWF antibody ab9378 1:50 
Biotinylated swine anti-rabbit IgG antibody E-0431 1:200 
Alkaline phosphatase conjugated anti-mouse IgG antibody A-3562 1:200 
Biotin-conjugated goat anti-rabbit IgG antibody E-0432 1:200 
Rabbit anti-rat HRP antibody P0450 1:100 
Goat anti-rabbit IgG antibody  sc-2012 1:100 
 
 
Table 2.4.1 Primers used for KASPar genotyping 
SNP Primer Sequence 
  
 
rs3825807 
  
Allele A-FAM 5’-GAAGGTGACCAAGTTCATGCTCCCAACGCTCCCGTCGAGA-3’ 
Allele G-HEX 5’-GAAGGTCGGAGTCAACGGATTCCAACGCTCCCGTCGAGG-3’ 
Common reverse 5'-CTCCAGTGTACCCAGAGCTGGA-3' 
  
 
rs1994016 
  
Allele T-FAM 5’-GAAGGTGACCAAGTTCATGCTGAAAGCTCTCCCGCTCCTTTACT-3’ 
Allele C-HEX 5’-GAAGGTCGGAGTCAACGGATTAAAGCTCTCCCGCTCCTTTACC-3’ 
Common reverse 5'-GTTCTTGGTAGAGGAAGCCTGAGAA-3' 
  
 
rs4380028 
  
Allele C-FAM 5’-GAAGGTGACCAAGTTCATGCTGGCATGGAAAGGTTAAGTAACTTGC-3’ 
Allele T-HEX 5’-GAAGGTCGGAGTCAACGGATTGGGCATGGAAAGGTTAAGTAACTTGT-3’ 
Common reverse 5'-ACACTTCCAAATGTGGGACGTTGG-3' 
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Table 2.4.2 Primers, PCR reagents and condition for restricted enzymes genotyping 
Primer Sequence 
Forward Primer 5'-GGAAGTGACACGG GGAGATA-3' 
Reverse Primer 5'-CCATGTTCATGATGGTCAGC-3' 
 
PCR reaction system  
Reagent Volume(µl) 
ddH2O 14.86 
10x PCR buffer 2.5 
MgCl2 (50mM) 1 
dNTP (2mM) 2.5 
Primer F (10pM) 1 
Primer R (10pM) 1 
Taq Polymerase(5U/ul) 0.14 
DNA (5ng/ul)  2 
 
PCR reaction steps  
Step Temperature Time Cycle 
Pre-denature 95℃ 5 min 1 
Denature 95℃ 30 s   
Annealing 55℃ 30 s 35 
Extension 72℃ 30 s   
Final extension 72℃ 10 min 1 
 
 
 
Table 2.7.1 RT-PCR reaction reagents and conditions 
RT-PCR reaction system 
Reagent Volume(µl) 
ddH2O 4.5 
5x PCR buffer 5 
MgCl2 (25mM) 3 
dNTP (25mM) 1 
Reverse Transcriptase 1 
RNase inhibitor 0.5 
RNA and random primers mixture 10 
 
RT-PCR reaction steps  
Step Temperature Time 
Annealing 25℃ 5 minutes 
Synthesis 42℃ 90 minutes 
Inactive Reverse Transcriptase 70℃ 15 minutes 
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Table 2.7.2 Probes, reagents and conditions used in qRT-PCR 
Probe Manufactory Catalog Number 
ADAMTS7 probe Applied Biosystems Hs00276223_ml 
β-actin probe Applied Biosystems Hs03023943_g1 
 
qRT-PCR reaction system 
Reagent Volume(µl) 
ddH2O 2.5 
2x Master mix 5 
20x Primers and Probe mix 0.5 
cDNA (5ng/ul)  2 
 
qRT-PCR reaction steps  
Step Temperature Time Cycle 
Holding step 50℃ 2 min 1 
Activation of enzyme 95℃ 10 min 1 
Denature 95℃ 15 sec 
40 Annealing/extension 60℃ 1 min 
 
 
 
Table 2.8.1 Primers sequence, PCR reagents and condition for Allelic Imbalance Assay 
Primer Sequence 
gDNA Forward Primer 5'-GGAAGTGACACGG GGAGATA-3' 
cDNA Forward Primer 5'- TACTTCATTGAGCCCCTGGA -3' 
gDNA/cDNA Reverse Primer 5'- CCATGTTCATGATGGTCAGC -3' 
Sequencing primer 5'- CCATGTTCATGATGGTCAGC -3' 
 
PCR reaction system 
Reagent Volume (µl) 
ddH2O 14.86 
10x PCR buffer 2.5 
MgCl2 (50mM) 1 
dNTP (2mM) 2.5 
Primer F (10pM) 1 
Primer R (10pM) 1 
Taq Polymerase(5U/ul) 0.14 
gDNA/cDNA (5ng/ul)  2 
 
PCR reaction steps  
Step Temperature Time Cycle 
Pre-denature 95℃ 5 min 1 
Denature 95℃ 30 s   
Annealing 55℃ 30 s 35 
Extension 72℃ 30 s   
Final extension 72℃ 10 min 1 
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Table 2.9.1 Primers, reagents and PCR for ADAMTS7Pro-Cat pCMV5 Plasmids cloning 
Primer Sequence enzyme 
Outside Forward Primer 5'-GGAAGTGACACGG GGAGATA-3'  
Outside Reverse Primer 5'- TACTTCATTGAGCCCCTGGA -3'  
Inside Forward Primer 5’-CAGGTCGGTACCATGCCCGGCGGCCCCAGTC-3’ KpnI 
Inside Reverse primer 5’-TGGCACAAGCTTGAAGTCGATAATGTCCTTGGCAG-3’ Hind III 
 
PCR reaction system 
Reagent Volume(µl) 
ddH2O 14.87 
10x PCR buffer 2.5 
MgSO4 (50mM) 1 
dNTP (2mM) 2.5 
Primer F (10pM) 1 
Primer R (10pM) 1 
pfu high fidelity Taq Polymerase(5U/ul) 0.13 
cDNA (5ng/ul)  2 
 
PCR reaction steps  
Step Temperature Time Cycle 
Pre-denature 95℃ 5 min 1 
Denature 95℃ 30 s   
Annealing 55℃ 30 s 40 
Extension 68℃ 30 s   
Final extension 68℃ 10 min 1 
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Table 2.9.2 Primers sequence, PCR reagents and condition for Site-directed mutagenesis 
Primer Sequence 
Forward Primer 5’-CAGAGCTGGAGCCTCGACGGGAG-3’ 
Reverse Primer 5’-CTCCCGTCGAGGCTCCAGCTCTG -3’ 
 
Site-direct mutagenesis PCR reaction system 
Reagent Volume(µl) 
ddH20 38.64 
10x reaction buffer 5 
Quick solution 1.5 
dNTP mix(provided by kit) 1 
Primer forward(125ng,100ng/ul) 1.25 
Primer reverse(125ng,100ng/ul) 1.25 
Quickchange lighting enzyme 1 
Plasmid(100ng,280.3ng/ul) 0.36 
 
PCR reaction steps  
Step Temperature Time Cycle 
Pre-denature 95℃ 2 min 1 
Denature 95℃ 20 sec   
35 
  
Annealing 55℃ 30 sec 
Extension 65℃ 4 min 
Final extension 65℃ 10 min 1 
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Table 2.9.3 Primers, reagents and condition for PCR identification of ADAMTS7 plasmid 
ADAMTS7 cDNA Forward Primer 5'- TACTTCATTGAGCCCCTGGA -3' 
ADAMTS7 cDNA Reverse Primer 5'- CCATGTTCATGATGGTCAGC -3' 
 
PCR reaction system 
Reagent Volume(µl) 
ddH2O 11.86 
10x PCR buffer 2.5 
MgCl2 (50mM) 1 
dNTP (2mM) 2.5 
Primer F (10pM) 1 
Primer R (10pM) 1 
Taq Polymerase(5U/ul) 0.14 
Template DNA  5 
 
PCR reaction steps  
Step Temperature Time Cycle 
Pre-denature 95℃ 5 min 1 
Denature 95℃ 30 s   
Annealing 55℃ 30 s 35 
Extension 72℃ 30 s   
Final extension 72℃ 10 min 1 
 
 
Table 2.9.4 Primers sequence for ADAMTS7Pro-Cat plasmid sequencing  
ADAMTS7Pro-Cat  primer F1 CCACAGCTCCTGTACGACGCC 
ADAMTS7Pro-Cat  primer R1 GTTGCACGTCCTGGTGCGGG 
ADAMTS7Pro-Cat  primer R2 CCCGCACCAGGACGTGCAAC 
 
 
Table 2.9.5 Primers for ADAMTS7 full length plasmid sequencing 
ADAMTS7 primer F1 ATGCAAAGCTTGGTTCCTGCCATGCCCGGCGGCCCCAGTCCCCG 
ADAMTS7 primer R1 ATGCAGAATTCGCGGCGGGCAACCCGCTGAT 
ADAMTS7 primer F2 GATCACGCACCATGCAGAC 
ADAMTS7 primer R2 CTAGAGCTCAGGGGCAGGTC 
ADAMTS7 primer F3 GCTGTGACTTCGAGATTGAC 
ADAMTS7 primer R3 CATGGTGCCTGGCTTGGGTGATG 
ADAMTS7 primer F4 CAACGAGGCTGACTTCATC 
ADAMTS7 primer R4 CACCACAGCGGTCCTCCATAG 
ADAMTS7 primer F5 GAACCCAGGACCCAAGGGTC 
ADAMTS7 primer R5 CACTTGCAGAAGCTCTTCAG 
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Table 2.11.1 TSP-5 cleavage assay digestion buffer recipe, pH7.5 
Tris-HCl 50 mM 
NaCl 100 mM 
CaCl2 5 mM 
ZnCl2 2 mM 
Brij-35 0.05%, 
 
 
Table 2.14.1 Protease inhibitor cocktail recipe 
PMSF (phenylmethylsulfonyl fluoride) 1 mM 
Leupeptin 2 µM 
Pepstatin 1.5 µM 
Aprotinin 0.15 µM 
 
 
Table 2.14.2 Protein lysis buffer recipe 
Tris-HCl pH 7.5 50 mM 
NaCl 150 mM 
EDTA  pH 8.0 1 mM 
Triton X-100 0.5 % 
Protease inhibitor cocktail 1 x 
 
 
Table 2.14.3 5x protein loading buffer recipe 
Tris pH 6.8 312.5 mM 
Glycerol 50 % 
SDS 10 % 
2-ME 5% 
Bromophenol blue  0.5% 
 
 
Table 2.14.4 SDS-PAGE stacking gel recipe 
6% stacking gel, final volume 5ml 
ddH2O 2.6 ml  
30% acrylamide 1 ml 
Tris 0.5 M pH6.8 1.25 ml 
10% SDS 50 l 
10% Ammonium persulphate (APS) 50 l 
TEMED 5 l 
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Table 2.14.5 SDS-PAGE separating gel recipe 
10% separating gel, final volume 8ml 
ddH2O 3.2 ml  
30% acrylamide 2.67 ml 
Tris 1.5 M pH8.8 2 ml 
10% SDS 80 l 
10% Ammonium persulphate (APS) 80 l 
TEMED 8 l 
 
 
Table 2.14.6 Running buffer recipe 
Tris 25mM 
Glycine 0.192M 
SDS 0.1% 
 
 
Table 2.14.7 Transfer buffer recipe 
Tris 25mM 
Glycine 0.192M 
Methanol 20% 
 
 
Table 2.14.8 1x TBST recipe, pH7.6 
Tris 50 mM 
NaCl 150 mM 
Tween 20 0.5 % 
 
 
Table 2.14.9 List of antibodies used in WB 
Antibody Catalog No. Titration 
Rabbit anti-human ADAMTS-7 pro-domain antibody Ab45044 1:1000 
Rabbit anti-human ADAMTS-7 spacer domain antibody ab28557 1:1000 
Rat anti-human TSP-5 antibody  MABT36 1:500 
Mouse anti-cMyc antibody M4439 1:3000 
Mouse anti-human TSP-1 monoclonal antibody  MAB3074 1:200 
Goat anti-rabbit IgG conjugated with HRP antibody  7074 1:2000 
Rabbit anti-rat HRP antibody P0450 1:1000 
Anti-mouse IgG conjugated with HRP antibody 7076 1:3000 
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Table 3.1.1 Detailed information of VSMC genotype for ADAMTS7 variants 
Sample ID rs 3825807 Genotype rs 1994016 Genotype  rs4380028 Genotype 
HuSMC003   CC CC 
HuSMC004 AG TC TT 
HuSMC009 AA CC CC 
HuSMC010 AG TC TC 
HuSMC011 AA CC CC 
HuSMC012 AA CC TC 
HuSMC015 AA CC TC 
HuSMC016 AG CC TC 
HuSMC017 AG TC TT 
HuSMC023 AG TC CC 
HuSMC026 GG TC TT 
HuSMC028 AA CC CC 
HuSMC030 AA CC CC 
HuSMC031 AG TC TC 
HuSMC033 AA CC CC 
HuSMC034 AA CC TC 
HuSMC035 AG TC   
HuSMC036 GG TT TT 
HuSMC040 AA CC CC 
HuSMC044 AA CC CC 
HuSMC045   CC CC 
HuSMC046 AG TC   
HuSMC048 AA CC CC 
HuSMC049 AG CC CC 
HuSMC051 AA TC CC 
HuSMC052 AG CC CC 
HuSMC054 AA CC TC 
HuSMC055 AA CC CC 
HuSMC058 AA CC CC 
HuSMC059 AA CC CC 
HuSMC060 AA CC CC 
HuSMC065 AA CC TC 
HuSMC066 AA CC   
HuSMC067 AA CC CC 
HuSMC069 AA CC CC 
HuSMC070 AA CC CC 
HuSMC072 AG TC TC 
HuSMC074 AA CC   
HuSMC075 GG TT   
HuSMC077 GG TC TT 
HuSMC078 AA   CC 
HuSMC079 AA CC CC 
HuSMC080 AG TC TC 
HuSMC081 AG CC CC 
HuSMC083 GG CC CC 
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HuSMC085   CC TC 
HuSMC087 AA CC CC 
HuSMC088 AA CC CC 
HuSMC089 AA CC CC 
HuSMC090   CC CC 
HuSMC091 GG TC TC 
HuSMC092 AA CC CC 
HuSMC093 AA CC CC 
HuSMC094   CC CC 
HuSMC095 AA CC CC 
HuSMC096 AA TC CC 
HuSMC097 AA TC TC 
HuSMC098 AA   TC 
HuSMC099 GG TC CC 
HuSMC100   CC TT 
HuSMC102   CC TT 
HuSMC103   TC TT 
HuSMC104 AA CC CC 
HuSMC106 AG   CC 
HuSMC109 AG   TC 
HuSMC110 AG TC TC 
HuSMC112 AA CC CC 
HuSMC113 AA TC TT 
HuSMC114 AA TC TC 
HuSMC116   CC TT 
HuSMC118   CC CC 
HuSMC119   CC CC 
HuSMC121   TC CC 
HuSMC122   TC TC 
HuSMC124 AA TC CC 
HuSMC125   CC   
HuSMC129 GG TC TT 
HuSMC134     TC 
HuSMC135 AA TC CC 
HuSMC138 AG TC TT 
HuSMC139 AA CC CC 
HuSMC140   CC CC 
HuSMC144 AA CC CC 
HuSMC145   TC TC 
HuSMC147 AG TC TC 
HuSMC149 AG CC TC 
HuSMC151 AA TC CC 
HuSMC153 AA CC CC 
HuSMC154 AG CC CC 
HuSMC156   TC CC 
HuSMC159 AA CC   
HuSMC161   CC CC 
HuSMC162 AA   CC 
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HuSMC163   TT TC 
HuSMC164   TC CC 
HuSMC167 AG TC TC 
HuSMC168 AA TC TC 
HuSMC176 AG TC CC 
HuSMC177 AG TC TC 
HuSMC178 AA CC CC 
HuSMC179 AA CC CC 
HuSMC180 AG TC TT 
HuSMC181 AA CC TC 
HuSMC182 GG TC TC 
HuSMC183 GG TC TT 
HuSMC184 AA CC CC 
HuSMC185 AG TC TC 
HuSMC188 AA TC CC 
HuSMC189 GG TC TT 
HuSMC190 AG TC TC 
HuSMC191 AG TC TC 
HuSMC193 AG TC TC 
HuSMC194 AG TC TC 
HuSMC195 AA CC CC 
HuSMC196 AA CC   
HuSMC197 GG TC CC 
HuSMC198 AA CC TC 
HuSMC199 AA CC TC 
HuSMC200 AG TC TC 
HuSMC201 AA CC   
HuSMC203 AA CC CC 
HuSMC204 AG TC TC 
HuSMC205 AA CC TC 
HuSMC206 AA CC TC 
HuSMC207 AA CC TT 
HuSMC209 AG TC TC 
HuSMC210 AA CC CC 
HuSMC211 AG TC CC 
HuSMC212 AG TC TC 
HuSMC213 AA CC CC 
HuSMC214 AG TC TT 
HuSMC216 AA CC CC 
HuSMC217 AA CC CC 
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3. Qingzhong Xiao, Feng Zhang, Luyang Lin, Changcun Fang, Guanmei Wen, 
Tsung-Neng Tsai, Xiangyuan Pu, David Sims, Zhongyi Zhang, Xiaoke Yin, Binia 
Thomaszewski, Boris Schmidt, Manuel Mayr, Ken Suzuki, Qingbo Xu, Shu Ye. 
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Migration and Their Recruitment into Atherosclerotic Lesions. Circ Res 
112(1):35-47; 2013. 
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4. Yuan Huang, Luyang Lin, Xiaotian Yu, Guanmei Wen, Xiangyuan Pu, Hanqing 
Zhao, Changcun Fang, Jianhua Zhu, Qingbo Xu, Shu Ye, Li Zhang and Qingzhong 
Xiao. Functional Involvements of Heterogeneous Nuclear Ribonucleoprotein A1 
in Smooth Muscle Differentiation from Stem Cells in vitro and in vivo. Stem Cells 
31(5):906-17; 2013. 
 
5. Zhenling Luo, Guanmei Wen, Gang Wang, Xiangyuan Pu, Shu Ye, Qingbo Xu, 
Wen Wang, Qingzhong Xiao. MicroRNA-200C and -150 play an important role 
in endothelial cell differentiation and vasculogenesis by targeting transcription 
repressor ZEB1. Stem Cells 31(9):1749-62; 2013. 
 
Conference oral presentation and posters 
 
1. British Cardiology Society annual meeting (2013) young investigation session oral 
presentation. Xiangyuan Pu, Qingzhong Xiao, Stefan Kiechl, Kenneth Chan, Fu 
Liang Ng, Shivani Gor, Robin N. Poston, Changcun Fang, Ashish Patel, Ece C. 
Senver, Sue Shaw-Hawkins, Johann Willeit, Chuanju Liu, Jianhua Zhu, Arthur T. 
Tucker, Qingbo Xu, Mark J. Caulfield, Shu Ye. ADAMTS7 cleavage and vascular 
smooth muscle cell migration is affected by a coronary artery disease associated 
variant. Heart 2013; 99:A5-A6 doi:10.1136/heartjnl-2013-304019.270  
 
2. William Harvey Day 2013 poster.  
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